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Abstract 
 
γ-aminobutyric acid type-A (GABAA) receptors mediate inhibitory synaptic transmission in the 
CNS where neurosteroids and protein kinases are their most potent endogenous modulators. 
Acting individually, these can either enhance or depress receptor function depending on the 
type of neurosteroid or kinase present, and the subunit combination of the receptor. However, 
in vivo, these agents probably act in concert to modulate GABAA receptors and precisely ‘fine-
tune’ inhibitory neurotransmission; although how this is achieved remains unclear. Therefore, 
the relationship between these two modulators, at α1β3γ2L and α4β3δ GABAA receptors, 
expressed in HEK293 cells, was investigated using whole-cell patch clamp electrophysiology. 
 
At α1β3γ2L receptors, the potentiation of GABA responses by tetrahydrodeoxycorticosterone 
(THDOC) was reduced by PKC inhibition and enhanced by PKC activation, implying a role for 
this kinase in regulating neurosteroid potentiation. By comparison, neurosteroid potentiation 
was reduced at α1β3S408A,S409Aγ2L receptors, and was unaltered by PKC inhibitors or activators 
indicating that phosphorylation of the β3 subunit, by PKC, is important for regulating 
neurosteroid activity. To determine whether ‘extrasynaptic-type’ GABAA receptors are 
modulated similarly, experiments were also undertaken with α4β3δ and α4β3S408A,S409Aδ 
receptors. Neurosteroid potentiation was significantly reduced at both receptor subtypes after 
treatment with the protein kinase inhibitor, staurosporine. Staurosporine was notably less 
effective at α4β3S408A,S409Aδ receptors, suggesting that, although β3 subunit phosphorylation 
may play a role in the regulation of neurosteroid potentiation at α4β3δ receptors, it does not 
fully account for this modulation. Biochemical experiments on α4 subunits identified a new 
Ser/Thr phosphorylation site (S443). THDOC-mediated potentiation at α4S443Aβ3S408A,S409Aδ 
receptors was unaffected by protein kinase inhibition, strongly suggesting that 
phosphorylation of both the α4 and β3 subunits is required for the regulation of neurosteroid 
activity at α4β3δ receptors. Furthermore, Western blot analysis for wild-type α1β3γ2L 
receptors, revealed that THDOC increased phosphorylation of β3S408,S409 implying a ‘reverse’ 
pathway exists for neurosteroids to modulate the phosphorylation state of the GABAA 
receptor.  
 
Overall, these findings provide an important insight into the regulation of GABAA receptors in 
vivo, and into the mechanisms by which fine-tuning of GABAergic inhibitory transmission may 
be achieved by two endogenous neuromodulators. 
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Chapter 1 
 
Introduction 
 
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter of the mammalian 
CNS, with the activity of almost all mature neurons being inhibited by applied GABA (Burt and 
Kamatchi, 1991). These inhibitory effects of GABA are mediated through one of two subclasses 
of GABA receptor: the ionotropic GABAA or metabotropic GABAB receptors, of which, the 
GABAA receptor is the most extensively studied.  
 
1.1 The GABAA receptor 
GABAA receptors mediate the majority of fast synaptic inhibition in the brain and therefore the 
actions of GABA at these receptors are critically important for controlling CNS excitability. 
GABAA receptors are pentameric assemblies (Nayeem et al., 1994; Tretter et al., 1997), 
consisting of five subunits arranged to form a chloride-selective ion channel (see Fig. 1.1). As 
members of the Cys-loop family of ligand-gated ion channels, GABAA receptors possess a 
similar structural architecture to nicotinic acetylcholine receptors (nACh), serotonin (5-HT3) 
receptors and glycine receptors (Schofield et al., 1987; Nayeem et al., 1994; Rothlin et al., 
1999; Korpi et al., 2002; Connolly and Wafford, 2004).  
 
1.1.1 Receptor structure 
A wide range of GABAA receptor subunits have been identified to date which are divided into 
classes based on their sequence homology. These include: α1-α6, β1-β3, γ1-γ3, δ, ε, π and θ, 
and also ρ1-3 (Barnard et al., 1998; Sieghart et al., 1999; Korpi et al., 2002). There is typically 
70-80% identity within subunit families and 30-40% between classes (Burt and Kamatchi, 1991; 
Korpi et al., 2002). Additional diversity is also created through the alternative splicing of 
certain receptor subunits, with the most well characterised being the γ2 subunit, which has 
been shown to exist in two forms, γ2 short (γ2S) and γ2 long (γ2L). The γ2L subunit differs from 
the γ2S by the presence of an 8 amino acid insertion within the major TM3-4 intracellular 
domain (Whiting et al., 1990; Kofuji et al., 1991) and contains an additional consensus site for 
PKC (Moss et al., 1992; Machu et al., 1993), which generates the potential for additional 
functional modulation by protein kinases.  
 
Although the large number of subunits present could potentially enable vast receptor 
heterogeneity, numerous studies of both native and recombinant receptors have indicated 
[16] 
 
that the majority of synaptic GABAA receptors are composed of α, β and γ subunits (Sieghart et 
al., 1999; Whiting, 1999; Olsen and Sieghart, 2008). In vitro studies have shown that co-
expression of recombinant α, β and γ subunits is required to produce receptors with 
pharmacological properties akin to many native GABAA receptors (Pritchett et al., 1989; 
Sieghart et al., 1995) and furthermore, immunocytochemical and electron microscopic analysis 
of subunit expression in vivo has indicated a significant co-localisation of α, β and γ subunits in 
numerous regions of the brain (Benke et al., 1991; Fritschy et al., 1992; Somogyi et al., 1996). 
However, although most receptors are thought to be heteromers of α, β and γ subunits, due to 
the number of different isoforms within each subunit class, this still leaves the potential for 
numerous different receptor subtypes to be expressed in vivo. In fact, studies have shown that 
there is a broad spatial and temporal heterogeneity of subunit expression, with different 
neuronal populations expressing different complements of GABAA receptor subunits during 
different stages of development (Laurie et al., 1992a, 1992b; Wisden et al., 1992; Sperk et al., 
1997; Pirker et al., 2000). 
 
Each receptor subunit consists of four transmembrane domains (TM1-4), with TM2 thought to 
line the ion channel (Xu and Akabas, 1996; Goren et al., 2004). The extracellular N-terminal 
domain contains two cysteine residues purported to form the ‘Cys-loop’ important for GABA 
binding (Connolly and Wafford, 2004), along with two to four N-linked glycosylation sites. A 
large, poorly conserved intracellular domain is present between TM3-4 and has been shown to 
contain a number of consensus sites for phosphorylation (Moss and Smart, 1996; see Fig. 1.1). 
 
Although the exact subunit combination of any GABAA receptor expressed in vivo is yet to be 
determined, a number of studies using recombinant receptors have indicated that a subunit 
stoichiometry of 2α:2β:1γ (Chang et al., 1996; Tretter et al., 1997; Farrar et al., 1999) is most 
likely. However, some studies have shown that co-expression of α and β subunits alone can 
form functional receptors, although these possess different pharmacological and biophysical 
properties to those incorporating the γ subunit. αβ receptors exhibit reduced single channel 
conductance (13-15pS) compared to αβγ receptors (27-29pS; Moss et al., 1991; Angelotti and 
MacDonald, 1993; Fisher and MacDonald, 1997), as well as displaying altered kinetic 
properties (Haas and MacDonald, 1999; Boileau et al., 2003). Furthermore, receptors 
consisting of αβ subunits are insensitive to benzodiazepines, a modulation which requires the 
presence of a γ subunit within the receptor complex (Pritchett et al., 1989; Sigel et al., 1990; 
Sigel and Buhr, 1997). In addition, the incorporation of the γ subunit also results in the 
enhancement of the maximal GABA-activated current recorded (Angelotti et al., 1993). As the 
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presence of the γ subunit has been shown to be important for the clustering of GABAA 
receptors at post-synaptic sites (Essrich et al., 1998), αβ receptors are likely to be excluded 
from the synapse and instead located extrasynaptically, where they contribute to the 
generation of a slower ‘tonic’ form of GABAergic inhibition (Mortensen and Smart, 2006; see 
Chapter 5).  
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Figure 1.1 Proposed structure of the GABAA receptor 
(A/B) Schematic showing the proposed 2α:2β:1γ stoichiometry of GABAA receptor heteropentamers (as 
viewed from the top; A) and their proposed membrane topology (B). The subunits are arranged 
pseudosymmetricaly to form an ion channel which, when activated by GABA, is permeable to Cl
-
 and 
HCO3
-
 ions. (C) Schematic showing the proposed structure and membrane topology of a single GABAA 
receptor subunit. Each subunit consists of an extracellular N-terminal domain, which contains the Cys-
loop and two to four putative N-linked glycosylation sites (Y), 4 transmembrane domains (TM1-4), with 
TM2 thought to form the channel lining (as shown in A) and a large cytoplasmic domain which houses a 
number of consensus sites for phosphorylation.  
 
 
1.1.2 Receptor localization and trafficking  
Following assembly, a process which has been shown to occur in the endoplasmic reticulum 
(ER; Connolly et al., 1996), GABAA receptors must be transported to the cell surface and 
clustered at synaptic sites where they will be exposed to rapid, transient releases of GABA 
from nearby pre-synaptic terminals. GABAA receptors exhibit a high degree of spatial diversity, 
[18] 
 
with different neuronal populations expressing different complements of receptor subunits 
(Laurie et al., 1992a; Wisden et al., 1992; Sperk et al., 1997; Pirker et al., 2000). In addition, 
different subunits have also been shown to be targeted to specific subsets of synapses within 
the same neuron. For example, in hippocampal pyramidal neurons, α1 and γ2 subunits exhibit 
a uniform distribution across all pyramidal neuron synapses, whereas α2 is preferentially 
localised to the axo-axonic synapses at the axon initial segment and α5 is largely found around 
the soma and proximal dendrites (Nusser et al., 1996; Fritschy et al., 1998). Therefore, the 
processes controlling membrane targeting must be highly regulated in order to ensure that 
these specific subtypes of GABAA receptor reach their correct locations. However, due to the 
vast heterogeneity of GABAA receptors in vivo, it has proved difficult to identify proteins that 
are involved in transporting receptors to the cell surface. One protein which has been 
implicated in this process is the GABAA receptor-associated protein, GABARAP. GABARAP has 
been shown to interact directly with γ2 subunits as well as with microtubules in vitro (Wang et 
al., 1999), which, along with further evidence indicating an interaction with the proposed 
GABAA receptor scaffold protein, gephyrin (Kneussel et al., 2000), led to the initial conclusion 
that GABARAP was involved in the clustering of GABAA receptors at post-synaptic sites. 
However, in neurons, GABARAP has been shown to be predominately located within 
intracellular structures, particularly the ER, Golgi apparatus and other vesicular bodies 
(Kneussel et al., 2000; Kittler et al., 2001). Furthermore, in the hippocampus, negligible levels 
of co-localisation between GABARAP and γ2 subunits were observed at the cell surface, 
whereas, significant co-localisation was seen intracellularly, around the peri-nuclear region 
(Kittler et al., 2001; Leil et al., 2004). Therefore, it has been proposed that GABARAP is more 
likely to be involved in the trafficking of GABAA receptors to the cell surface (see Fig. 1.2). This 
is supported by further studies which have shown that GABARAP can interact with N-
ethylmaleimide-sensitive factor (NSF), a protein which plays a critical role in membrane fusion 
(Kittler et al., 2001).  
 
More recent studies have identified two further proteins thought to be involved in the 
transport of GABAA receptors to the cell surface, PRIP (Phospholipase C-related, but 
catalytically inactive protein), which is thought to form a complex with the GABAA receptor and 
GABARAP to facilitate membrane trafficking (Mizokami et al., 2007) and KIF5 (Kinesin family 
motor protein 5), which is linked to GABAA receptors via mutual interactions with huntintin-
associated protein 1 (HAP1) and acts to transport receptors to the cell membrane 
independently of GABARAP (Twelvetrees et al., 2010). In addition, the ubiquitin-like protein, 
Plic-1 is thought to be important for membrane insertion of receptors at the cell surface, with 
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studies showing the abolition of the interaction between GABAA receptors and Plic-1 results in 
a reduction in the number of receptors at the cell surface (Bedford et al., 2001). 
 
The post-synaptic clustering of GABAA receptors is considered to be crucial for mediating 
efficient synaptic transmission. However, once again, the identification of proteins involved in 
the clustering of GABAA receptors has been problematic. A potential candidate is gephyrin, 
which, although initially identified as a scaffold protein involved in the clustering of glycine 
receptors (Pfeiffer et al., 1982; Moss and Smart, 2001), has also been shown to co-localise with 
GABAA receptors in synapses devoid of glycinergic input (Essrich et al., 1998; Sassoè-Pognetto 
et al., 2000; Lüscher and Keller, 2004). Furthermore, gephyrin has been shown to bind tubulin 
(Kirsch et al., 1991) and studies of knock-out mice have indicated that deletion of the γ2 
subunit results in the disruption of receptor clustering as well as a concurrent loss of 
postsynaptic gephyrin clusters (Essrich et al., 1998; Schweizer et al., 2003), suggesting that the 
close association between γ2 subunits and gephyrin may be important for the clustering of 
GABAA receptors at post-synaptic sites (see Fig. 1.2). However, although the abolition of γ2 
subunit expression causes defects in the clustering of GABAA receptors at all synapses, ablation 
of gephyrin expression results in a selective loss of clustering at synapses containing α2 or α3 
subunits only (Essrich et al., 1998; Kneussel et al., 1999, 2001), implying the existence of 
gephyrin dependent and independent mechanisms for regulating the clustering of GABAA 
receptors. However, it is now possible that GABAA receptors and gephyrin may interact directly 
since α2 subunits have been shown to bind gephyrin (Tretter et al., 2008).  
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Figure 1.2 GABAA receptor trafficking - the current hypothesis 
GABAA receptors are assembled in the endoplasmic reticulum and matured as they pass through the 
Golgi. From here they are packaged into vesicles and transported to the cell membrane. Proteins 
including GABARAP, NSF, PRIP, Plic-1 and the HAP1/KIF5 complex (not shown) are reported to be 
involved in this process. Receptors are then inserted into the membrane and clustered at synaptic sites. 
The γ2 subunit along with the scaffold protein, gephyrin are thought to play at least some role here. To 
alter synaptic efficacy, receptor number is dynamically regulated through both constitutive endocytosis 
and the lateral diffusion of receptors between synaptic and extrasynaptic sites. Once internalised, 
receptors are transported to the endosomal system where they will either be recycled back to the cell 
surface or targeted for degradation via the lysosomal pathway.  
 
 
The number of GABAA receptors present at the synapse has been shown to be a critical 
determinant of synaptic efficacy (Nusser et al., 1997, 1998; Kittler et al., 2000; Smith et al., 
2008; Arancibia-Cárcamo et al., 2009; Bannai et al., 2009) and therefore, the processes which 
regulate insertion and removal of receptors from the cell surface are of particular interest.  A 
number of studies have indicated that GABAA receptors can undergo constitutive endocytosis, 
shuttling between the cell surface and intracellular compartments as a mechanism of rapidly 
altering inhibitory synaptic strength (Lüscher and Keller, 2004; see Fig. 1.2). Studies conducted 
in heterologous expression systems and neuronal cultures have indicated that endocytosis is 
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mediated through a clathrin-dependent mechanism (Tehrani and Barnes, 1993; Kittler et al., 
2000), with a direct interaction demonstrated between GABAA receptor β and γ subunits and 
the clathrin adaptor protein, AP2 (Kittler et al., 2000; Smith et al., 2008). Further studies have 
indicated that PRIP may also be involved in the constitutive internalisation of GABAA receptors, 
with disruption of the binding of PRIP to β subunits resulting in the inhibition of receptor 
endocytosis (Kanematsu et al., 2007). Furthermore, co-immunoprecipitation studies have 
shown that GABAA receptors form a complex with PRIP and clathrin/AP2, indicating that PRIP is 
likely to play a role in clathrin-dependent receptor endocytosis (Kanematsu et al., 2007). Once 
internalised, receptors enter the endosomal system where they can either be recycled back to 
the cell surface via a direct interaction with HAP1 (Kittler et al., 2004) or targeted for 
degradation, a process thought to be mediated by ubiquitination at the γ2 subunit (Arancibia-
Cárcamo et al., 2009). The balance between receptor internalisation and their delivery back to 
the cell surface is the key determinant of receptor number and processes which can interfere 
with this balance can have significant implications for inhibitory synaptic strength and overall 
neuronal network activity. For example, the actions of protein kinases have been reported to 
interfere with the recycling of receptors from endosomal compartments back to the cell 
surface, resulting in a reduction in the cell surface expression of GABAA receptors (Connolly et 
al., 1999; Brandon et al., 2002). In addition to receptor internalisation, rapid control of 
synaptic efficacy can also be achieved via the lateral diffusion of GABAA receptors between 
synaptic and peri- and extra-synaptic sites (Thomas et al., 2005).  
 
1.1.3 Physiological and pathophysiological roles of GABAA receptors 
Upon binding of GABA, the intrinsic GABAA receptor ion channel is opened, causing a rapid 
influx of chloride ions into the cell. The resulting hyperpolarisation leads to a concurrent 
enhancement of inhibitory tone, thus GABAA receptors are important for regulating neuronal 
excitability. GABAergic neurotransmission is also important for the generation and 
maintenance of rhythmic network activities in a number of brain regions including cortex, 
hippocampus, thalamus and olfactory bulb (Farrant and Nusser, 2005). For example, studies of 
the hippocampus have shown that the generation of both theta and gamma oscillatory activity 
is dependent upon the spatially and temporally precise firing of GABAergic interneurons (Jonas 
et al., 2004; Farrant and Nusser, 2005). These rhythmic activities occur during a number of 
behaviours including movement, exploratory behaviour, memory tasks and REM sleep and are 
thought to be important for working memory as well as the storage and retrieval of long term 
memories, providing a temporal coding system for information storage (Gonzalez-Burgos and 
Lewis, 2008). 
[22] 
 
In contrast to its inhibitory effects in the adult nervous system, GABA acts as an excitatory 
neurotransmitter during embryonic and early postnatal development (Ben-Ari et al., 1989; 
Cherubini et al., 1990; Luhmann and Prince, 1991; Ben-Ari, 2002). During this time, neurons 
express the NKCC1 transporter (Plotkin et al., 1997; Li et al., 2002), which leads to an 
accumulation of chloride within the neuron, thus, activation of GABAA receptors results in a 
rapid efflux of chloride ions causing depolarization of the cell (Yamada et al., 2004). Between 
postnatal days 3 and 12, NKCC1 is down-regulated and the expression of the potassium and 
chloride co-transporter, KCC2 is enhanced. KCC2 pumps chloride ions out of the cell, switching 
the actions of GABA from excitatory to inhibitory (Rivera et al., 1999). Therefore, GABAA 
receptors have an important function during development, as, in the absence of glutamatergic 
synapses at this time, the GABAergic system acts as the major mode of excitatory 
neurotransmission. Furthermore, during development, GABA also acts as a trophic factor, 
supporting neuronal migration, cell division and neurite outgrowth (Ben-Ari et al., 2002; 
Cancedda et al., 2007).  
 
Dysfunction of GABAergic neurotransmission has been implicated in a number of neurological 
and psychiatric disorders, including epilepsy, anxiety, schizophrenia, Angleman syndrome and 
some neurodegenerative conditions such as Huntington’s disease and Alzheimer’s disease 
(Armstrong et al., 2003; Fritschy and Brϋnig, 2003; Lϋscher and Keller, 2004). Perhaps the most 
well characterised pathological condition associated with abnormal GABAA receptor function is 
epilepsy. Mutations in the GABAA receptor α1, β3, γ2 and δ subunits have been linked to a 
wide range of genetic epilepsies, with numerous studies indicating that these mutations can 
alter both the function and expression of specific receptor subtypes, leading to reduced 
inhibitory neurotransmission and ultimately an enhancement in neuronal excitability in the 
affected brain regions (MacDonald et al., 2010). Other forms of epilepsy have also been 
associated with perturbed GABAergic transmission, for example, temporal lobe epilepsy has 
been linked with the altered expression of a number of receptor subunits, including decreased 
δ and enhanced α4 and γ2 (Brooks-Kayal et al., 1998; Zhang et al., 2007), with further studies 
showing that these changes are sufficient to alter both phasic and tonic inhibition in the 
dentate gyrus (Zhang et al., 2007). The GABAA receptor also forms the major target for a 
number of clinically useful drugs (see 1.1.4), including the benzodiazepines, which are 
commonly used for the treatment of epilepsy, anxiety and insomnia, as well as barbiturates 
and some general anaesthetics (Korpi et al., 2002).  
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Due to their essential role in controlling neuronal excitability, it is important to elucidate the 
cellular mechanisms by which GABAA receptors are regulated in vivo, as this will not only 
provide a further insight into the control of GABAergic transmission under physiological 
conditions, but may also help in identifying potential therapeutic targets for the treatment of 
conditions associated with GABAA receptor dysfunction.  
 
1.1.4 GABAA receptor modulation 
GABAA receptors are known to be modulated by a number of exogenous and endogenous 
compounds, the actions of which can result in altered receptor function and/or cell surface 
expression. Exogenous modulators include a number of clinically important drugs, such as 
benzodiazepines, barbiturates and some general anaesthetics. The most well characterized 
example is the benzodiazepines, which are routinely used in the clinic for the treatment of 
anxiety, insomnia and some forms of epilepsy (Sigel and Buhr, 1997; Bateson, 2004). 
Therefore, as one of the most widely prescribed drugs in the clinic, the benzodiazepines have 
been the subject of numerous investigations to determine their mechanism of action. These 
studies have shown that the benzodiazepines act by enhancing GABAA receptor function, an 
effect which is mediated by its binding to a discrete site located within the receptor complex 
(Sieghart, 1995). Studies using chimeras formed from the benzodiazepine sensitive α1 subunit 
and the relatively insensitive α6 showed that histidine 101, which is present in α1, but is 
replaced with an arginine in α6, is essential for benzodiazepine binding (Wieland et al., 1992). 
It was later confirmed that this histidine residue is conserved in the benzodiazepine sensitive 
α2, α3 and α5 subunits but not in the benzodiazepine insensitive α4, confirming its importance 
for benzodiazepine modulation (Wieland et al., 1992; Benson et al., 1998). Furthermore, the 
presence of a γ subunit within the receptor complex has also been shown to be necessary for 
benzodiazepine binding (Pritchett et al., 1989; Sigel et al., 1990), indicating that the 
benzodiazepine binding site is likely to be located at the interface between the α and γ 
subunits. Interestingly, studies using knock-in mice which carry the histidine to arginine 
mutation within specific α subunit isoforms showed that the different actions of 
benzodiazepines are mediated through different GABAA receptor subtypes, for example, α1 
subunit-containing receptors are responsible for the sedative and anticonvulsant properties, 
whereas receptors containing α2 are involved in anxiolysis and muscle relaxation (Rudolph and 
Möhler, 2004). This discovery is particularly important for the development of new 
benzodiazepine-site drugs, as compounds can now be designed to have more specific 
therapeutic profiles, eliminating some of the undesired effects which are associated with 
classical non-specific benzodiazepine drugs, such as diazepam.  
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A number of studies have reported that ethanol may also act as a positive allosteric modulator 
at GABAA receptors, although the evidence for this remains contentious. Low, sobriety-
impairing doses of ethanol (10-30mM) have been shown to potentiate GABAA receptor 
function in a number of neuronal populations including those from the cortex, cerebellum, 
dentate gyrus and thalamus (Reynolds et al., 1992; Wei et al., 2004; Hanchar et al., 2005; 
Glykys et al., 2007; Mody et al., 2007). This is supported by studies of recombinant receptors 
which showed that GABA-activated currents recorded from receptors composed of α4β2δ, 
α4β3δ or α6β3δ subunits were also enhanced by low doses of ethanol (Sundstrom-Poromaa et 
al., 2002; Wallner et al., 2003). However, other studies, which have investigated both native 
and recombinant GABAA receptors have reported no such effect, with results showing that low 
concentrations of ethanol had negligible effects upon GABAA receptor function, although some 
enhancement was observed with much higher doses (White et al., 1990; Borghese et al., 2006; 
Yamashita et al., 2006; Casagrande et al., 2007). The reasons for these discrepancies are 
unclear but one potential explanation is that ethanol may only modulate specific 
subpopulations of GABAA receptors, for example, those composed of specific subunit-
combinations or those located in particular regions of the brain. Offering support for this 
notion are studies from recombinant systems which showed that, although GABA-activated 
currents recorded from α4β2δ, α4β3δ and α6β3δ GABAA receptors were enhanced by ethanol, 
those recorded from receptors incorporating other subunits, including those containing γ2, 
were not significantly altered (Sundstrom-Poromaa et al., 2002; Wallner et al., 2003). 
Furthermore, Wei et al. (2004) demonstrated that, although ethanol acted to enhance GABAA 
receptor function in dentate gyrus granule cells, no effect was observed in CA1 neurons of the 
hippocampus, indicating that ethanol modulation at GABAA receptors may be neuron specific. 
However, two independent studies, both utilizing recombinant α4β3δ GABAA receptors, have 
also yielded contradictory results (Borghese and Harris, 2007), although it has been suggested 
that these differences may be due to the problematic expression of these receptors or 
differences in the expression systems used (Mody et al., 2007; Wallner and Olsen, 2008). 
Ethanol modulation at GABAA receptors has also been reported to be PKC dependent (Qi et al., 
2007; Choi et al., 2008) and therefore differing levels of PKC activity may also have contributed 
to these differences in ethanol sensitivity.  
 
Endogenous modulators perhaps play a more important role, acting to regulate and ‘fine tune’ 
inhibitory transmission under physiological conditions, ensuring that neuronal excitability is 
precisely controlled. GABAA receptors are modulated by numerous endogenous molecules 
including protons (Wilkins et al., 2002), Zn2+ (Smart et al., 1994, 2004), neurosteroids (Belelli 
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and Lambert, 2005) and protein kinases (Moss and Smart, 1996). Proton modulation is 
complex, with studies reporting that protons can potentiate, inhibit or have no effect upon 
GABAA receptor function (Robello et al., 1994; Pasternack et al., 1996; Krishek and Smart, 
2001), depending on the subunit combination of the receptor (Krishek et al., 1996). Zn2+ acts as 
an inhibitor at GABAA receptors, with the extent of this inhibition once again dependent on the 
receptor’s subunit composition (Smart et al., 1991; 1994). Neurosteroids and protein kinases 
are among the most potent modulators of the GABAA receptor and therefore these 
compounds play a particularly important regulatory role in the CNS.  
 
1.2 Protein kinase modulation at the GABAA receptor 
The first indication that phosphorylation, by protein kinases, may be an important mechanism 
for regulating GABAA receptor function was inferred by the receptor’s significant structural 
homology to that of the nACh receptor, which had previously been shown to be functionally 
modulated by the activity of protein kinases (Huganir et al., 1986; Hopfield et al., 1988; Swope 
et al., 1992). This was supported by the presence of consensus sites for phosphorylation within 
the major intracellular domains of some GABAA receptor subunits (Ymer et al., 1989; Whiting 
et al., 1990) as well as by biochemical studies using purified brain preparations, which showed 
that GABAA receptors could be phosphorylated by PKC and PKA, although unequivocally 
discriminating the subunits which were phosphorylated by these protein kinases proved 
difficult due to the heterogeneous nature of these preparations (Kirkness et al., 1989; 
Browning et al., 1990). Therefore, since these early reports, numerous studies have been 
conducted in order to elucidate the actions of protein kinases in more detail, with the aim of 
determining: which protein kinases are able to phosphorylate the GABAA receptor, which 
subunits and/or residues act as their substrates in this process and finally, what are the 
functional consequences for GABAA receptors in vivo.  
 
1.2.1 Identification of the sites for GABAA receptor phosphorylation 
Studies investigating the phosphorylation of GABAA receptors in vivo have proven difficult due 
to the heterogeneous nature of the receptor and its relatively low abundance in the CNS. 
Therefore, in order to circumvent these problems, initial studies were carried out using 
purified GST fusion proteins produced from the large TM3-4 intracellular domains of specific 
GABAA receptor subunits, with these experiments indicating that a number of residues located 
within the β1-3 and γ2 subunits are substrates for specific protein kinases. These studies 
showed that the β1-3 subunits contain a conserved serine residue, S409 (S410 in β2), which is 
phosphorylated by protein kinase C (PKC), protein kinase A (PKA), protein kinase G (PKG) and 
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calcium/calmodulin-dependent protein kinase II (CaMKII; Moss et al., 1992a, McDonald and 
Moss, 1994, 1997). An additional site for CaMKII was also identified in both β1 and β3 
subunits, at S384 and S383, respectively (McDonald and Moss, 1994, 1997). Furthermore, the 
β3 subunit was shown to possess a unique phosphorylation site, at S408, which was 
phosphorylated by PKC (McDonald and Moss, 1997). Both the γ2S and γ2L subunits were 
phosphorylated at S327 by PKC and both contain two additional sites for CaMKII, at S348 and 
T350 (Moss et al., 1992a; McDonald and Moss, 1994). The γ2L isoform, which contains an 8 
amino acid insertion within its large intracellular domain (Whiting et al., 1990; Kofuji et al., 
1991), was also shown to contain a further site which was a substrate for both PKC and CaMKII 
(Moss et al., 1992a; Machu et al., 1993; McDonald and Moss, 1994; summarised in Table 1.1).  
 
Further studies using HEK293 cells expressing α1β1γ2L GABAA receptors showed that the β1 
and γ2 subunits are also substrates for phosphorylation by tyrosine kinases. The γ2 subunit 
appears to be the major target, with results showing that it is highly phosphorylated at Y365 
and Y367 when HEK293 cells are co-transfected with the tyrosine kinase vSRC. By contrast, the 
β1 subunit, which was phosphorylated at Y384 and Y386, was subject to much lower levels of 
phosphorylation (Moss et al., 1995). Phosphorylation at Y365 and Y367 has also been observed 
in vivo using phospho-specific anti-sera to assess the level of phosphorylation present in whole 
brain extracts and cultured cortical neurons (Brandon et al., 2001). 
 
 
 
Subunit 
 
 
Isoform(s) 
 
Residue(s) 
 
Protein Kinase(s) References 
 
β 
β1, β2, β3 
S409 (S410 in β2) PKC, PKA, CaMKII, PKG 
Moss et al., 1992a, 1995; 
McDonald and Moss, 1994, 
1997 
Y384, Y386 Tyrosine Kinases 
β1, β3 S384 (S383 in β3) CaMKII 
β3 S408 PKC, PKA 
 
γ2 
 
γ2S, γ2L 
S327 PKC Moss et al., 1992a, 1995; 
Machu et al., 1993; 
McDonald and Moss, 1994; 
Brandon et al., 2001 
S348, T350 CaMKII 
Y365, Y367 Tyrosine Kinases 
γ2L S343 PKC, CaMKII 
 
Table 1.1 Summary of the GABAA receptor phosphorylation sites identified to date 
(Sites are conserved in mouse, rat and human DNAs) 
 
Interestingly, although experiments carried out using HEK293 cells expressing recombinant 
GABAA receptors have, in the most part, confirmed the results obtained from the study of 
fusion proteins in vitro, some of the results obtained have been contradictory. For example, 
PKC has been shown to phosphorylate GABAA receptor β1-3 subunits at S409/S410 (Krishek et 
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al., 1994; McDonald et al., 1998; Brandon et al., 2000), a result which mimics that obtained 
from the study of fusion proteins. However, although studies by Moss et al. (1992a) showed 
that β1, β2 and β3 fusion protein constructs could be phosphorylated by PKA, experiments in 
HEK293 cells indicated that only the β1 and β3 subunits were substrates for PKA, with no 
phosphorylation observed at β2 (Moss et al., 1992b; McDonald et al., 1998). This suggests that, 
in a cell environment, there may be additional factors which can determine whether a protein 
kinase is able to phosphorylate a specific target. 
 
Studies to investigate phosphorylation at the γ2 subunit in recombinant cell systems have 
proven to be technically challenging, with biochemical approaches unable to detect the 
expression of the γ2 subunit protein (Hadingham et al., 1992; Krishek et al., 1994). This is 
thought to be due to the γ2 subunit being more susceptible to proteolysis, as demonstrated by 
its appearance as a diffuse band at approximately 42kD, much smaller than that predicted 
from the amino acid sequence of the protein (Hadingham et al., 1992; Krishek et al., 1994). 
This lack of γ2 detection was not due to a failure in the transfection of this protein as γ2 
subunit mRNA was readily detected via Northern blot (Hadingham et al., 1992).  
 
Although studies in recombinant cell systems act as a good indicator of phosphorylation in 
vivo, it has been difficult to confirm these observations at native GABAA receptors. However, 
with the development of phospho-specific anti-sera it is becoming increasingly easy to 
determine whether specific subunits and/or residues are substrates for specific protein kinases 
in intact neurons. Using an antibody which specifically targets phosphorylated β3 at both S408 
and S409, it has been possible to confirm that the β3 subunit is phosphorylated by both PKC 
and PKA in cortical and striatal neurons and furthermore, that this subunit is phosphorylated 
under basal conditions by PKC in both of these neuronal populations (Brandon et al., 2000; 
Brandon et al., 2003; Jovanovic et al., 2004).  
 
1.2.2 Functional effects of GABAA receptor phosphorylation 
 
1.2.2.1 PKC 
A number of studies have indicated that phosphorylation by PKC acts to inhibit GABAA receptor 
function. Experiments using recombinant receptors showed that the activation of PKC results 
in a significant decrease in the GABA-activated currents recorded from receptors consisting of 
both αβ and αβγ subunits, with this effect being observed with multiple receptor subtypes 
including those incorporating α1, α3, α5, β1, β2 and γ2 subunits (Kellenberger et al., 1992; 
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Sigel et al., 1991; Leidenheimer et al., 1992; Krishek et al., 1994). At α1β2γ2S GABAA receptors, 
this inhibition was shown to be mediated through direct phosphorylation at both β2 S410 and 
γ2S S327, with phosphorylation at both sites thought to be required to produce the full 
modulatory effect (Kellenberger et al., 1992). Studies of α1β1γ2S and α1β1γ2L GABAA 
receptors also showed that activation of PKC resulted in a decrease of GABAA receptor 
function, with this effect being dependent upon phosphorylation at β1 S409 and γ2 S327, with 
S343 in the γ2L subunit also playing a role. Although phosphorylation at any of these sites was 
sufficient to induce a decrease in GABA-activated currents (Leidenheimer et al., 1992; Krishek 
et al., 1994), at receptors composed of α1β1γ2L subunits, PKC-mediated phosphorylation at 
γ2L S343 was shown to produce the largest inhibitory effect (Krishek et al., 1994).  
 
PKC activation has also been shown to decrease GABAA receptor function in a number of 
neuronal preparations, including cultured superior cervical ganglion (SCG) neurons, cerebellar 
microsacs and retinal bipolar cells (Leidenheimer et al., 1992; Feigenspan and Bormann, 1994; 
Krishek et al., 1994). More recent experiments have shown that, in cultured cortical neurons, a 
direct correlation exists between the extent of phosphorylation at the GABAA receptor β3 
subunit and receptor function, with results showing that enhancement of PKC-mediated 
phosphorylation causes a decrease in the peak amplitude of the mIPSCs recorded. 
Furthermore, it was also shown that the β3 subunit is phosphorylated by PKC under basal cell 
conditions, which, when inhibited by calphostin C, resulted in a significant increase in GABAA 
receptor function indicating that, not only is PKC acting to negatively modulate GABAA 
receptors, but also that there is the potential for a bi-directional modulation by PKC in these 
neurons (Brandon et al., 2000). The ability of PKC to phosphorylate the β3 subunit under basal 
cell conditions is thought to be due to its close association with the receptor, facilitated by the 
accessory protein, RACK-1 (Receptor for activated-C kinase 1), which binds to GABAA receptor 
β subunits and acts to target PKC to the receptor (Brandon et al., 1999). 
 
Although the majority of studies have indicated that PKC acts to inhibit GABAA receptor 
function, some studies have obtained contradictory results. Lin et al. (1996) reported that co-
expression of a high dose of PKM, a constitutively active form of PKC, resulted in an increase in 
the GABA-activated currents recorded from L929 cells expressing α1β1γ2L GABAA receptors. 
The reasons for this discrepancy are unclear, but differences in the expression systems and 
experimental protocols used have been implicated (Moss and Smart, 1996). For example, the 
availability of RACK-1 may be important. In HEK293 cells expressing recombinant α1β1 GABAA 
receptors, activation of PKC reduced the peak amplitude of the GABA-activated current, 
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however, this effect was abolished by the inclusion of a peptide sequence designed to perturb 
the interaction between RACK-1 and β1 (Brandon et al., 2002b). This indicates that RACK-1 is 
not only involved in the targeting of PKC to its substrate, but it also acts to facilitate the 
phosphorylation of GABAA receptor β subunits by PKC. Therefore, the differential effects of 
PKC activation in different expression systems may reflect differences in the anchoring 
proteins present. Activation of PKC has also been shown to enhance or have no effect on 
GABAA receptor function in neurons of the dentate gyrus and CA1 region of the hippocampus, 
respectively (Poisbeau et al., 1999). One potential factor which may contribute to the 
differential effects of PKC in different neuronal populations is the differences in the receptor 
subunits which are expressed. However, in recombinant studies, subunit combination did not 
appear to affect the actions of PKC (Sigel et al., 1991; Krishek et al., 1994) and therefore, it is 
more likely that these differences are due to other factors. The interaction between PKC and 
RACK-1 has been shown to be important for the effects of PKC in some neurons, for example, 
in studies of SCG neurons, perturbation of the interaction between RACK-1 and the β1 subunit 
resulted in a reduction in the effects of PKC (Brandon et al., 2002b). Therefore, the expression 
of different accessory proteins in different neuronal populations may account for the 
differences in the effects of PKC observed. 
 
1.2.2.2 PKA 
The functional effects of PKA have been shown to be dictated by the identity of the β subunit 
within the receptor complex. PKA-mediated phosphorylation at receptors containing the β1 
subunit has been shown to result in a reduction in GABAA receptor function, whereas at β3 
subunit-containing receptors, phosphorylation by PKA causes an enhancement of GABA-
activated responses (Moss et al., 1992b; McDonald et al., 1998). This PKA-mediated increase in 
function at receptors incorporating the β3 subunit was shown to be dependent upon 
phosphorylation at S408, with studies showing that replacement of S408 with a neutral alanine 
residue resulted in a switch in the functional effects of PKA from enhancing to inhibitory 
(McDonald et al., 1998). Interestingly, at receptors containing the β2 subunit, PKA activation 
had no functional effects, which is consistent with its inability to phosphorylate this subunit 
when expressed in HEK293 cells (McDonald et al., 1998).  
 
Given that PKA-mediated phosphorylation can cause differential modulation of GABAA 
receptors depending on their subunit composition, it is perhaps unsurprising that studies in 
neurons have yielded conflicting results. For example, activation of PKA has been shown to 
decrease GABAA receptor function in SCG neurons, cerebellar granule cells and hippocampal 
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pyramidal neurons (Moss et al., 1992b; Robello et al., 1993; Poisbeau et al., 1999), whereas an 
enhancement or no effect was observed in studies of Purkinje neurons and dentate gyrus 
granule cells, respectively (Kano and Konnerth, 1992; Poisbeau et al., 1999). Some of these 
effects may be due to differences in the β subunits expressed within the different neuronal 
populations however, studies of olfactory bulb neurons, which have shown to predominately 
express the β3 subunit (Nusser et al., 1999), indicate there may be other factors which act to 
determine the functional effects of PKA in neurons. The results from recombinant studies 
would predict that, due to the high level of β3 subunit expression in these neurons, PKA 
activation would cause an enhancement of GABAA receptor function. However, PKA has been 
shown to both positively (Nusser et al., 1999) and negatively (Brunig et al., 1999) modulate 
GABAA receptor function in neurons from the olfactory bulb, although the results reported by 
Brunig et al. (1999) may be confounded by the fact that PKA was activated via D1 receptors, 
which may modulate GABAA receptor function through other signalling pathways. Further 
studies of cerebellar stellate and basket cells, which are thought to predominately express β2 
subunits, have shown that PKA acts to prolong the time course of the mIPSCs recorded from 
these neurons. This is in contrast to earlier recombinant studies which indicated that PKA 
could not phosphorylate the β2 subunit when expressed in HEK293 cells. The ability of PKA to 
phosphorylate GABAA receptor β subunits has been shown to be dependent upon its 
association with A-kinase anchoring protein 79/150 (AKAP79/150; Brandon et al., 2003), a 
neuronal accessory protein which binds to and targets PKA to its prospective substrate 
(Colledge and Scott). AKAP79/150 has been shown to interact with the β1 and β3 subunits, but 
not with β2 in some neuronal populations (Brandon et al., 2003). This result is consistent with 
the recombinant studies, but contradicts the results reported by Nusser et al. (1999), which 
showed that PKA was able to modulate GABAA receptor function in cerebellar stellate and 
basket cells. However, it is possible that the effects of PKA in these neurons are facilitated by 
another member of the AKAP family or alternatively, through the activation of other PKA-
dependent signalling pathways.  
 
1.2.2.3 CaMKII 
CaMKII can enhance GABAA receptor function in a number of neuronal populations. Infusion of 
pre-activated CaMKII (termed α-CaMKII) has been shown to potentiate GABA-activated 
currents in spinal dorsal horn neurons as well as increase the amplitude of IPSCs recorded from 
CA1 hippocampal neurons (Wang et al., 1995). α-CaMKII also enhances mIPSC amplitudes 
recorded from cerebellar Purkinje cells (Kano et al., 1996), with this process thought to be 
crucial for the establishment of ‘rebound potentiation’, a form of inhibitory synaptic plasticity 
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in which GABAergic inhibition mediated by Purkinje neurons is potentiated by the activation of 
excitatory climbing fibre inputs (Kano et al., 1992). Increasing intracellular Ca2+ in mouse 
cortical neurons has also been shown to cause an enhancement of GABAA receptor function, 
an effect which was blocked by the CaMKII inhibitor, KN-93, indicating a role for CaMKII in 
modulating the GABAA receptors in these neurons (Aguayo et al., 1998). Further studies have 
focused on the effects of CaMKII at GABAA receptors containing specific β subunit isoforms. α-
CaMKII has been shown to potentiate GABA-activated currents recorded from CGCs in both 
wild-type and β2-/- mice to a similar extent, indicating that these effects are not mediated by 
phosphorylation at the β2 subunit (Houston and Smart, 1996). CGCs are thought to 
predominately express β2 and β3 subunits (Wisden et al., 1996) and therefore, it was 
suggested that the CaMKII-dependent enhancement of GABAA receptor function was mediated 
by phosphorylation at the β3 subunit-containing receptors. This is consistent with results from 
recombinant receptors, which showed that GABA-activated currents recorded from cells 
expressing α1β3 or α1β3γ2S GABAA receptors, but not those expressing α1β2 or α1β2γ2S, 
were potentiated by exposure to α-CaMKII (Houston and Smart, 2006). Interestingly, inclusion 
of the γ2S subunit significantly increased the CaMKII-induced potentiation in both NG108 cells 
and CGCs, indicating that phosphorylation at the γ2S subunit contributes to this modulation. 
Further studies showed that, at α1β3 GABAA receptors, the enhancement of receptor function 
was due to phosphorylation at S383 alone. At α1β3γ2S receptors, mutation of S383 only 
partially abolished the α-CaMKII-induced potentiation, supporting notion that phosphorylation 
of the γ2 subunit is also important for the effects of CaMKII at GABAA receptors (Houston et al., 
2007). However, site-specific mutation of γ2 S348 and T350, the residues which were 
identified as substrates for CaMKII phosphorylation is studies using fusion proteins (McDonald 
and Moss, 1994), did not affect the potentiation induced. Moreover, α-CaMKII still induced 
some potentiation at αβS408A,S409A,S383Aγ2SS348A,T350A GABAA receptors, which contained mutations 
at all known CaMKII phosphorylation sites, indicating that CaMKII must be acting via other sites 
on the receptor (Houston et al., 2007). Curiously, mutation of Y365 and Y367 to neutral alanine 
residues abolished this residual potentiation, suggesting that some of the actions of CaMKII 
were mediated via the activation of tyrosine kinases. This was confirmed by experiments using 
phospho-specific antibodies, which showed that infusion of α-CaMKII caused an up-regulation 
of phosphorylation at Y365 and Y367 (Houston et al., 2007). 
 
Although studies of recombinant GABAA receptors indicated that receptors incorporating the 
β3, but not the β2 subunit were potentiated by CaMKII-dependent phosphorylation (Houston 
and Smart, 2006, 2007), further studies investigating the effects of CaMKII on synaptic 
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inhibition showed that the function of both β2 and β3 subunit-containing receptors could be 
modulated by CaMKII, although these effects occurred via different mechanisms. Studies 
comparing synaptic inhibition in CGCs from wild-type and β2-/- mice identified two separate 
populations of sIPSCs which possessed different kinetic properties and were differentially 
modulated by exposure to α-CaMKII (Houston et al., 2008). The β2-mediated sIPSCs were large 
in amplitude and fast decaying, with CaMKII acting to potentiate their amplitude with no effect 
on decay. By contrast, the sIPSCs mediated by β3 subunit-containing receptors, which had 
smaller amplitudes and more variable decay, displayed increased decay times in response to 
CaMKII with no effect on amplitude. Therefore, CaMKII can modulate both β2 and β3 subunit-
containing receptors in CGCs, but via different mechanisms. These subunits are likely to be 
located at distinct synapses within CGCs (Houston et al., 2008) allowing differential modulation 
by CaMKII to occur at these different synapses.  
 
1.2.2.4 Tyrosine kinases 
Studies of recombinant GABAA receptors have indicated that phosphorylation by tyrosine 
kinases causes a significant enhancement of receptor function. In HEK293 cells expressing 
α1β1γ2L GABAA receptors, intracellular dialysis of the tyrosine kinase cSRC, along with the 
tyrosine phosphatase inhibitor, sodium vanadate, resulted in a significant enhancement of the 
GABA-activated current. In addition, infusion of tyrosine kinase inhibitors has been shown to 
decrease GABA-activated currents recorded from HEK293 cells expressing α1β2 or α1β2γ2 
GABAA receptors (Wan et al., 1997a) and Xenopus oocytes expressing α1β1 or α1β1γ2L 
receptors (Valenzuela et al., 1995). In both cases, the decrease in GABA responses was more 
pronounced at receptors incorporating γ2 subunits, suggesting that tyrosine kinase-mediated 
phosphorylation at either the β or γ2 subunit is able to modulate GABAA receptor function to 
some extent. This is consistent with studies by Moss et al. (1995) which showed that both the 
β and γ2 subunits are phosphorylated by tyrosine kinases and is also supported by a more 
recent study which showed that the tyrosine kinase, SRC can directly interact with both β and γ 
subunits in HEK293 cells (Brandon et al., 2001). However, contradictory results were obtained 
by Moss et al. (1995), who reported that, although the β subunit was a substrate for tyrosine 
kinases, phosphorylation at this subunit did not result in any functional effect. Therefore, this 
implies that tyrosine phosphorylation at the GABAA receptor β subunit may act to enhance the 
functional effect conveyed by the γ2 subunit, rather than producing a direct modulatory effect 
in itself. This discrepancy could also reflect differences in the subunit composition of the 
receptors expressed (β1 versus β2 containing receptors) or the expression system used 
(HEK293 cells versus Xenopus oocytes).  
[33] 
 
Tyrosine kinases have also been shown to enhance GABAA receptor function in neurons. 
Inclusion of cSRC in the patch electrode resulted in a significant enhancement of GABA-
activated currents recorded from both SCG and spinal dorsal horn neurons (Moss et al., 1995; 
Wan et al., 1997a). Furthermore, intracellular dialysis of the tyrosine kinase inhibitor, genistein 
caused a decrease in the peak response elicited by GABA in both sets of neurons (Moss et al., 
1995; Wan et al., 1997a; Dunne et al., 1998). Taken together, this indicates that tyrosine 
kinases act to positively modulate the function of GABAA receptors.  
 
1.2.2.5 PKG 
The functional effects of PKG-mediated phosphorylation at the GABAA receptor are not well 
defined, with very few studies having been conducted to date. In neurons, activation of 
intracellular PKG via the infusion of cGMP or its analogue 8BrGMP has been shown to both 
inhibit and enhance GABAA receptor-mediated currents, depending on the neuronal 
preparation studied. Activation of PKG resulted in a decrease of the GABA-activated currents 
recorded from neurons from the nucleus of the tractus solitarus (Glaum and Miller, 1993) and 
cultured retinal amacrine cells (Wexler et al., 1998), whereas an enhancement was reported in 
studies of bullfrog dorsal root ganglia (Bradshaw and Simmons, 1995). The latter result was 
mimicked in recombinant studies from Xenopus oocytes expressing α1β2γ2L GABAA receptors 
(Leidenheimer, 1996), although, curiously, the increase in GABAA receptor function observed in 
this study was not due to phosphorylation at β2 S410. This is inconsistent with the results 
obtained from in vitro fusion proteins which showed that β2 S410 was the only residue in the 
receptor which could be phosphorylated by PKG (McDonald and Moss, 1997). This suggests 
that PKG may mediate this effect through phosphorylation at an unidentified site or, 
alternatively, it may alter other intermediary proteins or signaling pathways which 
subsequently act to modulate the function of GABAA receptors.  
 
1.2.3 Mechanisms mediating functional modulation by protein kinases 
Modulation of GABA-activated currents by protein kinases has been proposed to be mediated 
via the alteration of intrinsic ion channel function. For example, single channel recordings in 
SCG neurons showed that tyrosine kinases act to enhance both the mean open time and the 
probability of the channel opening, resulting in an increase in receptor function (Moss et al., 
1995). However, studies investigating the actions of PKA have shown that, in mouse spinal 
neurons, PKA acts to depress receptor function by decreasing the frequency of channel 
opening, with no effect on mean open time or probability of opening (Porter et al., 1990). 
Therefore, this indicates that different protein kinases may act through different mechanisms 
[34] 
 
to alter GABAA receptor function. The mechanism of action may also be dependent upon the 
subunit-combination of the receptor. In neurons, protein kinases have been shown to 
modulate the amplitude and/or decay times of synaptic events (e.g. Wang et al., 1995; Kano et 
al., 1996; Poisbeau et al., 1999), which is consistent with an alteration of GABAA receptor 
channel function.  
 
Protein kinases have also been shown to alter desensitization of GABAA receptors, which may 
also contribute to their ability to modulate receptor function. PKA activation has been shown 
to enhance the rate and extent of fast desensitization at α1β1γ2L and α1β3γ2L GABAA 
receptors expressed in HEK293 cells (Hinkle and Macdonald, 2003). Furthermore, infusion of 
pre-activated α-CaMKII into rat spinal dorsal horn neurons was also shown to decrease 
desensitization (Wang et al., 1995). Finally, in rat hippocampal neurons, promotion of 
phosphorylation via the inhibition of protein phosphatase 2B (calcineurin) enhances the rate 
and extent of macroscopic desensitization (Jones and Westbrook, 1997).  
 
1.2.4 Regulation of GABAA receptor trafficking by protein kinases 
In addition to altering ion channel function, protein kinases are also thought to modulate the 
trafficking of GABAA receptors. GABAA receptors are dynamically regulated and have been 
shown to shuttle between the cell surface and endosomal compartments. Therefore, any 
alterations to this process can result in changes to the number of receptors expressed on the 
cell surface, a parameter which is a critical determinant of synaptic efficacy (Nusser et al., 
1997, 1998; Kittler et al., 2000; Smith et al., 2008; Arancibia-Cárcamo et al., 2009; Bannai et al., 
2009).  
 
Studies have reported that, in both HEK293 cells and Xenopus oocytes expressing α1β2γ2L 
GABAA receptors, activation of PKC results in a significant depression of the GABA-activated 
current, which is associated with a decrease in the number of receptors expressed on the cell 
surface (Chapell et al., 1998; Connolly et al., 1999; Filipova et al., 2000). This decrease in 
receptor surface expression was thought to be due to PKC preventing the recycling of receptor 
back to the surface (Connolly et al., 1999). Interestingly, these studies indicated that the PKC-
mediated internalisation of GABAA receptors was independent of direct receptor 
phosphorylation (Chapell et al., 1998; Connolly et al, 1999).  
 
GABAA receptors have been shown to directly interact with parts of the endocytic machinery, 
including the clathrin adaptor protein, AP2, a protein which plays a critical role in recruiting 
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cargo to clathrin-coated pits ready for internalisation into endocytic vesicles (Schmid, 1997). 
Initial biochemical experiments showed that GABAA receptors are co-immunoprecipitated with 
AP2 (Kittler et al., 2000), with further studies showing that the µ2 subunit of AP2 could bind 
directly to both β and γ GABAA receptor subunits (Kittler et al., 2000; Kittler et al., 2005; Smith 
et al., 2008). In the β subunit, the AP2 binding motif overlaps with the major site(s) for 
phosphorylation, indicating that the actions of protein kinases may be important for 
controlling the interaction between the GABAA receptor β subunit and the AP2 adaptor (Kittler 
et al., 2005). This was confirmed by in vitro binding assays, which showed that phosphorylation 
at the β1 or β3 subunits by PKC or PKA resulted in a significant reduction in its ability to bind 
AP2 (Kittler et al., 2005). Moreover, in cortical neurons, interfering with the interaction 
between β3 and AP2 resulted in an increase in the peak amplitude of the mIPSCs recorded 
from these neurons, suggesting an enhancement in the number of receptors expressed on the 
cell surface (Kittler et al., 2005).  
 
In the γ2 subunit, the AP2 binding motif encompasses the major tyrosine phosphorylation sites 
located at Y365 and Y367 (Kittler et al., 2008; Smith et al., 2008), with phosphorylation at 
these sites also acting to decrease its ability to bind AP2 (Kittler et al., 2008). Furthermore, 
perturbation of the γ2-AP2 interaction in striatal neurons resulted in an increase in the number 
of receptors expressed on the cell surface and a concurrent enhancement in the amplitude of 
the mIPSCs recorded (Kittler et al., 2008). 
 
Some extracellular signaling molecules, including insulin and BDNF have also been shown to 
modulate the number of GABAA receptors expressed on the cell surface, effects which are 
thought to be mediated via the activation of specific protein kinases. In hippocampal neurons, 
insulin signaling has been shown to result in a rapid increase in the number of GABAA receptors 
expressed on the cell surface (Wan et al., 1997b). This effect is thought to be mediated via the 
protein kinase, Akt (also called PKB), which has been shown phosphorylate β2 S410 both in 
vitro and in vivo (Wang et al., 2003). Activation of Akt mimics the effects of insulin, increasing 
cell surface expression of GABAA receptors in both HEK293 cells and rat hippocampal neurons 
(Wang et al., 2003). Furthermore, site-specific mutation of β2 S410 abolished the insulin-
dependent increase in GABAA receptor surface expression, indicating that this effect is 
mediated through direct phosphorylation at the GABAA receptor (Wang et al., 2003).  
 
BDNF signaling via the TrkB receptor has been shown to transiently increase mIPSC amplitude, 
an effect which is associated with an enhancement of GABAA receptor cell surface stability 
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(Jovanovic et al., 2004). The increase is evident within 5 min of BDNF stimulation and is 
thought to be due to the rapid recruitment of PKC and RACK-1 to the receptor which acts to 
phosphorylate the β3 subunit, enhancing its stability in the cell membrane. The mIPSC 
amplitude returns to baseline within approximately 30 min, an effect which is associated with 
dephosphorylation of the receptor by protein phosphatase 2A (PP2A; Jovanovic et al., 2004). 
Therefore, this highlights how phosphorylation dependent modulation of GABAA receptor 
trafficking can bi-modally alter synaptic inhibition, providing an ideal mechanism for rapidly 
controlling neuronal excitability in vivo.  
 
1.2.5 Actions of phosphatases at GABAA receptors 
Phosphorylation at the GABAA receptor is not solely controlled by protein kinases, but also by 
protein phosphatases, with the balance of activities between the two determining the overall 
functional effect. In both HEK293 cells and cortical neurons, inhibition of tyrosine 
phosphatases results in a significant increase in the levels of phospho-tyrosine present, 
indicating that high intrinsic phosphatase activity keeps basal tyrosine phosphorylation low in 
these cells (Moss et al., 1995; Brandon et al., 2001). The activities of phosphatases are also 
important for controlling phosphorylation by serine/threonine protein kinases, for example, 
phosphatases PP1 and PP2A have been shown to dephosphorylate the β1 and β3 subunits and 
are important in determining GABAA receptor function both in vitro and in vivo (McDonald et 
al., 1998; Jovanovic et al., 2004; Terunuma et al., 2004). 
 
Similar to protein kinases, protein phosphatases have also been shown to associate with the 
GABAA receptor through their interactions with specific anchoring proteins. For example, in 
addition to binding and targeting PKA to the GABAA receptor, AKAP79/150 also binds PP2B 
(also termed calcineurin), with ternary complexes containing PKA, AKAP79/150 and PP2B being 
isolated from bovine brain (Coghlan et al., 1995). Furthermore, immunocytochemistry 
experiments have demonstrated a co-localisation between PKA and PP2B in hippocampal 
neurons, suggesting that they may function co-operatively to control receptor 
phosphorylation. Interestingly, the binding of AKAP79/150 to PP2B was shown to inhibit its 
phosphatase activity, implying that AKAP79/150 may be crucial for controlling the balance 
between protein kinase and phosphatase activities (Coghlan et al., 1995).  
 
The phosphatase PP1α can associate directly with the GABAA receptor, being co-
immunoprecipitated along with β3 and PRIP-1 from mouse brain (Terunuma et al., 2004). PRIP-
1 is important for this interaction, as demonstrated by the reduced levels of PP1α associated 
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with β3 in PRIP-1-/- mice (Terunuma et al., 2004), indicating that PRIP-1 is likely to act as an 
anchoring protein, facilitating the interaction between PP1α and the GABAA receptor.  
 
1.2.6 Physiological importance of GABAA receptor phosphorylation 
The importance of protein kinase modulation at GABAA receptors has been highlighted by the 
study of knock-out mice, in which specific protein kinases have been ablated. PKCε-/- mice have 
been shown to exhibit enhanced GABAA receptor responses (Hodge et al., 1999), which is 
consistent with earlier studies showing that PKC-mediated phosphorylation acts to decrease 
GABAA receptor function (Kellenberger et al., 1991; Sigel et al., 1991; Leidenheimer et al., 
1992; Krishek et al., 1994; Brandon et al., 2000). This was coupled with decreased anxiety 
behaviour, as determined by open field testing and the elevated plus maze, an effect which 
was restored to normal by treatment with the GABAA receptor antagonist, bicuculline (Hodge 
et al., 2002). Similar results have been reported for PKCγ-/- mice, which also displayed 
decreased anxiety behaviours (Bowers et al., 2000). Therefore, taken together, these results 
suggest that the actions of PKC at GABAA receptor may be important for regulating anxiety in 
vivo.  
 
Studies of knock-in mice in which tyrosine phosphorylation at the GABAA receptor γ2 subunit is 
ablated (via Y365/7F mutations) have also provided an insight into the importance of tyrosine 
phosphorylation at GABAA receptors in vivo. Homozygous knock-in of this mutation was 
embryonic lethal, perhaps suggesting a crucial role for GABAA receptor tyrosine 
phosphorylation during development (Tretter et al., 2009). Heterozygous mice exhibited 
enhanced mIPSCs in hippocampal CA3 pyramidal neurons, which was associated with an 
increase in cell surface expression of GABAA receptors (Tretter et al., 2009). This was 
correlated with deficits in spatial object recognition, a behavioural paradigm which has been 
shown to be dependent upon the CA3 region of the hippocampus (Stupien et al., 2003; 
Hunsaker et al., 2007), indicating that tyrosine phosphorylation at the GABAA receptor is 
important for spatial cognition.  
 
Dysfunction of protein kinases has also been shown to be a key feature in epilepsy. During 
status epilepticus, the number of GABAA receptors expressed on the cell surface is reduced, 
resulting in a decrease in inhibitory synaptic transmission. This is thought to be mediated by 
reduced PKC-mediated phosphorylation at the GABAA receptor β3 subunit due to its decreased 
association with PKC as well as its enhanced interaction with the phosphatase, PP2A 
(Terunuma et al., 2008). This dephosphorylation of the receptor causes an increase in binding 
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of the β3 subunit to the AP2 clathrin adaptor, resulting in increased receptor internalisation. 
Therefore, PKC-mediated phosphorylation at the GABAA receptor is vital for controlling 
neuronal excitability in vivo.    
 
1.3 Neurosteroid modulation at the GABAA receptor 
Endogenous neurosteroids are among the most potent allosteric modulators of the GABAA 
receptor. Their importance as highly effective neuromodulators first came to light when 
progesterone and some of its metabolites were reported to induce sedation and anaesthesia 
in rats (Selye, 1941). Later studies provided a feasible molecular mechanism when it was 
shown that the synthetic anaesthetic steroid, alphaxalone, potently enhanced the function of 
the GABAA receptor (Harrison and Simmonds, 1984). It soon became evident that a number of 
steroids are synthesised de novo in the brain, termed neurosteroids, which share this ability to 
enhance neuronal inhibition via a selective interaction with the GABAA receptor. These include 
the progesterone metabolite, 5α-pregnan-3α-ol-20-one (allopregnanolone) and the 
deoxycorticosterone metabolite, 5α-pregnan-3α-diol-20-one (THDOC), which are considered to 
be two of the most prevalent neurosteroids in the mammalian CNS (reviewed in Lambert et al., 
2009). Investigation into the effects of neurosteroids at the GABAA receptor have shown that, 
unlike the classical genomic mechanism of action for steroid hormones, neurosteroids mediate 
their effects over a much faster time course, which is compatible with a direct interaction with 
the receptor itself, through binding to a novel recognition site. In addition, as with other 
endogenous regulators of the GABAA receptor, some neurosteroids act as positive modulators, 
to enhance GABAA receptor responses (e.g. allopregnanolone and THDOC), whereas others act 
in a negative manner to reduce receptor function (e.g. pregnenolone sulphate; Belelli and 
Lambert, 2005). The actions of the positively modulating neurosteroids are the most well 
characterised, with these forming the basis of this thesis work. 
 
1.3.1 Neurosteroid synthesis in the CNS 
Neurosteroids are synthesised from cholesterol via a series of enzymatic reactions, with the 
first of these, mediated by the P450 side-chain-cleavage enzyme (P450scc), taking place in 
mitochondria (Baulieu et al., 1998; Compagnone and Mellon, 2000; Chisari et al., 2010). 
Cholesterol is thought to be delivered to the outer mitochondrial membrane by the 
chaperone, StAR (steroidogenic acute regulatory protein; Sierra et al., 2004; Chisari et al., 
2009), where it is subsequently transferred to the inner membrane by the 18kDa translocator 
protein (TSPO, also known as the peripheral benzodiazepine receptor; Papadopoulos et al., 
1997; Rone et al., 2009). Once the cholesterol molecule is inside the mitochondrion, P450scc 
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mediates side-chain cleavage, converting the cholesterol to pregnenolone (Baulieu et al., 1998; 
Compagnone and Mellon, 2000; Fig. 1.3). Due to its hydrophobic nature, cholesterol cannot 
readily diffuse across the mitochondrial intermembrane space and therefore this requirement 
for a transporter means that the access of cholesterol to P450scc at the inner membrane is the 
rate limiting step in neurosteroid biosynthesis (Miller, 1995).  
 
Upon exiting the mitochondrion, pregnenolone can be converted to progesterone by 3β-
hydroxysteroid dehydrogenase/isomerase (3β-HSD). Subsequent catalysis by the 21β-
hydroxylase enzyme, CYP21 converts progesterone to deoxycorticosterone. Reduction by 5α-
reductase reduces progesterone and deoxycorticosterone to the pregnane steroids, 5α-
dihydroprogesterone and 5α-dihydrodeoxycorticosterone, which undergo further reduction by 
3α-hydroxysteroid dehydrogenase (3α-HSD), to form the neurosteroids, 3α5α-
tetrahydroprogesterone (allopregnanolone) and 3α5α-tetrahydrodeoxycorticosterone 
(THDOC), respectively (Baulieu et al., 1998; Compagnone and Mellon, 2000; see Fig. 1.3). 
Peripheral steroids, which are able to cross into the brain via the blood-brain barrier can feed 
into this synthetic pathway, augmenting the levels of neurosteroids produced, as 
demonstrated by a partial loss of pregnenolone and some of its metabolites in the brains of 
rats after the removal of peripheral sources of steroids by gonadectomy and adrenalectomy 
(Corpéchot et al., 1981, 1983, 1993).  
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Figure 1.3 Biosynthesis of neurosteroids 
Schematic showing the biosynthetic pathway of some of the most prevalent neurosteroids in the CNS 
including, the positively modulating neurosteroids, allopregnanolone and THDOC and the inhibitory 
neurosteroid, pregnenolone sulphate. Neurosteroids are synthesised from cholesterol via a series of 
enzymatic reactions, the first of which occurs in mitochondria, where cholesterol is converted to 
pregnenolone. Upon exiting the mitochondrion, pregnenolone is subject to further catalysis to form a 
number of neurosteroids.  
 
 
The first evidence that steroids could be synthesised de novo in the CNS was obtained from 
studies by Baulieu and colleagues, who reported that, in rats, levels of some steroids, such as 
pregnenolone and dehydroepiandrosterone (DHEA), as well as neurosteroids, such as 
allopregnanolone, were present at higher concentrations in tissue from the nervous system 
than in the plasma and furthermore, that these steroids remained in the nervous system long 
after the removal of peripheral steroid sources (Corpéchot et al., 1981, 1983, 1993), an 
observation that was mimicked in other mammalian species including rabbits, dogs and 
monkeys (Robel and Baulieu, 1985; Robel et al., 1987; Jo et al., 1989; Mathur et al., 1993). 
Together, these results indicated that steroids were either synthesised within the brain or 
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were accumulated there. Accumulation of steroids was ruled out by clearance assays, which 
showed that radiolabelled pregnenolone was cleared from the plasma and brain over similar 
timecourses (Corpéchot et al., 1981). In addition, further studies showed that a number of 
important steroidogenic enzymes were expressed in the brain (reviewed in Compagnone and 
Mellon, 2000), strongly suggesting that steroids can be synthesised here.  
 
Immunohistochemical experiments showed that the P450scc enzyme, which is required to 
convert cholesterol to pregnenolone, is present in the brain and is particularly enriched in the 
white matter (Le Goascogne et al., 1987; Iwahashi et al., 1990). Furthermore, cultures of cells 
dissociated from rat forebrain, the majority of which were oligodendrocytes and glial cells, 
were also highly immunopositive for P450scc (Jung-Testas et al., 1989) and moreover, 
cholesterol was shown to be converted to pregnenolone in these cells, indicating that the 
enzyme is active. This suggests that the conversion of cholesterol to pregnenolone may take 
place in the glial cells of the nervous system. RT-PCR and Western blotting techniques have 
also identified P450scc mRNA and protein in the brain, particularly in glial cells (Iwahashi et al., 
1990; Mellon and Deschapper, 1993; Kohchi et al., 1998), supporting the notion that 
pregnenolone may be synthesised in the glial cells of the CNS. However, more recent studies 
have begun to focus on expression of P450scc in specific neuronal populations, with Ukena et 
al. (1998) demonstrating that both the mRNA and protein are present in the Purkinje neurons 
of the cerebellum in rats. P450scc has also been found in other neurons including those from 
dorsal root ganglia, spinal cord dorsal horn and somatosensory cortex (Patte-Mensah et al., 
2003). Therefore, taken together, these results indicate that steroids can be synthesised de 
novo in both the neurons and glial cells of the mammalian nervous system. 
 
The neurosteroids, allopregnanolone and THDOC, are synthesised from progesterone and 
deoxycorticosterone, respectively, by the sequential actions of two enzymes, 5α-reductase and 
3α-HSD. Studies have shown that these two enzymes are also expressed in the mammalian 
CNS, indicating that neurosteroids can be synthesised here. RT-PCR and Western blot 
experiments have determined that both the mRNA and protein corresponding to 5α-reductase 
and 3α-HSD enzymes are present in the brains of rats, mice and humans (Thigpen et al., 1993; 
Dong et al., 2001; Steckelbroeck et al., 2001; Stoffel-Wagner et al., 1998). The activities of 
these enzymes have also been investigated in rat brains using cultures of neurons, 
oligodendrocytes and astrocytes. Cells were treated with radiolabelled progesterone or 
dihydroprogesterone in order to determine the activities of 5α-reductase and 3α-HSD, 
respectively. The results showed that 5α-reductase was most active in neurons, although some 
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activity was observed in both oligodendrocytes and astrocytes. By contrast, 3α-HSD was most 
active in astrocytes, with less in oligodendrocytes and neurons (Melcangi et al., 1994). 
Therefore, this suggests that both neurons and glia are important for neurosteroid synthesis in 
the CNS. Recent studies have used immunohistochemistry coupled with in situ hybridization in 
mouse brain slices to determine the expression of 5α-reductase and 3α-HSD mRNA in specific 
neuronal populations. Interestingly, these enzymes were shown to co-localise in principle 
glutamatergic neurons of the cortex, hippocampus, and olfactory bulb and in some output of 
neurons of the thalamus and amygdala. Furthermore, although 5α-reductase and 3α-HSD are 
significantly expressed in principal GABAergic neurons, such as Purkinje neurons of the 
cerebellum, no signal was detected in cortical and hippocampal GABAergic interneurons. This 
indicates that expression of these enzymes is not uniform, which is likely to affect the regional 
distribution of neurosteroids in the brain (Agís-Balboa et al., 2006). Given that neurons express 
the necessary enzymes for neurosteroidogenesis, it has been proposed that, once synthesised, 
neurosteroids may diffuse into the extracellular space where they can modulate local synaptic 
transmission in an autocrine or paracrine fashion.  
 
1.3.2 Dynamic fluctuations of neurosteroids in the brain 
A number of techniques have been employed in order to determine the concentrations of 
neurosteroids present in the brain. In rats and humans, radioimmunolabelling techniques have 
obtained varied results, with concentrations of allopregnanolone between 0.5 and 20nM being 
reported, depending upon the brain region being examined (Purdy et al., 1991; Bernardi et al., 
1998; Weill-Engerer et al., 2002). However, an additional study in humans observed much 
higher concentrations of between 30 and 70nM (Bixo et al., 1997). This large variance in 
results has been proposed to be due to a lack of specificity in the antibodies used in the assay, 
which may result in higher levels of signal being detected (Thienpont et al., 1991). Techniques 
which are considered to be more accurate and have yielded more consistent results are those 
which identify the neurosteroids present in brain homogenates by three sequential 
techniques: high performance liquid chromatography (HPLC), followed by gas chromatography 
and finally, mass fragmentography (termed GC-MF). Studies using this and similar techniques 
in rats have shown that concentrations of allopregnanolone present in the brain are around 3-
10nM (Cheney et al., 1995; Uzunov et al., 1996; Uzunova et al., 2003). Furthermore, these 
studies showed that the distribution of allopregnanolone across the brain is not uniform, with 
the highest concentrations observed in olfactory bulb, striatum, hypothalamus and cerebellum 
and less in the cerebral cortex, hippocampus and amygdala (Cheney et al., 1995; Weill-Engerer 
et al., 2002; Uzunova et al., 2003). Another interesting observation from these studies is that 
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in rats which have undergone adrenalectomy and castration, levels of allopregnanolone fall by 
around 30% compared to sham operated animals, indicating that peripheral steroids 
contribute around a third of the total neurosteroid concentration in the brain (Cheney et al., 
1995; Uzunov et al., 1996).  
 
More recent experiments have used immunohistochemistry to investigate the presence of 
neurosteroids within specific subsets of neurons. THDOC and allopregnanolone were found to 
be present in a number of neuronal populations, including glutamatergic neurons of the 
cortex, hippocampus and thalamus as well as in projecting GABAergic neurons such as reticular 
thalamic neurons, striatal cells and cerebellar Purkinje neurons. However, very few local 
GABAergic interneurons were immunoreactive (Saalmann et al., 2007). This distribution of 
neurosteroids is very similar to the expression pattern of the key neurosteroidogenic enzymes, 
5α-reductase and 3α-HSD (Agís-Balboa et al., 2006), supporting the notion that neurosteroids 
are synthesised de novo within these neurons.  Interestingly, although some studies have 
suggested that both neurons and glia are able to synthesise neurosteroids, this study reported 
very few immunopositive glial cells (Saalmann et al., 2007), which may suggest that only some 
of the synthetic pathway takes place in glia or alternatively, could reflect the rapid diffusion of 
neurosteroids out of glial cells once synthesised, resulting in them being difficult to detect 
here.  
 
The concentration of neurosteroids present in the brain is not static but instead it undergoes 
dynamic changes in response to various physiological and pathophysiological conditions. In 
rats, swim stress has been shown to enhance CNS levels of allopregnanolone and THDOC to as 
much as 50nM (Purdy et al., 1991; Paul and Purdy, 1992). Measurements of allopregnanolone 
in the brains of pregnant rats showed that levels can increase to 100nM (Paul and Purdy, 
1992), an observation which was mimicked in humans, where, during pregnancy, plasma levels 
of allopregnanolone were reported to rise to a peak of around 60nM just prior to parturition 
(Parizek et al., 2005). Cyclic changes in neurosteroid levels have been observed during ovarian 
cycle, with concentrations of around 1nM reported during follicular phase, rising to between 4 
and 12nM during the luteal phase (Bäckström et al., 2003; Maguire and Mody, 2009; Sanna et 
al., 2009). Further studies have shown that CNS concentrations of neurosteroids are 
significantly decreased with age (Schumacher et al., 2003). Concentrations of allopregnanolone 
were measured in the cerebral cortices of male rats at 6, 12, 16, 18 and 20 months of age, with 
results showing that levels decreased from 6.5ng/g at 6 months to around 3ng/g at 20 months 
(Bernardi et al., 1998).  Neurosteroid concentrations have also been shown to fluctuate in 
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response to the administration of some psychoactive drugs such as ethanol, γ- 
hydroxybutyrate (GHB) and anti-depressants such as fluoxetine (Uzunov et al., 1996; Sanna et 
al., 2004).  
 
Alterations in neurosteroid levels are also a common feature in some pathological conditions, 
including depression and Alzheimer’s disease. In the olfactory bulbectomised rat model of 
depression, although an overall increase in allopregnanolone was reported in the whole brain, 
specific decreases were observed in the amygdala and frontal cortex (Uzunova et al., 2003). 
These two areas are considered to be important in regulating mood and emotion (Akwa et al., 
1999; Rupprecht and Holsboer, 1999) and therefore this reduction may contribute to the 
appearance of depressive behaviours. A study comparing neurosteroid levels in the brains of 
Alzheimer’s and non-demented humans showed that the neurosteroids pregnenolone 
sulphate and dehydroepiandrosterone sulphate were significantly reduced in the brains of 
patients with Alzheimer’s disease (Weill-Engerer et al., 2002).  
 
1.3.3 Neurosteroid actions at GABAA receptors: potentiation 
The first indication that certain steroids could potentiate GABAA receptor responses came from 
studies by Harrison and Simmonds (1984) who reported that the synthetic steroid, alphaxalone 
enhanced stimulus evoked inhibition as well as potentiating the actions of the GABAA receptor 
agonist, muscimol in rat cuneate nucleus slices. Subsequent studies showed that endogenously 
produced neurosteroids could also enhance GABAA receptor function, with concentrations as 
low as 10nM able to potentiate GABA-activated currents recorded from a number of 
preparations including hippocampal and spinal cord neurons from rats, bovine 
adrenomedullary chromaffin cells and HEK293 cells expressing recombinant GABAA receptors 
(Majewska et al., 1986; Callachan et al., 1987; Morrow et al., 1987; Peters et al., 1988; Puia et 
al., 1990). Thus, at the low, nanomolar concentrations known to exist in vivo (see 1.3.2), 
neurosteroids can enhance GABAA receptor responses. Interestingly, more recent experiments 
have indicated that much lower concentrations of neurosteroid (around 3-5nM) can also 
potentiate GABAA receptor function, although these effects take much longer to develop than 
those elicited by higher concentrations of neurosteroid (Li et al., 2007). It was suggested that 
this was due to the ability of neurosteroids to diffuse between the cell membrane and 
intracellular compartments, effectively reducing the concentration of neurosteroid present in 
the membrane and decreasing the modulatory effect observed for a given concentration of 
neurosteroid. During longer applications, the neurosteroid equilibrates between the 
membrane and intracellular compartments, thus the neurosteroid is no longer removed from 
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the membrane and therefore the concentration of neurosteroid present at the GABAA receptor 
is more similar to that which has been applied (Li et al., 2007). However, more recently, it has 
been suggested that, due to the lipophilicity of neurosteroids, concentrations present within 
the membrane may be much higher than those measured in aqueous compartments, implying 
that the potency of neurosteroids at GABAA receptors may be much less than that indicated in 
earlier experiments (Chisari et al., 2010). 
 
Following this work, many studies have been carried out in order to characterise the 
mechanisms by which neurosteroids act to potentiate GABAA receptor function. Early patch 
clamp studies showed that neurosteroids had little effect on the single channel conductance of 
the receptor, but greatly promoted its ion channel open state (Callachan et al., 1987; Lambert 
et al., 1987; Twyman and Macdonald, 1992). Using outside-out membrane patches from 
bovine chromaffin cells, Callachan et al. (1987) showed that 300nM pregnanolone induced a 
272% increase in channel open probability (Popen). More recent evidence from studies using 
HEK293 cells expressing recombinant α1β2γ2L GABAA receptors has revealed that 
neurosteroids alter a number of kinetic properties in order to enhance Popen. In the absence of 
neurosteroid, the GABAA receptor open and close time distributions each contain three 
components (open times: OT1, OT2, OT3; closed times: CT1, CT2, CT3). Application of the 
synthetic neurosteroid analogue, (3α,5α,17β)-3-hydroxyandrostane-17-carbonitrile (ACN) 
caused an increase in prevalence and duration of the longest open times (OT3) as well as a 
decrease in the prevalence of the longest closed time durations (CT3), resulting in an increase 
in the time the receptor spends in its open state (Akk et al., 2004, 2005).  
 
The effects of neurosteroids at synaptic GABAA receptors have been studied using whole-cell 
patch clamp electrophysiology to record mIPSCs from neurons in brain slices. Experiments 
have been conducted in a number of neuronal populations including: CA1 hippocampal 
neurons (Harney et al., 2003), cortical neurons (Puia et al., 2003), dentate gyrus granule cells 
(Cooper et al., 1999; Harney et al., 2003), the oxytocin-producing neurons of the 
hypothalamus (Brussaard et al., 1997; Fancsik et al., 2000; Koksma et al., 2003) and the 
Purkinje, granule and stellate neurons of the cerebellum (Cooper et al., 1999; Hamann et al., 
2002; Vicini et al., 2002). In these neurons, neurosteroids (10nM-1µm) had little effect on 
mIPSC rise times or amplitudes, but instead caused a dramatic prolongation of the decay 
phase, a modulation which results in the potentiation of GABAergic synaptic transmission.  
 
Interestingly, although neurosteroids had similar effects in all of these neuronal populations, 
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the effective concentration range was neuron specific. For example, low, physiological 
concentrations of neurosteroids prolonged mIPSCs in hippocampal CA1 neurons (Harney et al, 
2003), cerebellar granule cells (Cooper et al., 1999; Hamann et al., 2002; Vicini et al, 2002) and 
cerebellar Purkinje neurons (Cooper et al., 1999); whereas concentrations above those seen 
physiologically are required to produce similar effects in hypothalamic neurons (Brussaard et 
al., 1997; Fancsik et al., 2000; Koksma et al., 2003). Thus, in vivo, it appears that neurosteroids 
may only affect GABAA receptors in particular brain regions and it is not until levels rise that 
receptors in other brain regions are modulated. Further experiments have shown that even 
neurons in the same brain structure can be differentially affected, for example, in rat 
hippocampal slices, mIPSCs recorded from the CA1 region are prolonged by concentrations of 
allopregnanolone of 10nM and above whereas, in dentate gyrus granule cells, 300nM is 
required to induce a similar effect (Harney et al., 2003).  
 
Neurosteroid sensitivity is also modulated during development, for example, in P10 rats, 
mIPSCs recorded from dentate gyrus granule cells were prolonged by 100nM THDOC, whereas, 
at P20, this concentration had no effect (Cooper et al., 1999). It has been suggested that these 
changes may be due to alterations in expression patterns of some GABAA receptor subunits, 
which have also been shown to occur during this developmental period (Lambert et al., 2003). 
More rapid alterations in neurosteroid sensitivity have also been described, for example, the 
magnocellular neurons of the hypothalamus are sensitive to allopregnanolone 1 day prior to 
parturition, however, after parturition, these neurons become neurosteroid insensitive 
(Brussaard et al., 1997).  
 
In addition to synaptic or phasic inhibition, which is mediated by the rapid, transient release of 
GABA from pre-synaptic terminals which diffuses rapidly across the synaptic cleft to activate 
receptors clustered at the postsynaptic site, GABAA receptors also generate a slower ‘tonic’ 
form of inhibition in response to the persistent activation of extrasynaptic receptors by low, 
ambient concentrations of GABA (Farrant and Nusser, 2005; see Chapter 5). Recent studies 
have shown that, in some regions of the brain, this tonic inhibition is also modulated by 
neurosteroids, with results showing that low concentrations of neurosteroids can potentiate 
the tonic currents recorded from dentate gyrus granule cells and cerebellar granule cells 
(Hamann et al., 2002; Stell et al., 2003;). In fact, in the dentate gyrus granule cells of adult rats, 
physiological concentrations of neurosteroid exclusively modulate the tonic conductance, with 
no effect at synaptic receptors (Harney et al., 2003; Stell et al., 2003). By contrast, tonic 
conductance recorded from the thalamus and hippocampal CA1 region was not sensitive to 
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neurosteroids (Belelli and Lambert, 2005), indicating that tonic inhibition is subject to 
neurosteroid modulation in a neuron-specific manner.  
 
1.3.4 Neurosteroid actions at GABAA receptors: direct activation 
At concentrations higher than those required to potentiate GABA-mediated neurotransmission 
(above 1µm), neurosteroids are capable of directly activating the GABAA receptor in the 
absence of GABA (Callachan et al., 1987; Peters et al., 1988; Shu et al., 2004). Callachan et al. 
(1987) showed that application of the neurosteroid, pregnanolone to bovine adrenomedullary 
chromaffin cells resulted in an increase in membrane current, an effect which was abolished 
by the GABAA receptor antagonist, bicuculline, indicating that pregnanolone was directly 
activating the GABAA receptor. This was supported by single channel recordings which showed 
that, at concentration in excess of 1µM, pregnanolone induced currents with similar kinetic 
properties to those induced by GABA (Callachan et al., 1987). However, due to this effect being 
elicited by concentrations of neurosteroid above those that would be expected in vivo, this 
effect is not considered to be physiologically relevant.  
 
1.3.5 Effect of subunit composition 
Many of the pharmacological properties of the GABAA receptor are dependent upon its subunit 
composition, for example, the isoform of β subunit present in the receptor complex infers its 
sensitivity to the general anaesthetic, etomidate, whereas the α and γ isoforms present greatly 
influence the receptors response to benzodiazepines (Korpi et al., 2002). However, the affinity 
with which neurosteroids bind to and modulate the GABAA receptor appears to be largely 
independent of subunit composition. Studies investigating the dose-response relationships of 
allopregnanolone (co-applied with an EC10 concentration of GABA) at recombinant receptors 
consisting of different subunit combinations have shown that the presence of different α 
subunit isoforms has only modest effects on neurosteroid actions, with the EC50’s for 
potentiation not differing significantly between receptors expressing α1-6 in combination with 
β1 and γ2L subunits (Belelli et al., 2002; Hosie et al., 2007). Some small differences in 
potentiation were observed with low concentrations of neurosteroid, with results showing 
that GABA-activated currents recorded from receptors incorporating α1 or α3 subunits, but 
not those containing α2, α4, α5, or α6, were significantly enhanced by 3nM allopregnanolone, 
although the extent of this potentiation was small (Belelli et al., 2002).  
 
The presence of different γ subunit isoforms also had modest effects on neurosteroid 
sensitivity, with γ2 subunit-containing receptors being the most sensitive, with an EC50 of 89 ± 
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6nM and γ1-containing receptor the least sensitive (EC50 = 559 ± 22nM; Belelli et al., 2002). 
However, the magnitude of potentiation elicited by physiological concentrations of 
allopregnanolone (3-100nM) did not differ significantly between receptors containing γ1-3 
subunits. In addition, the identity of the β subunit expressed did not affect the activity of 
neurosteroids at the receptor, with the extent of potentiation elicited by concentrations of 
allopregnanolone between 3nM and 10µM, not differing significantly between receptors 
containing β1, β2 or β3 subunits (Hadingham et al., 1993; Belelli et al., 1996, 2002).  
 
Although the majority of synaptic GABAA receptors are thought to be composed of α, β and γ 
subunits (Sieghart et al., 1999; Whiting, 1999; Olsen and Sieghart, 2008), a number of studies 
have indicated that some extrasynaptic receptors populations consist of α and β subunits in 
combination with δ (Farrant and Nusser, 2005; Sieghart, 2008). One early study suggested that 
inclusion of the δ subunit significantly reduced the magnitude of potentiation induced at 
GABAA receptors (Zhu et al., 1996). However, a number of more recent studies have shown 
that, in both HEK293 cells and Xenopus oocytes expressing recombinant GABAA receptors, 
incorporation of the δ subunit actually enhanced neurosteroid potentiation compared to those 
containing γ2 (Belelli et al., 2002; Brown et al., 2002; Wohlfarth et al., 2002). This is consistent 
with results obtained from knock-out mice, which showed that deletion of the δ subunit 
caused a reduction in behavioural responses to alphaxalone, ganaxolone and pregnenolone 
(Mihalek et al., 1999), implying that, in these mice, the δ subunit-containing receptors convey 
much of the animal’s sensitivity to neuroactive steroids.  
 
Receptors incorporating the δ subunit have been shown to exhibit high affinity, but low 
efficacy for GABA, that is, GABA acts as a partial agonist at these receptors (Brown et al., 2002; 
Bianchi and Macdonald, 2003; Stórustovu and Ebert, 2006). Using full and partial agonists of 
both γ and δ subunit-containing receptors, Bianchi and Macdonald (2003) demonstrated that 
neurosteroids enhance partial agonist activity to a greater extent than full agonist activity, an 
effect which was independent of receptor subunit composition. Therefore, this indicated that 
the enhanced neurosteroid sensitivity displayed by δ subunit-containing receptors is a 
consequence of altered functional properties of the receptor rather than the ability to 
neurosteroids to bind with greater affinity. As mentioned previously, δ subunit-containing 
receptors are thought to be located extrasynaptically to inhibitory synapses where they 
generate a slow ‘tonic’ inhibition in response to low, ambient concentrations of GABA (Farrant 
and Nusser, 2005). Therefore, this demonstration that δ subunit-containing receptors are 
more sensitive to neurosteroids has important implications for the regulation of tonic 
inhibition in vivo.  
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1.3.6 Neurosteroid binding sites 
 
1.3.6.1 Evidence for the presence of a specific binding site 
The first evidence that neurosteroids modulate GABAA receptors by binding to a discrete site 
located on the receptor complex was obtained from studies that showed that the actions of 
neurosteroids were not influenced by other GABAA receptor modulators such as 
benzodiazepines (Callachan et al., 1987; Cottrell et al., 1987) or barbiturates (Gee et al., 1988; 
Peters et al., 1988), suggesting that the neurosteroids act through a separate binding site. 
Further studies investigating the structure-activity relationships of steroids demonstrated that 
specific features of neurosteroid molecules were required for their actions at GABAA receptors. 
In the case of the pregnane-based neurosteroids (e.g. allopregnanolone and THDOC), the 
presence of a hydroxyl group in the α conformation at C3 of ring A, together with a keto group 
at C20 in ring D are crucial for their potentiation and direct activation of GABAA receptors 
(Simmonds et al., 1991; Covey et al., 2001; see Fig. 1.4). This structure specificity argued for 
the existence of a specific binding site on the GABAA receptor rather than a non-specific action 
of neurosteroids upon cell membranes, a second theory which had been proposed due to the 
lipophilic nature of neurosteroids and their ability to accumulate within the membrane.  
 
 
Figure 1.4 Structural requirements for potentiating neurosteroids 
Chemical structure of the neurosteroid, allopregnanolone. The 2D image (left) shows the 4 ring 
structure (labelled A to D), with the 8 chiral centres highlighted with red circles and carbon positions 
indicated in blue. The 3D image shows the C3 hydroxyl group in the α conformation and the C20 keto 
group, which are obligatory for potentiation. Figure is adapted from Hosie et al., 2007.  
 
 
Studies using enantiomers of allopregnanolone also provided strong evidence that 
neurosteroids act by binding to a specific site. Wittmer et al., (1996) created an enantiomeric 
form of (+)-allopregnanolone, by inverting the configuration of all 8 chiral centres (see Fig. 1.4) 
to produce its mirror image compound, ent-allopregnanolone. This compound elicited 
markedly reduced potentiation of GABA currents compared to (+)-allopregnanolone and was 
unable to directly activate the receptor (Wittmer et al., 1996), indicating the presence of a 
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specific neurosteroid binding site which has stringent structural requirements. Furthermore, 
both (+)-allopregnanolone and ent-allopregnanolone have been shown to exhibit similar 
membrane perturbing properties (Alakoskela et al., 2007) and, in experiments using 
fluorescently labeled enantiosteric neurosteroids, these compounds also displayed identical 
timecourses for membrane accumulation and similar cellular partitioning (Chisari et al., 2009). 
Therefore, their differential abilities to modulate GABAA receptor responses are not well 
correlated with their membrane perturbing properties, indicating that neurosteroids are 
unlikely to act by simply perturbing membrane lipids.  
 
These studies of enantiomeric neurosteroids also revealed the potential for multiple binding 
sites on the GABAA receptor. Although different potentiation and direct activation profiles 
were observed with the (+)- and ent- forms of allopregnanolone, this was not the case for all 
pairs of neurosteroid enantiomers, with both forms of the 5β-reduced neurosteroid, 
pregnanolone, exhibiting similar abilities to potentiate and directly activate GABA responses 
(Covey et al., 2000). It was therefore suggested that there may be more than one binding site, 
enabling the receptor to accommodate neurosteroids with different structural conformations. 
More recent studies investigating the effects of neurosteroids on the single channel properties 
of GABAA receptors have also indicated that more than one neurosteroid binding site may 
exist, with results showing that two different synthetic neurosteroids (ACN and B285 
((3α,5α,17β)-3-hydroxyandrostane-17-carbonitrile)) had different effects on single channel 
kinetics. For example, ACN increased the duration and prevalence of OT3 (longest open time), 
whereas B285 increased the prevalence of OT3, but only increased its mean duration at very 
high concentrations (Akk et al., 2004). Therefore, it was proposed that multiple binding sites 
may exist, each associated with a different functional effect, and thus the ability of each 
neurosteroid to bind these sites would determine its effects upon single channel kinetics. 
 
1.3.6.2 Identification of neurosteroid binding sites on the GABAA receptor 
The first clues as to the nature of the neurosteroid binding site came from studies of the ligand 
binding domains present on other steroid binding proteins (reviewed in Hosie et al., 2007). 
Using X-ray crystallography, it was revealed that the ligand binding domains of the nuclear 
steroid receptor family are wedge-like structures which incorporate a ligand binding cavity at 
their narrow end. The ligand binding cavities were shown to be lined with hydrophobic 
residues, which interact with the steroid’s ring structure via van der Waals forces as well as 
containing apical polar residues, which facilitate hydrogen bonding with the C3 and C17/C20 
oxygen groups present on the molecule (Weatherman et al., 1999). These features are also 
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conserved within the ligand binding cavities of other steroid binding proteins including the 
synthetic enzymes, 3α-HSD and 20α-HSD (Jin et al., 2001; Nahoum et al., 2001), therefore 
suggesting that the neurosteroid binding site(s) on the GABAA receptor may contain similar 
features.  
 
In order to identify the location of neurosteroid binding sites, initial studies utilised chimeras 
formed from the GABAA receptor and the relatively neurosteroid insensitive glycine receptor. 
Rick et al. (1998) produced a series of chimeric receptors using the GABAA receptor α2 or β1 
subunits and the glycine receptor α1 subunit and showed that potentiation by the synthetic 
steroid, alphaxalone was mediated by the N-terminal half of the GABAA receptor α2 or β1 
subunits (N-terminus + TM1 + TM2). Furthermore, the neurosteroid sensitivity of the glycine 
receptor could be markedly enhanced by replacing TM4 and the C-terminus of the glycine α1 
subunit with the corresponding region of the GABAA receptor α1 (Ueno et al., 2004), indicating 
that the TM4 region of the α1 subunit may also play a part in neurosteroid binding at the 
GABAA receptor. Therefore, it was suggested that the transmembrane domains of the GABAA 
receptor were likely to be the location for neurosteroid binding.  
 
To locate the specific transmembrane residues that were important for neurosteroid binding, 
Hosie et al. (2006) utilised chimeras formed from the mammalian GABAA receptor α1 and β2 
subunits and the corresponding regions of the Drosophila melanogaster RDL GABA receptor, 
which is homologous to the mammalian GABAA receptor but is relatively neurosteroid 
insensitive (Chen et al., 1994; Hosie and Sattelle, 1996). Replacement of TM1 and TM2 of the 
mammalian GABAA receptor α1 subunit resulted in the abolition of both the potentiation and 
direct activation effects of neurosteroids. By contrast, similar modification to the β2 subunit 
had no effect, indicating that the TM1 and TM2 regions of the α1, but not the β2 subunit are 
important for the actions of neurosteroids. Secondly, given that polar residues were shown to 
be important for the binding of steroid molecules to nuclear steroid receptors and some 
steroid synthetic enzymes, Hosie et al. (2006) then identified a number of polar residues that 
were present in the α1 TM1 and TM2 domains but replaced with hydrophobic residues in the 
RDL receptor. Sequential mutation of these residues to their hydrophobic RDL equivalents 
showed that Threonine 236 was required for direct activation whereas Glutamine 241 was 
necessary for both potentiation and direct activation by neurosteroids. In addition, the 
requirement for polar residues at these positions indicated that hydrogen bonding is important 
for the actions of neurosteroids.  Furthermore, these mutations had no effect on the actions of 
diazepam, pentobarbitone or mefanamic acid, indicating that these residues are likely to 
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contribute to a specific neurosteroid binding site rather than modulating allosteric 
potentiation more generally.  
 
It was suggested that, due to the differential effects of mutating T236 and Q241, these two 
residues may contribute to separate neurosteroid binding sites. This was confirmed using 
homology modelling, which suggested that T236 is situated at the α-β subunit interface, 
whereas Q241 is located at the base of a water-filled cavity between the α1 TM1 and TM4 
domains. Interestingly, substituted cysteine accessibility experiments have shown that this 
pocket can increase in depth and volume following receptor activation by GABA (Williams and 
Akabas, 1999) and therefore, it has been hypothesized that this increase in volume may 
facilitate entry of the neurosteroid into the cavity, allowing it to bind Q241, stabilizing the 
receptor in its open conformation and resulting in potentiation of the GABA current (Hosie et 
al., 2007).  
 
Finally, by estimating the dimensions of the neurosteroid molecule, Hosie et al. (2006) 
identified further residues which may provide potential hydrogen bonding partners at the 
opposite end of the neurosteroid molecule. In the case of the Q241 site, hydrogen bonding at 
α1 TM4 Asparagine 407 and Tyrosine 410 were shown to be important for both potentiation 
and direct activation by neurosteroids. For the T236 site, Tyrosine 284 on TM3 of the β2 
subunit was shown to be important for direct activation only (see Fig. 1.5). Therefore, taken 
together, these data indicate that the GABAA receptor contains two distinct neurosteroid 
binding sites, the first is located within the transmembrane region of the α1 subunit and is 
important for both potentiation and direct activation by neurosteroids and the second is found 
on the putative interface between the α1 and β2 subunits and is required for direct activation 
only. Furthermore, for maximal receptor activation by neurosteroids, occupation of both sites 
is required (Hosie et al., 2006). Although this study indicated that hydrogen bonding between 
polar residues housed within the binding cavity and the neurosteroid molecule was imperative 
for the actions of neurosteroids, a more recent study has suggested that this may not be the 
case, with results showing that a synthetic neurosteroid containing a C17 group that cannot 
form hydrogen bonds can still potentiate α1β2γ2L GABAA receptors expressed in HEK293 cells 
(Li et al., 2009). However, some hydrogen bonding capabilities still remain on this steroid 
molecule, at C3, which may therefore be sufficient to induce this potentiation. Furthermore, 
mutation of N407 and Y410 abolished this potentiation indicating that these residues are still 
important for the effects of this synthetic neurosteroid (Li et al., 2009).  
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Figure 1.5 Neurosteroid binding sites 
(A) Schematic diagram showing the positions of residues which contribute to the neurosteroid 
potentiation site (black: Q241 (circle), Y410 (square), N407 (triangle)) and the direct activation site (red: 
T236 (circle), Y284 (square)). (B) Homology model (taken from Hosie et al., 2007) showing the GABAA 
receptor α1 (green) and β2 (blue) subunit transmembrane domains (TM2 domains are shown in pale 
yellow). The positions of key residues which form the neurosteroid potentiation and direct activation 
sites as well as the proposed positions of the neurosteroids within the binding cavities are indicated.   
 
 
The potentiation site has been shown to be conserved across the α subunit family, with 
mutation of the glutamine equivalent to Q241 in these subunits, resulting in the abolition of 
neurosteroid potentiation (Hosie et al., 2008). This is consistent with the observation that the 
identity of the α subunit does not significantly alter the receptor’s sensitivity to neurosteroids 
(Belelli et al., 2002). In addition, although some studies have indicated that receptors 
incorporating the δ subunit are more sensitive to neurosteroids, Hosie et al. (2008) showed 
that the δ subunit is unlikely to contribute to the neurosteroid binding site, with results 
showing that α4Q246Lβ3δ GABAA receptors expressed in HEK293 cells were not potentiated by 
THDOC. This is consistent with results from previous studies which indicated that the increase 
in neurosteroid sensitivity observed at δ subunit-containing receptors was due to GABA having 
a low efficacy interaction with this receptor rather than the presence of the δ subunit acting to 
modify neurosteroid binding (Bianchi and Macdonald, 2003).   
 
As there are two copies of the α subunit within each pentameric GABAA receptor, recent 
studies have used concatemers of subunits to investigate the relative contributions of each 
potentiation site to the overall neurosteroid effect. Concatemers enable individual subunit 
cDNAs to be tethered together and transfected as a single construct, allowing for greater 
control over the subunit arrangement of the receptor, as well as permitting each neurosteroid 
potentiation site to be mutated individually in order to assess its contribution. Concatemers 
formed from α1-β2 and α1-β2-γ2 subunits were expressed in Xenopus oocytes or HEK293 cells 
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and were shown to have similar single channel kinetic properties as receptor formed from 
single subunits, although whole-cell concentration-response relationships indicated that they 
have a lower affinity for GABA (Akk et al., 2009). Mutation of Q241 in a single potentiation site 
resulted in only a modest decrease in neurosteroid activity, whereas mutation of both sites 
resulted in a complete abolition of potentiation (Akk et al., 2009; Bracamontes and Steinback, 
2009). This indicates that neurosteroid binding to a single site is sufficient to induce 
potentiation and that both sites are functionally equivalent. However, the use of two 
concatemers encoding α1-β2 and α1-β2-γ2 means that it is not possible to rule out the 
formation of unnatural GABAA receptors composed of four or even six subunits which, if 
functional, may act to confound the results obtained.  
 
1.3.6.3 Neurosteroid access to its binding site 
Conventional models of ligand-receptor interactions usually involve a molecule accessing an 
extracellular binding site on the aqueous accessible domain of the receptor. Early evidence 
suggested that this may be the case for the neurosteroids with Lambert et al. (1990) showing 
that intracellular application of alphaxalone did not potentiate GABA-activated currents 
recorded from bovine chromaffin cells, which indicated that the neurosteroid binding site can 
only be accessed from the extracellular surface of the receptor.  However, recent evidence 
obtained by Akk et al. (2005) has indicated that, to the contrary, neurosteroids may access 
their binding site via the membrane. In cell-attached patch recordings from HEK293 cells 
expressing α1β2γ2 GABAA receptors, application of the synthetic neurosteroid, ACN resulted in 
potentiation of GABA-activated currents, despite the fact that direct aqueous access to the 
receptor was prevented. Furthermore, in excised patches formed from HEK293 cells after 
preincubation with ACN, potentiation continued long after excision, indicating that 
neurosteroid which has accumulated in the membrane is sufficient to induce potentiation (Akk 
et al., 2005). Finally, internal application of neurosteroid was able to potentiate GABA 
responses to a similar degree to that applied extracellularly and a membrane impermeable 
neurosteroid analog could only potentiate the GABAA receptor when applied to the inner 
membrane leaflet. Therefore, taken together, these results indicate that neurosteroids are 
likely to access their binding site via a membrane rather than an aqueous route (Akk et al., 
2005).  
 
1.3.7 Neurosteroid modulation of GABAA receptor expression 
In addition to directly modulating GABAA receptor ion channel kinetics, other studies have also 
proposed that neurosteroids may act by altering cell surface expression of some GABAA 
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receptor subunits, which may, in turn, alter GABAA receptor sensitivity to neurosteroids and 
other endogenous modulators. Using RNAase protection assays to quantify mRNA expression, 
a number of studies have shown that long term exposure to both progesterone and 
allopregnanolone results in changes to the expression patterns of specific GABAA receptor 
subunit mRNAs (reviewed in Biggio et al., 2006). Follesa et al. (2000) showed that, in rat 
cerebellar granule cells, exposure to progesterone for 5 days caused a significant decrease in 
the amount of mRNA encoding α1, α3, α5 and γ2 subunits but had no effect on levels of α2, 
α4, β1 or β2 subunit mRNAs. This effect was abolished by treatment of the neurons with 
finasteride, a specific inhibitor of 5α-reductase, indicating that these effects are mediated by 
the conversion of progesterone to allopregnanolone (Follesa et al., 2000). Different patterns of 
down-regulation have been seen in other neuronal types, with exposure of rodent cortical 
neurons to neurosteroids having no significant effect on the abundance of mRNA encoding α1, 
α4, or γ2S (Follesa et al., 2001), but instead leading to a decrease in α2, α3, β2 and β3 subunit 
mRNAs (Yu et al., 1996). It has been postulated that such variations in the levels of GABAA 
receptor mRNAs in different types of neurons has the effect of differentially altering the 
sensitivity of their surface GABAA receptors to endogenous modulators. In fact, after prolonged 
exposure to progesterone, cerebellar granule cells exhibited reduced sensitivity to the 
benzodiazepine, diazepam (Follesa et al., 2000). This effect is consistent with the down-
regulation of diazepam sensitive α subunits (α1, α3 and α5) and with the decrease in γ2 
subunit expression, the presence of which has been shown to be necessary for benzodiazepine 
modulation (Pritchett et al., 1989; Sigel et al., 1990).  
 
Further studies using pregnant rats have addressed the effects of prolonged neurosteroid 
exposure on GABAA receptor mRNA expression in vivo. During the late stages of pregnancy, 
neurosteroid levels have been shown to rise, peaking at around 100nM just prior to parturition 
(Paul and Purdy et al., 1992). Using RNase protection assays it has been demonstrated that, 
during pregnancy, γ2L mRNA expression is decreased in the cerebral cortex and hippocampus, 
an effect which is reversed by finasteride treatment (Concas et al., 1998). In addition, mRNAs 
corresponding to α1-4, β1-3 and γ2S subunits were unaltered, indicating the specificity of this 
modulation (Concas et al., 1998). In the oxytocin-producing neurons of the hypothalamus, 
there was a specific increase in α1 mRNA expression during pregnancy, which rapidly declined 
to normal after parturition, a time which is associated with rapid decline in neurosteroid levels 
(Fenelon and Herbison, 1996).  
 
More recent studies have focussed on investigating the changes in cell surface expression of 
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GABAA receptor subunit proteins in response to the chronic increases in CNS neurosteroid 
concentrations during pregnancy and the briefer, cyclic fluctuations that occur during the 
ovarian cycle. Maguire et al., (2005) showed that, in the dentate gyrus of female mice, 
fluctuating levels of neurosteroids during the ovarian cycle resulted in cyclic changes in the cell 
surface expression of δ subunits. When levels of circulating progesterone are high in diestrous, 
a concurrent increase in membrane localised δ subunits was observed. This was coupled with a 
decrease in surface expression of γ2 subunits during this time (Maguire and Mody, 2005). 
Further studies showed that this increase in δ subunit expression resulted in a significant 
increase in the magnitude of the tonic conductance (Maguire and Mody, 2007), thus, 
neurosteroid-induced changes in GABAA receptor subunit expression during the ovarian cycle 
can have profound effects on neuronal excitability. By contrast, the prolonged enhancement of 
neurosteroid levels which occurs during pregnancy have been shown to cause a down-
regulation of cell surface δ subunit expression in a number of brain regions including the 
thalamus, striatum and CA1 region of the hippocampus (Maguire et al., 2009), an effect which 
has been suggested to occur as a homeostatic mechanism in order to maintain normal levels of 
neuronal excitability during this period (Maguire and Mody, 2008; Maguire et al., 2009; see 
1.3.8). 
 
1.3.8 Physiological importance of neurosteroid modulation 
 
1.3.8.1 Presence of an underlying neurosteroid tone 
The importance of the actions of neurosteroids in the CNS has been highlighted by studies in 
which their synthesis has been perturbed. Injection of mice with the 5α-reductase inhibitor, 
SKF105111 was shown to cause a reduction in the decay time of mIPSCs recorded in situ from 
cortical neurons (Puia et al., 2003), indicating the presence of an underlying neurosteroid tone 
in these neurons. These mice were also shown to exhibit a reduction in behavioural responses 
to the GABAA receptor agonist, muscimol, as demonstrated by a decrease in the induction of 
the loss of righting reflex (Sanna et al., 2004). Therefore, this indicates that this underlying 
neurosteroid tone is important for regulating GABAergic inhibitory transmission and that 
synaptic GABAA receptors are an important physiological target for neurosteroids. An 
underlying neurosteroid tone has also been observed in the dentate gyrus, but interestingly, 
treatment of CA1 pyramidal neurons with the 5α-reductase inhibitor, finasteride, did not affect 
mIPSC decay times however, stimulation of neurosteroid synthesis using a TSPO agonist 
resulted in a prolongation of mIPSCs, an effect which was blocked by finasteride (Sanna et al., 
2004). This indicates that different neuronal populations are subject to differential control by 
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neurosteroids under physiological conditions and that basal synthesis of neurosteroids may 
play a large role in this process.  
 
1.3.8.2 Role of neurosteroids in neurological and psychiatric disorders 
Dysfunction of neurosteroid activity is associated with a number of neurological and 
psychiatric disorders. Catamenial epilepsy describes the appearance of seizure exacerbations 
in women during certain phases of the ovarian cycle. As discussed previously, the ovarian cycle 
is associated with cyclic changes in the levels of circulating neurosteroids in the brain (Paul and 
Purdy, 1992; Bäckström et al., 2003) and these changes in seizure susceptibility have been 
correlated with these fluctuations in neurosteroid concentrations (Maguire et al., 2005). It has 
been shown that, when neurosteroid levels are high in diestrous, the tonic current present in 
dentate gyrus granule cells is markedly increased, resulting in decreased neuronal excitability 
in these neurons, coupled with a significantly increase latency to first seizure appearance and 
shorter seizure durations after kainic acid injection (Maguire et al., 2005). This indicates that 
neurosteroid modulation at GABAA receptors is critically important for regulating neuronal 
excitability and therefore, when neurosteroid levels are low, for example, during estrous, 
neuronal excitability will be increased, causing decreased seizure thresholds. The increase in 
tonic current during diestrous has been shown to be due to the enhancement of δ subunit 
expression, with results showing that treatment of neurons with an antisense δ RNA abolishes 
this effect (Maguire et al., 2005; Maguire and Mody, 2007). Studies using rodent models have 
also implicated neurosteroids in the aetiology of temporal lobe epilepsy. Induction of status 
epilepticus via pilocarpine injection or through continuous hippocampal stimulation had the 
effect of reducing the neurosteroid sensitivity of both phasic and tonic conductance in dentate 
gyrus granule cells (Peng et al., 2004; Sun et al., 2007). This decrease in sensitivity is thought to 
be due to alterations in the cell surface expression of specific subunits, including decreases in 
extrasynaptic δ subunits (Peng et al., 2004) and relocation of α4 subunits from peri-synaptic to 
synaptic regions (Sun et al., 2007) and may contribute to the perturbation of inhibitory 
transmission, leading to seizure propagation and reoccurrence.  
 
Ovarian cycle-linked changes in neurosteroid levels are also thought to contribute to certain 
mood disorders, including premenstrual disphoric disorder (PMDD; reviewed by Bäckström et 
al., 2003). Maguire et al. (2005) reported that, in female mice, anxiety levels, as tested by the 
elevated plus maze, were increased during estrous, when neurosteroid levels are low, an 
effect which correlates with the reduction of tonic conductance in the dentate gyrus granule 
cells during this time. Therefore, this indicates that physiological changes in neurosteroid 
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levels during the ovarian cycle can result in increased anxiety and this may contribute to the 
feeling of dysphoria in PMDD patients. Interestingly, women with PMDD have a higher 
incidence of catamenial epilepsy than the general population, which implies a shared 
pathogenesis, thus, decreases in neurosteroid-dependent augmentation of GABAergic 
inhibition may underlie both of these conditions.  
 
During pregnancy, levels of neurosteroid present in the brain are increased, peaking at around 
100nM (Paul and Purdy, 1992). During this time it has been shown that both phasic and tonic 
inhibition are decreased in the dentate gyrus, an effect which results from the down-
regulation of γ2 and δ subunits, respectively (Maguire and Mody, 2008). This decrease in 
inhibition has been shown to lead to an enhancement of neuronal excitability, as shown by a 
leftward shift in the input-output curves recorded from the dentate gyrus molecular layer in 
response to lateral perforant path stimulation (Maguire et al., 2009). Addition of 
allopregnanolone, at the concentration expected during pregnancy (100nM) shifted the input-
output relationships back towards those recorded from virgin mice (Maguire et al., 2009), 
indicating that during pregnancy, decreases in δ subunit expression result in enhanced 
neuronal excitability, an effect which is rectified by the high levels of circulating neurosteroid. 
Therefore, it has been suggested that the decrease in δ subunit expression during this time 
may act as a homeostatic mechanism in order to maintain normal levels of neuronal 
excitability (Maguire and Mody, 2008). Interestingly, studies of δ-/- mice, which cannot regulate 
δ subunit expression during pregnancy and the post-partum period, showed that these mice 
exhibit abnormal maternal behaviours, with the appearance of a depression-like phenotype, 
which results in decreased pup survival (Maguire and Mody, 2008). Therefore, it has been 
suggested that a failure to restore normal δ subunit expression following the rapid decline in 
neurosteroid levels post-partum could lead to hyper-excitability in certain neuronal networks 
which may contribute to the appearance of post-partum depression in humans (Maguire and 
Mody, 2008). However, in contrast to these findings, Sanna et al. (2009) reported that, in 
pregnant rats, tonic current recorded from dentate gyrus granule cells was increased and that 
this effect is mediated by an enhancement of δ subunit expression. The reasons for these 
discrepancies are unclear but may be due to species differences with Maguire and colleagues 
recording from mice and Sanna et al. from rats.  
 
Puberty is also associated with mood disturbances and recent evidence suggests that 
neurosteroids may play a substantial role in the appearance of enhanced levels of anxiety 
during this time. Shen et al. (2007) have shown that, in contrast to its anxiolytic effects in adult 
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mice, allopregnanolone enhances anxiety in pubertal female mice. This effect is thought to be 
mediated by extrasynaptic α4βδ subunit-containing GABAA receptors, which are up-regulated 
in the CA1 region of the hippocampus during puberty. These receptors generate outward 
currents and, in stark contrast to the reported potentiating actions of neurosteroids, are in fact 
inhibited by allopregnanolone, resulting in enhanced tonic inhibition and increased neuronal 
excitability in the hippocampus (Shen et al., 2007). This effect was shown to be dependent 
upon arginine 353, a non-conserved residue located within the large TM3-4 intracellular 
domain of the α4 subunit (Shen et al., 2007).  
 
Alterations in neurosteroid concentrations have also been implicated in stress and depression. 
Studies in rodents revealed that allopregnanolone levels in the brain were increased during 
stressful situations to levels sufficient to modulate GABAA receptors (Purdy et al., 1991). These 
increases in allopregnanolone have also been correlated with decreased dopamine and 
noradrenaline levels in the prefrontal cortex, suggesting that allopregnanolone may also 
influence the mesolimbocortical dopamine pathway, a system that is crucial for the 
neurochemical stress response (Zimmerberg and Brown, 1998). In an animal study involving 
social isolation, the development of depressive behaviour was paralleled by a reduction in 5α-
reductase activity and consequent reduction in allopregnanolone levels in the frontal cortex 
and olfactory bulb (Dong et al., 2001). These neurochemical perturbations were accompanied 
by the development of aggressive behaviour, which was rectified by restoration of ‘normal’ 
levels of allopregnanolone, indicating a possible role for neurosteroids in depression. 
 
One of the strongest demonstrations of the importance of neurosteroids in vivo comes from 
the study of Niemann-Pick Disease (type c), a fatal childhood condition associated with faulty 
cholesterol transport (reviewed in Mellon et al., 2007). This genetic abnormality produces 
dramatic reductions in allopregnanolone levels in mouse brain at birth (Griffin et al., 2004), a 
change which is associated with a progressive loss of motor and neuronal function, particularly 
in Purkinje neurons, resulting in premature death. Administration of allopregnanolone delays 
the onset of the motor symptoms and extends survival, with the impact of this treatment 
being more pronounced the earlier the steroid is administered after birth (Griffin et al., 2004). 
The neurosteroid effect on cell survival is bicuculline–sensitive, indicating that modulation of 
GABAA receptor function by neurosteroids is crucial for normal brain development, perhaps 
undertaking a neuroprotective function. Neurosteroid levels have also been shown to be 
perturbed in some other neurodegenerative conditions, including Alzheimer’s and Parkinson’s 
disease (Weill-Engerer et al., 2002; Luchetti et al., 2010). For example, quantification of 
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neurosteroid levels in the post-mortem brains of patients with Alzheimer’s disease showed 
that they had significantly lower levels of striatal and cerebellar pregnenolone sulphate and 
dehydroepiandrosterone sulphate compared to non-demented control subjects (Weill-Engerer 
et al., 2002). The level of pregnenolone sulphate present was negatively correlated with the 
appearance of cortical β-amyloid plaques, suggesting that this neurosteroid may have 
neuroprotective effects which are compromised in Alzheimer’s disease.  
 
Modulation of GABAA receptors by neurosteroids has also been suggested to be important for 
cognitive processing. The level of pregnenolone sulphate present in the brain has been shown 
to affect the cognitive behaviour of aged rats, with low concentrations correlating with 
memory impairment. These aged rats gained a temporary improvement in memory tasks after 
administration of pregnenolone sulphate (Mayo et al., 1993). A further study showed that 
pregnenolone sulphate can enhance hippocampal neurogenesis in young and aged rats and 
that these effects are dependent upon modulation of the GABAA receptor (Mayo et al., 2005), 
suggesting that this may be the mechanism by which pregnenolone sulphate enhances 
cognitive abilities in aged rats. More recently, it has been reported that mental retardation in a 
number of patients is caused by mutations in the neurosteroid synthetic enzyme, 
hydroxysteroid (17β) dehydrogenase, which results in decreased or abolished function of this 
enzyme and a perturbation of neurosteroid metabolism (Yang et al., 2009). The severity of the 
mutation (limited versus no functionality) was closely correlated with the severity of the 
phenotype observed, with the mutation resulting in a non-functional enzyme proving fatal 
(Yang et al., 2009). This indicates a role for neurosteroids in normal cognitive development, 
which, when perturbed, can result in severe cognitive deficits as seen in patients with mental 
retardation. 
 
Taken together, these studies indicate that modulation of GABAA receptors by neurosteroids 
plays a considerable role in maintaining neuronal excitability in the brain, an importance that is 
highlighted by the large number of disorders associated with perturbations in the activity of 
these compounds. Clarifying the role of endogenous neurosteroids in these processes may 
therefore aid in the development of effective therapeutic strategies to treat such conditions.  
 
1.3.9 Therapeutic potential of neurosteroids 
Consistent with their enhancement of GABAA receptor function, administration of 
neurosteroids to rodents exhibits clear behavioural effects including anxiolysis, sedation, 
hypnosis, anticonvulsion, and at high concentrations, anaesthesia (Gasior et al., 1999; 
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Rupprecht, 2003), all of which are clinically useful properties. The therapeutic potential of 
steroids has been recognised since the demonstration by Selye in 1941 that some steroids 
could rapidly induce anaesthesia. This eventually led to the development of a number of 
steroid based intravenous anaesthetic agents. Potential therapeutic uses for neurosteroids 
have also been addressed in a number of more recent studies involving the treatment of 
conditions associated with dysfunction of GABAergic inhibitory neurotransmission, for 
example epilepsy. 
 
In mice, pre-treatment with allopregnanolone, THDOC or pregnanolone protected against 
seizures induced by injection of pilocarpine or kainic acid (Kokate et al., 1996). Furthermore, 
these neurosteroids also protected against progression of seizures to generalised status 
epilepticus. More recent studies have shown that, in rats, the intra-hippocampal 
administration of allopregnanolone blocked the audiogenic seizures induced by nicotine 
(Martin-Garcia and Pallares, 2005) and therefore, taken together, this indicates a potential 
therapeutic role for neurosteroids in the treatment of seizure disorders. Animal models have 
also been used to investigate potential therapies for catamenial epilepsy (Reddy and Rogawski, 
2009). To investigate this, pseudopregnancy is induced for 12-13 days as a means of 
physiologically elevating progesterone and allopregnanolone levels in order to mimic those 
found in humans during the luteal phase of the ovarian cycle. This is followed by finasteride 
injection to rapidly decrease neurosteroid concentrations, similar to that seen during 
menstruation in humans, a time when seizure exacerbations appear. After neurosteroid 
withdrawal, seizure susceptibility can then be tested in order to evaluate the effectiveness of 
various therapeutic interventions (reviewed in Reddy and Rogawski, 2009). Using this model it 
has been shown that conventional antiepileptic drugs are less effective at protecting against 
seizures that occur during the period of enhanced seizure susceptibility induced by 
neurosteroid withdrawal. By contrast, naturally occurring neurosteroids such as 
allopregnanolone and THDOC as well as the synthetic neurosteroid, ganaxolone exhibited 
enhanced sensitivity at this time (Reddy and Rogawski, 2000, 2001). Ganaxolone is useful from 
a clinical point of view as it undergoes only minimal conversion back to its hormonally active 
derivative, and therefore, administration of this compound will have less impact upon levels of 
circulating hormones. Interestingly, administration of ganaxolone to rats undergoing 
neurosteroid withdrawal resulted in increased protection against seizures induced by 
pentylenetetrazol (Reddy and Rogawski, 2009) compared to control animals, indicating that 
neurosteroid replacement therapy is a promising candidate for the treatment of catamenial 
epilepsy.  
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In clinical studies into potential treatments for schizophrenia, the neurosteroid, 
dehydroepiandrosterone was given to schizophrenic patients, resulting in significant dose-
related improvements in the negative symptoms as well as depressive and anxiety symptoms 
that are associated with this condition (Strous et al., 2003). Furthermore, neurosteroids have 
also been tested in relation to age-related cognitive dysfunction, with results showing that 
intra-hippocampal infusion of pregnenolone sulphate in aged, cognitively impaired rats 
reverses their memory deficits (Vallee et al., 1997). Therefore, this may provide a potential 
starting point for the development of therapies for the prevention or alleviation of age-related 
cognitive decline.  
 
Neurosteroids have also been suggested to be promising candidates for the treatment of pain. 
The anti-nociceptive properties of steroids were demonstrated by studies in which intrathecal 
injection of steroid anaesthetics resulted in spinally mediated anti-nociception, as tested by 
the tail flick and electrical current nociceptive tests (Goodchild et al., 2000). This effect was 
abolished by treatment with the GABAA receptor antagonist, bicuculline, indicating that the 
anti-nociceptive actions of these compounds were mediated by spinal GABAA receptors 
(Goodchild et al., 2000). In addition, studies investigating the effects of synthetic steroid 
alphadalone in rats showed that, whereas intravenous injection of this compound resulted in 
sedation and anaesthesia, intragastric or intraperitoneal injections caused anti-nociceptive 
effects without any visible signs of sedation (Nadeson and Goodchild, 2001). Further studies of 
alphadalone in humans showed that, after surgery, oral administration resulted in a significant 
reduction of patient-controlled morphine use as well as decreased pain scores, indicating that 
this steroid may be useful for the treatment of post-operative pain (Goodchild et al., 2001).  
 
1.4 Co-modulation of the GABAA receptor 
Neurosteroids and protein kinases are among the most potent modulators of the GABAA 
receptor, which, as discussed previously, can enhance or depress receptor function depending 
on the type of neurosteroid or kinase present and the subunit combination of the receptor 
(Belelli et al., 2005; Moss et al., 1996). However, in vivo, these agents cannot be treated as 
discrete modulators of the GABAA receptor as it is likely that they will act in concert to achieve 
a precise fine-tuning of inhibitory neurotransmission. 
 
The activity of protein kinases has been shown to modulate the actions of a number of other 
GABAA receptor modulators, including benzodiazepines and ethanol. Studies in Xenopus 
oocytes expressing α1β2γ2L GABAA receptors showed that pre-treatment with the PKC 
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activator, PMA resulted in a significant enhancement in the diazepam-mediated potentiation 
of GABA-activated currents, indicating that PKC acts to positively modulate the actions of 
benzodiazepines at GABAA receptors (Leidenheimer et al., 1993). However, in contrast to these 
findings, PKCε-/- mice were shown to exhibit increased behavioural responses to 
benzodiazepines, suggesting that PKCε acts as to negatively modulate the actions of 
benzodiazepines (Hodge et al., 1999; Qi et al., 2007). Interestingly, PKCγ-/- mice showed no 
alterations in their behavioural responses to benzodiazepines (Harris et al., 1995), indicating 
that specific isoforms of PKC may modulate benzodiazepine potentiation at GABAA receptors 
differently. Although caution must be exercised when interpreting the results from studies of 
knock-out animals as compensatory mechanisms may alter the actions of benzodiazepines 
through pathways unrelated to the abolition of PKCε or PKCγ, the lack of specific inhibitors has 
meant that knock-out animals are the only method to obtain a strictly specific abolition of 
PKCε activity. However, a recent study has used a chemical genetic approach to produce a 
mutant ATP-analog sensitive of PKCε which can be expressed in cell lines and selectively 
inhibited by 1Na (Qi et al., 2007). Using this approach it was shown that, in HEK293 cells 
expressing α1β2γ2L GABAA receptors, inhibition of PKCε results in an increase in the potency of 
the benzodiazepine, flunitrazepam, an effect which was abolished in cells expressing 
α1β2γ2LS327A GABAA receptors. This indicates that phosphorylation of γ2L S327 by PKCε causes 
a decrease in the potency of benzodiazepines at GABAA receptors, a result which is consistent 
with the increase in behavioural effects of benzodiazepines observed in PKCε-/- mice (Hodge et 
al., 1999; Qi et al., 2007). 
 
The effects of ethanol at GABAA receptors have proved to be extremely variable, an effect that 
has been suggested to be due to the activities of protein kinases in the chosen preparation, 
which have been shown to alter the activity of ethanol at GABAA receptors. Initial studies by 
Wafford and Whiting (1992) suggested that phosphorylation at S343 in the γ2L subunit was 
crucial for ethanol modulation with results showing that, in Xenopus oocytes, only GABA 
currents mediated by α1β1γ2L GABAA receptors could be potentiated by ethanol, with 
α1β1γ2S and α1β1 receptors remaining unaffected. However, more recent studies have 
suggested that the activity of protein kinases acts to modulate GABAA receptor responses to 
ethanol. Studies of knock-out mice have shown that deletion of PKCγ abolishes the ethanol-
mediated potentiation of GABAergic IPSCs recorded from hippocampal neurons whereas, in 
PKCε-/- mice, IPSCs become sensitive to potentiation by ethanol, an effect which was not 
observed in wild-type littermates (Proctor et al., 2003). The negative modulatory effects of 
PKCε are consistent with studies by Qi et al. (2007), who showed that, in HEK293 cells 
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expressing α1β2γ2L GABAA receptors, inhibition of a stably transfected ATP-analog sensitive 
mutant of PKCε caused a significant increase in ethanol potentiation, an effect which was 
dependent upon phosphorylation at γ2L S327. A further study has also implicated PKCδ in the 
modulation of ethanol potentiation, with results showing that PKCδ-/- mice display reduced 
intoxication when administered ethanol. Furthermore, this study also reported that, in L(tk-) 
cells expressing α4β3δ GABAA receptors, inhibition of a stably expressed ATP-analog sensitive 
mutant of PKCδ results in a reduction of ethanol potentiation, indicating that, similar to PKCγ, 
PKCδ acts to positively modulate the actions of ethanol at GABAA receptors (Choi et al., 2008). 
Therefore, the opposing effects of different PKC isoforms upon the actions of ethanol at GABAA 
receptors indicates that the activity of ethanol can be modulated differently, depending on the 
expression patterns of different PKC isoforms. In addition, different PKC isoforms may also 
associate with different subsets of GABAA receptors within the same neuron, enabling ethanol 
responses to be spatially regulated.  
 
There is also a growing body of evidence that the activity of protein kinases can modulate the 
potentiating effects of at least some neurosteroids on both recombinant and native GABAA 
receptors (see Chapter 3). However, the results presented to date have been complex and 
often conflicting. For example, Leidenheimer and Chapell (1997) reported that, in Xenopus 
oocytes expressing α1β2γ2L GABAA receptors, the magnitude of potentiation elicited by 
THDOC was enhanced after PKC activation. These results were supported by further studies 
which showed that inhibition of PKC and/or PKA resulted in a reduction of neurosteroid 
sensitivity in neurons from both the hippocampus (Harney et al., 2003) and hypothalamus 
(Fáncsik et al., 2000). Collectively, these results indicated that the actions of neurosteroids at 
GABAA receptors can be positively modulated by the activity of protein kinases. However, 
additional studies have indicated, to the contrary, that protein kinases act to negatively 
modulate neurosteroid potentiation, with results from studies of both the lamina II neurons of 
the spinal cord (Vergnano et al., 2007) and the hypothalamic neurons of pregnant rats 
(Koksma et al., 2003) showing that enhancement of protein kinase activity causes a reduction 
in the neurosteroid sensitivity of GABAA receptors. Inconsistent results have also been 
reported regarding the involvement of specific protein kinases in modulating the actions of 
neurosteroids, for example, in the CA1 pyramidal neurons of the hippocampus, inhibition of 
PKC or PKA resulted in a concurrent decrease in neurosteroid sensitivity (Harney et al., 2003), 
however, in hypothalamic neurons inhibition of PKA had no such effect (Fáncsik et al., 2000).  
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In addition to protein kinases acting to modulate the activity of neurosteroids at GABAA 
receptors, neurosteroids have also been shown to alter the actions of protein kinases at the 
receptor. In the oxytocin neurons of the hypothalamus, PKC activation results in a reduction of 
the amplitude of sIPSCs, an effect which can be abolished by pre-treating neurons with 
allopregnanolone (Brussaard et al., 2000). This effect is thought to be important for the timing 
of oxytocin release during parturition, as when allopregnanolone levels are high during late 
pregnancy, the combination of increasing sIPSC decay times and preventing PKC-mediated 
decreases in sIPSC amplitude, ensures that a high level of inhibition is present in these 
neurons, preventing the premature firing of the oxytocin neurons (Brussaard et al., 2000). At 
parturition, oxytocin neurons become less sensitive to allopregnanolone modulation 
(Brussaard et al., 1997), resulting in the disinhibition of oxytocin neurons, the firing of which 
releases oxytocin to initiate parturition. The oxytocin then acts to enhance PKC activity which 
continues to reduce inhibition, allowing further release of oxytocin via a positive feedback 
mechanism (Brussaard et al., 2000).  
 
Given the potency and physiological importance of neurosteroids and protein kinases, it is of 
utmost importance to determine how they act together to regulate GABAergic inhibition in 
vivo. In addition, due to the lack of specificity for any particular GABAA receptor subtypes, 
phosphorylation is thought to constitute one of the main ways in which the neuron and brain 
region specific actions of neurosteroids are achieved. Therefore, due to the conflicting nature 
of the results obtained to date, the aim of this thesis was to investigate the relationship 
between neurosteroids and protein kinases at GABAA receptors in more detail.  
 
1.5 Thesis aims 
 
 To determine whether protein kinases act to modulate neurosteroid potentiation at 
α1β3γ2L GABAA receptors. 
 
 To investigate the involvement of specific protein kinases in the modulation of 
neurosteroid potentiation. 
 
 To identify the mechanism by which protein kinases act to modulate neurosteroid 
activity at GABAA receptors, with a particular focus on determining whether direct 
phosphorylation is required and if so, the subunits and/or residues which are involved. 
 
[66] 
 
 To determine whether, in the reverse situation, neurosteroids can modulate the 
actions of protein kinases at the GABAA receptor. 
 
 To investigate whether the actions of neurosteroids at extrasynaptic GABAA receptors 
are also modulated by protein kinases and to determine whether phosphorylation at 
specific loci is important for this effect.  
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Chapter 2 
 
Materials and Methods 
 
2.1 Molecular Biology 
 
2.1.1 cDNA plasmids 
cDNA plasmids encoding murine α1, α1Q241W, α4, β3, β3S408A, β3S409A, β3S408A,S409A, γ2L, 
γ2LS327A,S343A and δ GABAA receptor subunits have all been described previously (Moss et al, 
1991; Connolly et al., 1996; McDonald et al., 1998; Hosie et al., 2006; Hosie et al., 2009). These 
constructs consist of the cDNA of interest cloned into the plasmid vector, pRK5. Additional 
mutant constructs used in this project were generated in collaboration with Mr. Mike Lumb 
using the method outlined below.  
 
2.1.2 Site-directed mutagenesis 
In order to generate the mutant cDNA construct encoding murine α4S443A, site-directed 
mutagenesis was carried out using plasmids containing the wild-type α4 gene insert. 
Appropriate oligonucleotides containing the S443A point mutation were designed and 
obtained from MWG (see Table 2.1). These primers were then used to amplify the relevant 
DNA product using the polymerase chain reaction (PCR).  
 
Construct Primer Sequence 
α4
S443A
 
Forward gccactcgccctgcatttggatctag 
Reverse agctgaccccaaagaagctggc 
 
Table 2.1 Primers used for PCR reactions 
 
The PCR reaction mixture contained: 1µl DNA of interest (10μg/ml stock) 
     0.25µl Forward primer (100pM/µl) 
     0.25µl Reverse primer (100pM/µl) 
     10µl HF buffer 
     1µl dNTP mix 
     0.5µl PHusion enzyme (New England Biolabs) 
     37µl H2O (to make a total volume of 50µl per reaction) 
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The PCR was carried out in a PTC-200 DNA engine thermal cycler (MJ Research) using the 
following protocol: 98°C for 30s, followed by 35 cycles of 98°C for 10s (denaturation), 63°C for 
30s (annealing) and 72°C for 5 min (extension) and lastly, a final extension step of 72°C for 5 
min.  
 
PCR products were run on 1% agarose gels containing 1µl/100ml ethidium bromide and 
successful PCR was denoted by the presence of a single band approximately 7kb in size. The 
band was excised from the gel and the DNA purified using the QIAquick Gel Extraction Kit 
(Qiagen). This was followed by a ligation step in which 10µl of DNA + 6µl H2O were incubated 
at 70°C for 5 min then placed on ice to prevent the DNA re-annealing. 2µl of T4 ligase buffer 
and 1µl of T4 kinase enzyme (New England Biolabs) were then added and the reaction mixture 
was incubated at 37°C for 30 min. Finally, 1µl of T4 ligase enzyme (New England Biolabs) was 
added and the mixture was then incubated at room temperature for 15 min before placing at 
4°C overnight.  
 
The ligation product was transformed into chemically competent XL1Blue E. coli bacteria by 
heat shocking at 42°C for 45s. Transformed bacteria were plated on LB agar containing 
50µg/ml ampicillin and incubated overnight at 37°C to allow bacterial colonies to grow. 
Bacterial colonies were then selected and grown overnight in LB medium to allow the bacteria 
to multiply. The mutant plasmid DNA was purified using the QIAprep Spin Miniprep Kit and 
fully sequenced (DNA sequencing service, The Wolfson Institute for Biomedical Research, UCL) 
to ensure that the mutation of interest had been incorporated into the DNA and that no 
additional, ectopic mutations were present. Once the mutation had been verified, the 
remaining bacterial stock was amplified in 200ml of LB medium overnight at 37°C and the DNA 
purified using the PureYield Plasmid Maxiprep System (Sigma). The concentration (OD at 
260nm) and quality (OD 260nm/OD 280nm and OD at 320nm) of the resulting DNA was 
determined using a spectrophotometer (Eppendorf). If acceptable results were obtained, the 
DNA was used for transfection of HEK293 cells.  
 
2.2 Cell culture 
 
2.2.1 HEK293 Cells 
HEK293 cells were cultured in Dulbecco’s modified Eagle medium (DMEM; Gibco) 
supplemented with 10% v/v foetal calf serum (FCS), 2mM glutamine, 100U/ml penicillin G, 
100µg/ml streptomycin and incubated at 37˚C in 95% air/5% CO2. Cells were passaged two to 
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three times per week; once they had reached approximately 70-80% confluency. For passage, 
cells were washed with 5ml Hank’s Balanced Salt Solution (HBSS; Gibco) and subsequently 
incubated with 2ml 0.05% w/v trypsin-EDTA (Gibco) until they detached from the culture dish. 
Cells were then suspended in 10ml of culture medium to quench the trypsin, transferred to a 
50ml falcon tube and centrifuged for 5 min at 1000rpm. Following removal of the supernatant, 
the cells were re-suspended in 5ml of culture medium and triturated using a fire polished 
Pasteur pipette to ensure a single cell suspension. Cells were then re-plated at the appropriate 
dilution onto new 10cm plates (Nunc) containing 10ml of fresh culture medium.  
 
2.2.2 Hippocampal neurons 
The hippocampi of postnatal day 5 (P5) Sprague-Dawley rats were removed and placed into ice 
cold HBSS (+Ca2+, +Mg2+; Gibco). The tissue was then transferred into a 35mm dish (Sterilin) 
containing 5ml trypsin (0.1% w/v; Sigma) and incubated at 37˚C in 95% air/5% CO2 for 10 min. 
The digested tissue was then placed into a solution of HBSS supplemented with BSA (1mg/ml) 
and 5% v/v FCS and triturated using a Pasteur pipette. Tissue was then centrifuged for 30s at 
1000rpm, before removing 1.5ml of supernatant into a fresh Falcon tube. A further 1.5ml of 
supplemented HBSS solution was then added to the remaining tissue and triturated once again 
with a medium bore fire-polished Pasteur pipette. Centrifugation was repeated as before and 
once again, 1.5ml of supernatant was removed and placed with that transferred previously. 
This process was repeated once more, with trituration being carried out with a narrow bore 
(approximately one third) Pasteur pipette. Once the final 1.5ml of supernatant had been 
transferred to the Falcon tube, this accumulated cell suspension was then centrifuged for 5 
min at 1000rpm. The supernatant was discarded and the cell pellet resuspended in Neurobasal 
medium supplemented with 5% v/v FCS, 0.5mM glutamine and 2% B27 (using 1ml per 
hippocampus isolated). A final trituration was then completed using a sterile quill tube, before 
plating the cells onto poly-D-lysine (100μg/ml made up in borate buffer) coated coverslips 
(0.5ml cell suspension per coverslip), prewashed with FCS. Coverslips contained within 
individual 35mm culture dishes (Nunc) were then incubated at 37˚C in 95% air/5% CO2  for 1 
hour after which a further 1ml of Neurobasal medium (supplemented as before) was added. 
After 3 days in vitro (DIV) cells were treated with an anti-mitotic solution containing 5-
fluorodeoxyuridine, uridine and cytosine-arabinofuranoside (final concentration = 100nM of 
each compound) for 5-6 hours, before washing and adding fresh supplemented Neurobasal 
medium.  
 
 
[70] 
 
2.3 Transfection 
 
2.3.1 Calcium phosphate precipitation 
Cells were transfected with 1µg of cDNA expression plasmid encoding each subunit plus 1µg of 
plasmid encoding enhanced green fluorescent protein (eGFP). The reaction mixture was as 
follows (per 35mm dish to be transfected):  
4µg cDNA plasmid mixture (3 x subunit plasmids + eGFP) 
    20µl CaCl2 (340mM, sterile filtered) 
24µl 2 x HBSS (280mM NaCl, 2.8mM Na2HPO4, 50mM HEPES, 
pH 7.2, sterile filtered) 
 
The transfection mixture was vortexed and immediately pipetted onto HEK293 cells plated at 
least 2 hours previously, at 20% confluency, onto poly-L-lysine (100µg/ml) coated coverslips. 
Cells were then used for electrophysiology 24-48 hours later.  
 
Alternatively, cells for biochemistry experiments were plated in 6cm culture dishes (Nunc) at 
approximately 50% confluency and transfected with 3μg of each subunit cDNA per plate (9μg 
total cDNA), with the other components of the reaction mixture being scaled up accordingly.  
 
2.4 Electrophysiology 
 
2.4.1 Whole-cell patch clamp recording 
Coverslips with cells attached were transferred into the recording chamber and perfused 
continuously with Krebs solution containing: 140mM NaCl, 4.7mM KCl, 1.2mM MgCl2, 2.52mM 
Glucose, 11mM HEPES and 5mM CaCl2 (pH  7.4), pre-filtered through Whatman paper (number 
1). Patch electrodes were fabricated from thin-walled borosilicate glass (1.5mm internal 
diameter; Havard apparatus) and filled with an internal solution containing: 120mM KCl, 1mM 
MgCl2, 11mM EGTA, 10mM HEPES, 1mM CaCl2 and 4mM ATP (pH 7.11; sterile filtered). The 
osmolarity of the Krebs and internal patch electrode solutions were confirmed as 300 ± 20 
mOsm using a vapour pressure osmometer (Wescor). 
 
An Axopatch 200B amplifier (Axon Instruments) was used to record whole-cell membrane 
currents from HEK293 cells viewed under a Nikon Eclipse TE300 microscope at 200-400X 
overall magnification. Transfected cells were identified by the presence of eGFP using the 
Nikon epifluorescence unit. Recordings were routinely made from single or occasionally 
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doublets of cells to ensure successful voltage clamp and to avoid errors associated with 
recording from groups of cells which are electrically-coupled via gap junctions. Cells were 
voltage clamped at -10mV and the membrane currents recorded were filtered at 3kHz (8 pole 
Bessel filter), digitized via a Digidata 1322A series (Axon Instruments) and viewed on a PC using 
Clampex 9.2 software (Axon Instruments). 
 
Once the patch electrode had been placed into the bath solution the resistance could be 
monitored using the seal test facility in Clampex 9.2. Electrodes used for recording exhibited 
resistances of 4-5MΩ. At this stage, the residual patch electrode capacitance transients were 
reduced using the fast capacitance compensation. The electrode was then manoeuvred into 
the correct position on the surface of the cell using a Sutter MP-285 micromanipulator. After 
whole-cell patch configuration had been achieved, the seal test facility was used to optimize 
the series resistance compensation and whole-cell capacitance before recording commenced. 
The resting membrane potential of the cell was determined as an indication of cell health. Cells 
selected for recording exhibited resting membrane potentials of between -15mV and -40mV. 
 
Once the whole-cell configuration had been established, a period of at least 2 min was allowed 
in order for the contents of the patch electrode to dialyse into the cell. Membrane currents in 
response to brief (3s) applications of GABA or GABA + THDOC were recorded using the gap 
free recording mode in pClamp 9.2 and stored for further analysis. Between each acquisition a 
voltage step protocol, consisting of three 100ms, -10mV steps, was used to give a 
measurement of the series resistance. Series resistance is a measure of the resistance resulting 
from the electrode and cell membrane in ‘series’ and changes can lead to errors in voltage 
clamping, resulting in inaccuracy of the membrane currents recorded. Therefore changes >15% 
in the currents recorded from the voltage step protocol resulted in cessation of the recording 
and exclusion of the data from subsequent analysis.  
 
2.4.2 Drug application 
Rapid application of drugs was achieved by the use of a modified U-tube system (see Fig. 2.1) 
positioned approximately 500μm from the cell. Under normal conditions (no drug applied), 
solenoid A was open allowing cells to be continuously perfused with Krebs solution via the 
auxiliary tube. During this time the U-tube was perfused with water (to preserve drug 
solutions) and, whilst solenoid B was open, the flow was powered by a vacuum pump, 
preventing water from exiting through the hole at the apex of the U-tube. Immediately before 
drug application, the water was replaced by the appropriate drug diluted in Krebs solution. To 
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apply the drug, firstly solenoid A was closed to stop the continuous flow of Krebs solution. 
Secondly, solenoid B was closed to isolate the vacuum, resulting in the drug solution exiting 
the hole in the U-tube and flowing rapidly over the cell undergoing recording. After a pre-
determined period of time (usually 3s), both solenoids were re-opened to reverse the flow of 
drug and to re-instigate the flow of Krebs from the auxiliary tube, resulting in a rapid ‘wash-off’ 
of the drug from the cell. Using the U-tube system, the onset of the drug response was 
approximately 100-150ms.   
 
 
 
 
Figure 2.1 Schematic diagram of the modified U-tube system 
The U-tube system was used to rapidly apply drugs to the recorded cell. The flow of Krebs solution via 
the auxiliary tube and the application of drug solution via the U-tube were controlled by solenoids A and 
B, respectively, which were in turn controlled electronically using a control panel interface.  
 
 
2.4.3 Protein kinase inhibition/activation experiments 
To monitor the effects of protein kinase inhibition/activation on neurosteroid potentiation the 
cell was first exposed to pulses of EC20 GABA until stability was reached with regard to 
response amplitude, then to two further brief applications of EC20 GABA. The EC20 GABA 
concentration was pre-determined by constructing a GABA concentration-response curve in 
HEK293 cells expressing the same GABAA receptor subunits as those utilised in the main 
experiment. New curves were constructed regularly to adjust for any drifts in EC20 which may 
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occur, and were always repeated when a new batch of HEK293 cells were used. This allowed 
the variation in potentiation due to changes in agonist EC20 to be minimized. EC20 
concentrations were 1-3µM for α1β3γ2L and 30-100nM for α4β3δ GABAA receptors.  
 
The two applications of EC20 GABA were separated by a 2 min interval, allowing the baseline 
response of the cell to be determined and to ensure the baseline response of the cell was 
stable. The neurosteroid-mediated potentiation was then measured by co-applying EC20 GABA 
with 50nM THDOC (Sigma Aldrich) in 2 successive applications, again separated by a 2 min 
interval. EC20 GABA alone was then re-applied to ensure the cell’s response had returned to 
baseline. This usually occurred within 4 min (see Fig. 3.1) and recording was ceased and the 
cell discarded from analysis if the responses did not return to baseline levels within this time. 
The cell was then perfused with the appropriate protein kinase inhibitor/activator (see Table 
2.2), diluted in Krebs solution, applied continuously via the auxiliary tube. The exceptions to 
this were PKG inhibitor, KT5823 and PKA activator, cAMP, as these drugs were not suitable for 
external perfusion and so were instead diluted to the appropriate concentration within the 
patch electrode internal solution and applied intracellularly.  
 
Drug 
Kinase 
Targeted 
Action Source 
Stock 
Concentration/Solvent 
Final 
Concentration 
Staurosporine 
Broad 
spectrum 
Inhibitor Calbiochem 1mM in DMSO 200nM 
Bisindolylmaleimide 
I 
PKC Inhibitor Calbiochem 1mM in DMSO 500nM 
Myristoylated PKA 
inhibitor peptide 
14-22 amide 
PKA Inhibitor Biomol 500μM in H2O 500nM 
KT5823 PKG Inhibitor Calbiochem 3mM in DMSO 3μM 
Phorbol-12-
myristate-13-
acetate (PMA) 
PKC Activator Calbiochem 1mM in DMSO 100nM 
cAMP PKA Activator Sigma 10mM in H2O 300μM 
 
Table 2.2 Protein kinase inhibitors and activators 
 
During the treatment period, the cell’s response to EC20 GABA alone was monitored every 2 
min in order to assess the effects of the inhibitor/activator on the receptor’s responses to 
GABA alone. Once the cell had been treated for the designated amount of time (see Chapters 
3-5), the neurosteroid-mediated potentiation was re-measured with 2 further co-applications 
of EC20 GABA + 50nM THDOC, followed by 2 applications of EC20 GABA alone to, once again, 
ensure that the cell’s response returned to baseline.  
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2.4.4 Data analysis 
The recorded whole-cell GABA currents were analysed in Clampex 9.2. Peak responses were 
measured by subtracting the baseline holding current from the peak amplitude of the 
response. For protein kinase inhibitor/activator experiments, current responses were 
normalized to the first response elicited by EC20 GABA, recorded at t = 2 min.  
 
The potentiation elicited by neurosteroid (see Chapters 3-5) was calculated by dividing the first 
potentiated response (induced by co-application of EC20 GABA + 50nM THDOC) by the cell’s 
preceding response to EC20 GABA alone and transformed to a percentage. In doing this, any 
changes in the receptor’s response to agonist alone, caused by the protein kinase 
inhibitor/activator treatment, could be separated from the effects of the treatment on the 
neurosteroid-mediated potentiation.  
 
All dose-response curves were constructed by plotting mean peak response amplitude against 
GABA concentration and fitting this data with the Hill equation: 
 
I = 1/(1 + (EC50/[GABA])
n) 
 
Where I = GABA-activated current, EC50 = concentration of GABA inducing a current response 
50% of the maximal GABA-activated current and n = Hill coefficient.  
 
All graphical representations of the data shown were plotted using Origin version 6.0 
(Microcal). Statistical analyses were carried out using GraphPad Instat version 3 employing 
either a student’s t-test (for comparing two values) or an ANOVA (for three or more values) 
followed by an appropriate post hoc test to compare selected data sets. Data from the same 
cell was treated as ‘paired’ whereas data obtained from different cell populations was 
considered ‘unpaired’. 
 
2.5 Biochemistry 
 
2.5.1 Preparation of cell lysates 
Post-transfection (24-48 hrs), HEK293 cells were treated with 50nM THDOC or 100nM PMA for 
the appropriate length of time (see Chapter 4). Before treatment, the culture medium was 
replaced with Krebs solution (see Electrophysiology 2.4) pre-warmed to 37°C. Once the 
treatment period was complete, the dishes of cells were placed on ice. Cells were washed 
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twice with ice-cold phosphate buffer solution (PBS) containing 20nM Calyculin A (Calbiochem). 
Cells were then lysed using RIPA lysis buffer containing: 150mM NaCl, 50mM Tris pH 8.0, 5mM 
EDTA, 1% v/v NP-40, 0.5% w/v deoxycholate, 0.1% SDS, supplemented with protease inhibitors 
(Phenylmethyl sulfonyl fluoride and Benzamidine) and phosphatase inhibitors (20mM NaF, 
10mM Sodium pyrophosphate and 20nM Calyculin A). The lysates were transferred to 
individual Eppendorf tubes and sonicated to ensure complete lysis. Lysates were then 
centrifuged (14000rpm, 5 min) at 4°C to sediment the cell debris and the supernatants 
transferred to fresh Eppendorf tubes and stored on ice. The concentration of protein present 
in the sample was measured using the BCA Protein Assay (Thermo Scientific).  
 
2.5.2 Polyacrylamide gel electrophoresis 
Samples (20µg protein) were boiled in SDS-PAGE buffer and loaded onto 10% polyacrylamide 
gels made up in Tris-HCl with 10% SDS and polymerized using TEMED and 10% APS (Sigma 
Aldrich). A molecular weight marker (GE Healthcare) was run alongside the samples in order to 
estimate the size of the proteins present. Gels were run at 300mA for 50 min. The gels were 
then transferred onto Hybond nitrocellulose transfer membrane (Amersham) using a semi-dry 
blotter (Camlab) at 0.8mA/cm2 of transfer membrane for 110 min. 
 
2.5.3 Western blotting 
Following protein transfer, membranes were blocked in either 5% milk or 0.2% BSA made up in 
TBST (Tris buffered saline + 0.1% v/v Tween) for 60 min. Membranes were then incubated with 
primary antibody (diluted in appropriate blocking solution; see Table 2.3) overnight at 4°C on 
an orbital shaker. On the following day the membranes were washed for 3 x 10 min in TBST 
and then incubated with secondary, HRP-conjugated antibody (diluted in TBST; see Table 2.3) 
for 60 min at room temperature on an orbital shaker. Membranes were then washed for 3 x 10 
min and imaged using the ECL detection system (GE Healthcare).  
 
Primary 
Antibody 
Epitope Location Species Source Dilution Used 
Anti-β3 
Intracellular loop 
(TM3-TM4) 
Rabbit Millipore 1:1000 in 5% milk 
Anti-Phosphoβ3 
Phosphorylated 
S408/S409 
Rabbit 
Gift from Dr. J 
Jovanavic 
1:1000 in 0.2% BSA 
Secondary 
Antibody 
Target Species Source Dilution Used 
Anti-rabbit HRP Rabbit Donkey GE Healthcare 1:2500 in TBST 
 
Table 2.3 Antibodies used for Western blotting 
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2.5.4 Data analysis 
Protein levels were quantified using a GS-800 densitometer. To determine the amount of 
phosphorylated β3 subunit, each reading was normalized to that from the corresponding band 
in the total β3 Western blot. For comparison purposes these values were then normalized to 
the levels of basal phosphorylation (in untreated cells) to determine whether any changes had 
taken place after treatment.  
 
2.6 Immunocytochemistry 
 
2.6.1 Immunolabelling of cultured hippocampal neurons 
After at least 7 DIV, hippocampal neurons were treated with either 10μM allopregnanolone or 
100nM diazepam (both obtained from Sigma Aldrich) and incubated at 37°C in 95% air/5% CO2 
for 1 hour along with the untreated control cells. After treatment, cells were washed twice in 
ice cold PBS and fixed in 4% v/v paraformaldehyde (PFA) for 15 min at room temperature. The 
fixative was then washed twice in PBS and quenched with 50mM NH4Cl for 10 min. Following 
two further washes in PBS, cells were then washed once with PBS supplemented with 10% v/v 
FCS and 0.4% w/v BSA. Cells were then incubated with primary antibody (see Table 2.4), 
diluted in the same supplemented PBS solution, for 45 min at room temperature. Following 
three washes with PBS (+ 10% v/v FCS, + 0.4% w/v BSA), cells were incubated with secondary 
antibody (see Table 2.4), diluted in the same buffer, for 45 min at room temperature, during 
which cells were protected from light using a foil lid. Finally, cells were washed three times in 
PBS and fixed to glass slides using 40μl pre-melted glycerol and stored at 4°C for imaging the 
following day. 
 
Primary 
Antibody 
Epitope Location Species Source Dilution Used 
Anti-α1 
Extracellular N-
terminus 
Guinea Pig Gift from Fritschy 1:200 
Secondary 
Antibody 
Target Species Source Dilution Used 
FITC conjugated 
anti-guinea pig  
Guinea Pig Donkey Jackson 1:100 
 
Table 2.4 Antibodies used for immunocytochemistry 
 
2.6.2 Image acquisition 
Images were acquired using a Zeiss laser-scanning confocal microscope (LSM 510 Meta), with a 
40x oil immersion objective. Light with a wavelength of 543nm was used to visualize 
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fluorescein isothiocyanate (FITC) fluorescence and images were captured and stored using a 
computer interface running Zeiss LSM confocal software (version 3.0).  
 
2.6.3 Image analysis 
Images were analysed using Igor Pro (version 5.02) with a Batch Image Processor plugin 
specifically designed for analysing fluorescent puncta (Bergsman et al., 2006). The number of 
puncta present along the entire length of dendrite was quantified for each neuron analysed. 
The length of the dendrites were then determined using the measuring facility in the LSM 
Image Browser (version 3.0), allowing the mean puntca density per μm of dendrite to be 
calculated for each neuron.  
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Chapter 3 
 
Neurosteroid modulation at GABAA receptors: regulation by protein 
kinases 
 
3.1 Introduction 
GABAA receptors are subject to modulation by a number of endogenous compounds, which, by 
acting to alter receptor function, have a significant impact on neural activity. Neurosteroids 
and protein kinases are among the most potent modulators of the GABAA receptor, which, 
when acting individually, can enhance or depress receptor function depending on the type of 
neurosteroid or kinase present and the subunit combination of the receptor (Belelli and 
Lambert, 2005; Moss and Smart, 1996). However, in vivo, these agents cannot be treated as 
discrete modulators of the GABAA receptor as it is more likely that they will act in concert to 
achieve a precise fine-tuning of inhibitory neurotransmission.  
 
Some studies have indicated that the activity of protein kinases can modulate the potentiating 
effects of at least some neurosteroids on both recombinant and native GABAA receptors. 
Leidenheimer and Chapell (1997) reported that for Xenopus oocytes expressing recombinant 
α1β2γ2L GABAA receptors, the potentiation of GABAA receptor mediated currents by the 
naturally-occurring neurosteroid, tetrahydrodeoxycorticosterone (THDOC) was enhanced by 
the activation of PKC, indicating that receptor phosphorylation may alter the modulatory 
effects of neurosteroids. These results were supported by further studies which showed that 
inhibition of PKC and/or PKA resulted in a reduction of neurosteroid sensitivity in neurons from 
both the hippocampus (Harney et al., 2003) and hypothalamus (Fáncsik et al., 2000). However, 
whilst many of the studies conducted to date agree that the activity of protein kinases has at 
least some modulatory effect on the activity of neurosteroids at GABAA receptors, the results 
presented are complex and often conflicting. For example, the aforementioned studies 
collectively showed that the magnitude of neurosteroid potentiation is positively regulated by 
the activity of protein kinases. In contrast, additional studies in both the lamina II neurons of 
the spinal cord (Vergnano et al., 2007) and the hypothalamic neurons of pregnant rats 
(Koksma et al., 2003) indicated that an inverse relationship exists between neurosteroids and 
protein kinases, with results showing that enhancement of protein kinase activity causes a 
reduction in the neurosteroid sensitivity of GABAA receptors. Inconsistent results have also 
been reported regarding the involvement of specific protein kinases in modulating the actions 
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of neurosteroids. Harney et al. (2003) reported that, in the CA1 pyramidal neurons of the 
hippocampus, inhibition of PKC or PKA resulted in a concurrent decrease in neurosteroid 
sensitivity. However, studies of hypothalamic neurons have shown that, although inhibition of 
PKC exhibited similar effects to those seen in hippocampal neurons, inhibition of PKA did not 
affect neurosteroid activity (Fáncsik et al., 2000).  
 
The reason for these discrepancies is currently unclear, but one factor which may affect the 
relationship between neurosteroids and protein kinases is the subunit combination of the 
GABAA receptor. Although the neurosteroids appear to display only modest changes in potency 
across most GABAA receptor subtypes tested (Belelli et al., 2002; Herd et al., 2007), 
phosphorylation, by protein kinases, has been shown to differentially alter GABAA receptor 
function, depending on the subunits present within the receptor complex (see Chapter 1; Moss 
and Smart, 1996). Therefore, when acting together, it could be hypothesized that protein 
kinases may modulate the activities of neurosteroids at the GABAA receptor in a manner that is 
dependent upon the receptor isoform. This may explain the variation in prior results, as many 
of the studies carried out to date have utilized different neuronal populations, which are likely 
to express a mixture of different subsets of GABAA receptor subunits. Therefore, in order to 
reduce the complexity associated with neurons and ultimately construct a clearer picture of 
how protein kinases modulate the activity of neurosteroids, the experiments in this 
investigation were carried out using HEK293 cells expressing specific recombinant GABAA 
receptors.  
 
The HEK293 cell line is epithelial in origin but has been extensively used as a tool to study the 
pharmacology and physiology of heterologously-expressed GABAA receptors. These cells can 
be readily transfected with cDNAs encoding for recombinant GABAA receptors, allowing their 
pharmacological profiles to be studied using whole-cell patch clamp electrophysiology 
(Thomas and Smart, 2005). Due to their non-neuronal lineage, HEK293 cells are not thought to 
express endogenous GABAA receptors (Thomas and Smart, 2005) making it possible to control 
the subunit composition of the receptors expressed in these cells, thus allowing functional 
analyses of the roles of different receptor subunit isoforms. To date, only one study has 
examined the relationship between neurosteroids and protein kinases at GABAA receptors 
containing defined subunits, with Leidenheimer and Chapell (1997) investigating the 
modulation of neurosteroid activity using α1β2γ2L GABAA receptors expressed in Xenopus 
oocytes. Interestingly, it has been shown that the effects of phosphorylation at β2 subunit-
containing GABAA receptors differ from those observed at receptors containing other β subunit 
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isoforms (see Chapter 1; Moss and Smart, 1996). Therefore, the initial aims of these 
experiments were to establish whether neurosteroid-mediated potentiation of α1β3γ2L 
subunit-containing GABAA receptors could also be modulated by protein kinases and if so, 
which protein kinase(s) were responsible for this modulation. It was anticipated that these 
results could then be compared to those obtained previously from the α1β2γ2L GABAA 
receptors, potentially exposing any differences between the co-modulatory effects of 
neurosteroids and protein kinases at these different GABAA receptor subtypes.  
 
3.2 Results 
In order to examine the effects of phosphorylation, by protein kinases, on the potentiation of 
GABAA receptor function by neurosteroids, HEK293 cells were transfected to express α1β3γ2L 
subunit-containing GABAA receptors. Cells were transfected using calcium phosphate 
precipitation (see Methods and Materials) with expression plasmids encoding each receptor 
subunit in a 1:1:1 ratio and co-transfected with plasmid DNA for the enhanced green 
fluorescent protein (eGFP), to enable the identification of transfected cells. Co-expression of α, 
β and γ subunits has been shown to result in the formation of functional GABAA receptors at 
the cell surface (Sigel et al., 1990; Verdoorn et al., 1990; Angelotti et al., 1993). It is also known 
that α and β subunits alone can form functional receptors (Levitan et al., 1988; Sigel et al., 
1990; Verdoorn et al., 1990; Angelotti et al., 1993), however it is thought that the majority of 
receptors expressed here will contain α and β subunits in combination with γ as this 
investigation, along with previous studies, have shown that when equal proportions of α, β 
and γ subunits are transfected, αβγ heteromers are preferentially formed, demonstrated by 
their robust sensitivity to the benzodiazepine, diazepam  (Angelotti et al., 1993), a modulation 
which requires the presence of a γ subunit within the receptor complex (Pritchett et al., 1989; 
Sigel et al., 1990; Sigel and Buhr, 1997). In contrast, other studies have reported that a 1:1:10 
ratio of α:β:γ cDNAs is optimal for the formation of αβγ heteromers (Boileau et al., 2002), 
however, this was not necessary in the present study.  
 
Whole-cell patch clamp electrophysiology was used to assess the magnitude of neurosteroid-
mediated potentiation before and after cell treatment with compounds to inhibit intracellular 
protein kinase activity. Peak currents were recorded in response to brief (3s) applications of 
either EC20 (the concentration eliciting 20% of the maximal GABA response) GABA alone 
(baseline control responses) or EC20 GABA co-applied with 50nM of the neurosteroid, 
tetrahydrodeoxycorticosterone (potentiated GABA responses). Tetrahydrodeoxycorticosterone 
(THDOC) is synthesised within neurons and glial cells in the CNS (Patte-Mensah et al., 2003; 
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Tsutsui, 2003; Agίs-Balboa et al., 2006; Saalmann et al., 2007) and is one of the most potent 
modulators of the GABAA receptor in vivo (Lambert et al., 2001). THDOC can potentiate GABAA 
receptor responses at low nanomolar concentrations (Morrow et al., 1987; Paul and Purdy, 
1992). Levels of neurosteroids present within the brain are thought to fluctuate between 3 and 
10nM but can rise in excess of 50nM during acute stress and may be increased to around 
100nM during pregnancy (Purdy et al., 1991; Paul and Purdy, 1992; Cheney et al., 1995; Weill-
Engerer et al., 2002). Therefore, 50nM THDOC was chosen as it is within the concentration 
range estimated in vivo and so its effects at the GABAA receptor are physiologically relevant. At 
this concentration neurosteroids act to potentiate GABAA receptor currents, with 
concentrations much larger than this, in the region of 1μM and above, required to induce 
direct activation of the receptor in the absence of agonist. Therefore, this investigation was 
solely focussed on the more physiological potentiating actions of THDOC.  
 
3.2.1 THDOC-mediated potentiation at α1β3γ2L GABAA receptors is decreased after 
protein kinase inhibition 
To investigate whether neurosteroid-mediated potentiation could be modulated by protein 
kinases in the HEK293 heterologous expression system, cells were treated with staurosporine, 
a broad-spectrum protein kinase inhibitor. Staurosporine acts to inhibit protein kinase activity 
by binding to the ATP-binding site (Meggio et al., 1995; Lawrie et al., 1997); the binding of ATP 
is crucial for the activity of protein kinases and due to the ATP-binding site being relatively 
conserved, staurosporine can inhibit a number of protein kinases (Meggio et al., 1995; 
Karaman et al., 2008). A major advantage of using staurosporine is that it is cell permeable, 
which allows the potentiation induced by THDOC to be measured before and after treatment 
within the same cell, eliminating the variation in results which could arise when comparing 
separate treated and untreated populations of cells. For each cell, the baseline response to 
EC20 GABA alone and potentiated response after co-application of EC20 GABA and 50nM THDOC 
were established under basal cell conditions (i.e. before protein kinase inhibitor treatment; Fig. 
3.1A). The cell was then treated with 200nM staurosporine, applied continuously via the bath 
perfusion. Staurosporine has been shown to inhibit protein kinase activity at nanomolar 
concentrations, with IC50 values ranging from 3nM for PKC to 8nM for PKA (Rüegg and Burgess, 
1989; Meggio et al., 1995) and therefore, 200nM was used to ensure full inhibition of protein 
kinase activity. All responses were normalised to the peak current of the first EC20 GABA-
activated response, recorded 2 min after achieving the whole-cell recording configuration 
(designated as t = 0). 
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During the treatment period the cell’s response to EC20 GABA was monitored every 2 min in 
order to examine the effect of the staurosporine treatment on the receptor’s response to 
GABA alone. The effects of phosphorylation at the GABAA receptor are well documented with a 
number of studies showing that phosphorylation can result in both enhancement and 
depression of the GABA-activated current, depending on the protein kinase present and the 
subunit combination of the receptor (Moss and Smart, 1996). However, in the current study, 
inhibition of protein kinase activity by staurosporine did not significantly alter the receptor’s 
response to EC20 GABA; both untreated and staurosporine treated cells showed no change in 
the mean peak GABA-activated current recorded at 32 min compared to that recorded at 2 
min (change = 5.1 ± 8.8% and 4.1 ± 9.1%, respectively, mean ± s.e.m., P > 0.05; n = 5-6; Fig. 
3.1B; at t = 0 min, GABA-activated response = 100%). Previous studies of β3 subunit-containing 
GABAA receptors have revealed that phosphorylation by PKA and PKC have opposing effects on 
receptor function; PKA-mediated phosphorylation has been shown to enhance GABA-activated 
current (McDonald et al., 1998) whereas phosphorylation by PKC results in a reduction in the 
magnitude of receptor responses to agonist (Brandon et al., 2000). It is thought that both PKC 
and PKA are present and active at GABAA receptors expressed in HEK293 cells, therefore, 
assuming that the receptors are basally-phosphorylated by both protein kinases under these 
conditions, it is possible that inhibition of both PKA and PKC simultaneously by staurosporine 
may mask the effects of each individual protein kinase, resulting in no overall change in the 
EC20 GABA-activated current, as seen in this study. 
 
After 14 min of staurosporine treatment the baseline and potentiated responses were re-
measured. To allow a direct comparison of the potentiation before and after staurosporine 
treatment, each potentiated response was normalised to the cell’s preceding response to EC20 
GABA alone. Control experiments carried out in cells which remained untreated for the 
duration of the recording showed a negligible change in the potentiation elicited by 50nM 
THDOC (change in potentiation = 2.5 ± 7.9%; n = 6). In contrast, cells treated with 
staurosporine exhibited a significant decrease in THDOC-mediated potentiation of 54.8 ± 9.1% 
(P < 0.05, paired t-test; n = 5; Fig. 3.1A). However, the potentiation was not completely 
abolished with 50nM THDOC still enhancing the EC20 GABA-activated response by 45.5 ± 12.7% 
after staurosporine treatment (Fig. 3.1A). This indicates that THDOC-mediated potentiation of 
recombinant α1β3γ2L GABAA receptors is modulated by, but does not require activated 
protein kinases.  
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Figure 3.1 Staurosporine decreases THDOC-mediated potentiation at α1β3γ2L GABAA 
receptors  
(A) Mean peak currents recorded from HEK293 cells expressing α1β3γ2L GABAA receptors in response to 
EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells either remained untreated 
for the duration of the recording (upper panel) or were treated with 200nM staurosporine (lower panel; 
as indicated by light blue shading). All responses were normalised to the peak current of the first EC20 
GABA-activated response, recorded 2 min after achieving the whole-cell recording configuration, 
designated as t = 0 (= 100%). Example whole-cell currents show the potentiation elicited by 50nM 
THDOC (grey bar) before and after staurosporine treatment (light blue bar). Current traces are 
representative of recordings at the time points indicated. Bar chart shows the potentiation of EC20 
GABA-activated currents by 50nM THDOC in untreated cells (grey bars, measured at 6 min and 26 min, 
respectively; n = 6) or in treated cells before (black bar) and after (light blue bar) 200nM staurosporine 
treatment (n = 6). (B) Bar chart showing the change in peak receptor response elicited by EC20 GABA in 
untreated cells (UT, black bar) or cells just treated with 200nM staurosporine (light blue bar). Change 
was measured between 2 min (before treatment) and 32 min (after treatment or at corresponding time 
points in untreated cells). Responses were normalised to the peak current recorded at 2 min. All data 
points represent mean ± s.e.m. Significant results are indicated by * (P < 0.05, paired t-test). 
 
 
To ensure that the application of staurosporine did not cause a decrease in THDOC-mediated 
potentiation due to an alteration of the GABA concentration-response relationship, dose-
response curves were constructed before and after staurosporine treatment (Fig. 3.2). Lateral 
displacement of the GABA dose-response curve would result in a concurrent change in the 
potentiation of receptor currents by THDOC if the GABA EC20 was not adjusted and therefore 
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could explain the decreased potentiation seen after staurosporine treatment. However, this 
was not the case, with GABA EC50 values not differing significantly before and after 
staurosporine treatment (2.97 ± 1.15µM and 2.70 ± 0.74µM, respectively; P > 0.05; n = 5; Fig. 
3.2).  This suggests that the decrease in THDOC-mediated potentiation seen after 
staurosporine treatment was not due to a change in the concentration-response relationship 
for GABA. 
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Figure 3.2 Effect of staurosporine on the GABA dose-response relationship for α1β3γ2L 
GABAA receptors 
GABA dose-response curves were established in HEK293 cells expressing α1β3γ2L GABAA receptors 
before (black) and after (light blue) staurosporine treatment (n = 5). Each cell was exposed to brief 
applications of GABA, at varying concentrations (0.01-1000µM), before being treated with 200nM 
staurosporine for 14 min. After the treatment period the responses to the same concentrations of 
GABA, in each cell, were re-measured. All data points represent mean ± s.e.m.  
 
 
The GABAA receptor can be phosphorylated by a number of protein kinases, including serine-
threonine kinases: PKA, PKC, PKG and CaMKII as well as by protein tyrosine kinases (PTK) such 
as SRC and PYK (Moss and Smart, 1996; Brandon et al., 2002a). As a broad-spectrum inhibitor, 
staurosporine cannot distinguish between the effects of individual protein kinases. Therefore, 
in order to identify the roles of specific protein kinases in modulating potentiation of the 
GABAA receptor by neurosteroids, this experiment was repeated using specific protein kinase 
inhibitors.  
 
3.2.2 THDOC-mediated potentiation is modulated by PKC 
Previous studies examining the modulation of neurosteroid-mediated potentiation by protein 
kinases have yielded complex and often conflicting results. Therefore, this series of 
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experiments aimed to elucidate whether the activity of a specific protein kinase(s) was 
responsible for modulating the potentiation of α1β3γ2L GABAA receptors by neurosteroids. 
Many of the studies conducted to date have indicated a role for PKC in the modulation of 
neurosteroid-mediated potentiation (Herd et al., 2007) and therefore PKC was the initial focus 
of this investigation. PKC activity was inhibited by treating cells with 500nM 
bisindolylmaleimide I (Bis I; Fig. 3.3). Bis I is a potent and selective inhibitor of PKC but with 
limited isoform specificity. IC50 values of 10-20nM for PKCα, βI, βII and γ and 100-200nM for δ 
and ε have been reported using in vitro kinase assays (Toullec et al., 1991; Martiny-Baron et 
al., 1993) and therefore, it would be expected that all of these isoforms would be inhibited by 
the concentration of Bis I used in this experiment. Similar to staurosporine, Bis I is cell-
permeable and so was applied via the bath perfusion.  
 
Previous studies have shown that inhibition of PKC causes an enhancement of α1β3γ2L GABAA 
receptor currents (Brandon et al., 2000). However, this was not the case in these experiments, 
with receptor responses elicited by EC20 GABA not changing significantly after Bis I treatment 
(percentage change in GABA-activated current measured between 2 and 58 min = 0.2 ± 9.4%; 
n = 5; Fig. 3.3B). A trend towards a modest increase in the GABA-activated current was evident 
after around 10 min exposure to 500nM Bis I (19.6 ± 15.3%), however this enhancement was 
neither significant nor persistent, with the magnitude of the response reverting back to 
baseline levels by 58 min. 
 
As in the previous experiment, baseline and potentiated responses were measured before and 
after Bis I treatment and the magnitude of potentiation induced by 50nM THDOC was 
compared. Untreated cells showed little change in the potentiation elicited by 50nM THDOC 
(decrease in potentiation = 1.6 ± 8.3%; n = 5; Fig. 3.3A). By contrast, cells treated with 500nM 
Bis I for 40 min exhibited a significant decrease in THDOC-mediated potentiation (43.5 ± 3.8%, 
P < 0.05, paired t-test; n = 5; Fig. 3.3A), indicating that potentiation of α1β3γ2L GABAA 
receptors by THDOC can be modulated by PKC. As before with staurosporine, the potentiation 
was not completely abolished after Bis I treatment (Fig. 3.3A), providing further support for 
the idea that protein kinases are not required for the induction of potentiation by 
neurosteroids.  
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Figure 3.3 Bisindolylmaleimide I decreases THDOC-mediated potentiation at α1β3γ2L GABAA 
receptors 
(A) Mean peak currents recorded from HEK293 cells expressing α1β3γ2L GABAA receptors in response to 
EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells either remained untreated 
for the duration of the recording or were treated with 500nM bisindolylmaleimide I (Bis I, as indicated 
by green shading). All responses were normalised to the peak current of the first EC20 GABA-activated 
response, recorded 2 min after achieving the whole-cell recording configuration, designated as t = 0. 
Example whole-cell currents show the potentiation elicited by 50nM THDOC (grey bar) before and after 
Bis I treatment (green bar). Current traces are representative of recordings at the time points indicated. 
Bar chart shows the potentiation of EC20 GABA-activated currents by 50nM THDOC in untreated cells 
(grey bars, measured at 6 min and 52 min, respectively; n = 6) or in treated cells before (black bar) and 
after (green bar) 500nM Bis I treatment (n = 5). (B) Bar chart showing the change in peak receptor 
response elicited by EC20 GABA in untreated cells (UT, black bar) or cells treated with 500nM Bis I (green 
bar). Change was measured between 2 min (before treatment) and 58 min (after treatment or at 
corresponding time points in untreated cells). Responses were normalised to the peak current recorded 
at 2 min. All data points represent mean ± s.e.m. Significant results are indicated by * (P < 0.05, paired t-
test). 
 
 
3.2.3 Inhibition of PKA or PKG does not affect THDOC-mediated potentiation  
The involvement of PKA in modulating the actions of neurosteroids remains confusing, with 
some studies reporting a role for PKA in modulating the sensitivity of GABAA receptors to 
applied neurosteroids (Harney et al., 2003), while others find no such effect (Fáncsik et al., 
2000). Therefore, in order to determine whether PKA plays a role in modulating neurosteroid 
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potentiation at α1β3γ2L GABAA receptors, PKA was inhibited using a cell-permeable peptide 
inhibitor (myristoylated PKA inhibitor peptide 14-22 amide; PKAI; Fig. 3.4). There is no 
evidence to date that indicates that PKG is involved in modulating neurosteroid activity at 
GABAA receptors, however, as PKG is able to phosphorylate the β subunit of the GABAA 
receptor (McDonald and Moss, 1994; McDonald and Moss, 1997) and is inhibited by 
staurosporine (Meggio et al., 1995), a specific inhibitor of PKG, KT5823, was also used to 
investigate the potential involvement of PKG (Fig. 3.5). PKAI is cell-permeable and was applied 
via the bath perfusion whereas KT5823 is cell-impermeable and so was applied intracellularly 
via the patch electrode.  
 
Inhibition of PKA caused a modest, but significant decrease in the response elicited by EC20 
GABA alone, with cells exhibiting a 21.6 ± 8.7% reduction in GABA-activated current after 
treatment with 500nM PKAI for 14 min (P < 0.05, paired t-test; n = 5; Fig. 3.4B). This suggests 
that, in the HEK293 cell, there may be some basal phosphorylation of the α1β3γ2L GABAA 
receptor by PKA. In contrast, cells treated with 3µM KT5823 showed no change in the EC20 
GABA-activated current (Fig. 3.5B), suggesting that PKG does not phosphorylate this receptor 
isoform under basal conditions in HEK293 cells.  
 
Comparison of the magnitude of potentiation elicited by 50nM THDOC before and after each 
treatment revealed no significant change in potentiation after 14 min exposure to either 
500nM PKAI or 3µM KT5823. In both cases the change in neurosteroid potentiation was 4.1 ± 
6.6% (n = 5; Fig. 3.4A) and 1.3 ± 4.8% (n = 6; Fig. 3.5A) in PKAI and KT5823 treated cells, 
respectively (P > 0.05).  
 
As KT5823 was applied intracellularly via the patch electrode, there was a small possibility that 
inhibition of PKG could be partially or fully complete before the recording commenced. 
Therefore, to ensure that the first ‘potentiated’ response was recorded before the onset of 
PKG inhibition, the diffusion rate of KT5823 into the cell was estimated. Using a mathematical 
model (as outlined by Thomas and Smart, 2005) it was estimated that the concentration of 
KT5823 within the cell would reach equilibrium at around 6 min. The first ‘potentiated’ 
response was recorded 6 min after achieving whole-cell recording configuration and therefore, 
taking into consideration the time lag which is likely to occur between the KT5823 diffusing 
into the cell and it binding to and inactivating intracellular PKG, this is likely to be before a 
significant amount of PKG inhibition had occurred. Therefore, the results indicate that neither 
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PKA nor PKG are involved in modulating THDOC-mediated potentiation of α1β3γ2L GABAA 
receptors.  
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Figure 3.4 Inhibition of PKA does not affect THDOC-mediated potentiation of α1β3γ2L GABAA 
receptor currents  
(A) Mean peak currents recorded from HEK293 cells expressing α1β3γ2L GABAA receptors in response to 
EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells either remained untreated 
for the duration of the recording or were treated with 500nM myristoylated PKA inhibitor peptide 14-22 
amide (PKAI; as indicated by orange shading). All responses were normalised to the peak current of the 
first EC20 GABA-activated response, recorded 2 min after achieving the whole-cell recording 
configuration, designated as t = 0. Example whole-cell currents show the potentiation elicited by 50nM 
THDOC (grey bar) before and after PKAI treatment (orange bar). Current traces are representative of 
recordings at the time points indicated. Bar chart shows the potentiation of EC20 GABA-activated 
currents by 50nM THDOC in untreated cells (grey bars, measured at 6 min and 26 min, respectively; n = 
6) or in treated cells before (black bar) and after (orange bar) 500nM PKAI treatment (n = 5). (B) Bar 
chart showing the change in peak receptor response elicited by EC20 GABA in untreated cells (UT, black 
bar) or cells treated with 500nM PKAI (orange bar). Change was measured between 2 min (before 
treatment) and 32 min (after treatment or at corresponding time points in untreated cells). Responses 
were normalised to the peak current recorded at 2 min. All data points represent mean ± s.e.m. 
Significant results are indicated by * (P < 0.05, paired t-test). 
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Figure 3.5 PKG inhibition does not affect THDOC-mediated potentiation of α1β3γ2L GABAA 
receptor currents 
(A) Mean peak currents recorded from HEK293 cells expressing α1β3γ2L GABAA receptors in response to 
EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells either remained untreated 
for the duration of the recording or were treated with 3µM KT5823 (as indicated by pink shading). All 
responses were normalised to the peak current of the first EC20 GABA-activated response, recorded 2 
min after achieving whole-cell recording configuration, designated as t = 0. Example whole-cell currents 
show the potentiation elicited by 50nM THDOC (grey bar) before and after KT5823 treatment (pink bar). 
Current traces are representative of recordings at the time points indicated. Bar chart shows the 
potentiation of EC20 GABA-activated currents by 50nM THDOC in untreated cells (grey bars, measured at 
6 min and 26 min, respectively; n = 6) or in treated cells before (black bar) and after (pink bar) 3µM 
KT5823 treatment (n = 6). (B) Bar chart showing the change in peak receptor response elicited by EC20 
GABA in untreated cells (UT, black bar) or cells treated with 3µM KT5823 (pink bar). Change was 
measured between 2 min (before treatment) and 32 min (after treatment or at corresponding time 
points in untreated cells). Responses were normalised to the peak current recorded at 2 min. All data 
points represent mean ± s.e.m. Significant results are indicated by * (P < 0.05, paired t-test). 
 
 
In addition to PKA, PKC and PKG, the GABAA receptor has also been shown to be 
phosphorylated by CaMKII (Machu et al., 1993; McDonald and Moss, 1994; McDonald and 
Moss, 1997) and so this could potentially have a role in modulating neurosteroid potentiation. 
However, in HEK293 cells, GABAA receptor function has been shown to be unaffected by 
CaMKII (Houston and Smart, 2006). In these studies, pre-activated CaMKII was infused into the 
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cells however, due to their non-neuronal lineage, it is thought that these cells may lack the 
necessary trafficking or scaffolding machinery required to facilitate phosphorylation by CaMKII 
(Houston and Smart, 2006). For this reason, the role of CaMKII in modulating neurosteroid-
mediated potentiation was not investigated.  
  
Taken together, the results indicate that the activity of PKC is important for regulating the 
potentiation of GABAA receptor function by neurosteroids. To further examine the relationship 
between PKC and the actions of neurosteroids, the effects of activating PKC were investigated. 
 
3.2.4 Activation of PKC enhances THDOC-mediated potentiation  
As PKC inhibition caused a reduction in neurosteroid potentiation, it was of interest to 
investigate whether PKC activation might promote enhancement of neurosteroid activity at 
GABAA receptors. Accordingly, PKC was activated using phorbol-12-myristate-13-acetate 
(PMA). PKC activation is the result of a signalling cascade initiated by the activation of 
phospholipase C, leading to the release of diacylglycerol (DAG) which subsequently binds to 
and activates PKC. Phorbol esters such as PMA act as a substitute for DAG, thus directly 
activating PKC (Castagna et al., 1982; Sharkey et al., 1984; Tanaka and Nishizuka, 1994). Due to 
its mechanism of action, PMA shows some isoform specificity; the ‘atypical’ PKC isoforms (ζ 
and λ) are activated via a DAG-independent mechanism and therefore are insensitive to 
activation by PMA (Ono et al., 1989; Tanaka and Nishizuka, 1994). However, the ‘classical’ (α, 
βI, βII and γ) and ‘novel’ (δ, ε, η and θ) classes of PKC isoforms can be activated by phorbol 
esters at nanomolar concentrations (Dimitrijevid et al., 1995) and therefore, in this 
experiment, during which cells were treated with 100nM PMA, the actions of these individual 
isoforms cannot be distinguished. PMA is cell-permeable and so was applied via the bath 
perfusion. 
 
Treatment of cells with 100nM PMA for 36 min resulted in a significant reduction in the EC20 
GABA-activated current (31.0 ± 8.2%, P < 0.05, paired t-test; n = 6; Fig. 3.6B). This supports 
results from previous studies which, as discussed earlier, have shown that PKC-mediated 
phosphorylation of β3 subunit-containing GABAA receptors causes a decrease in receptor 
function (Brandon et al., 2000). The potentiation induced by 50nM THDOC was calculated as in 
the previous experiments; potentiation was increased by 58.0 ± 18.3% (P < 0.05, paired t-test; 
n = 6; Fig. 3.6A) after treatment with 100nM PMA for 30 min, indicating that activation of PKC 
can enhance THDOC-mediated potentiation at α1β3γ2L GABAA receptors.  
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Figure 3.6 PMA increases THDOC-mediated potentiation of α1β3γ2L GABAA receptor currents  
(A) Mean peak currents recorded from HEK293 cells expressing α1β3γ2L GABAA receptors in response to 
EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells either remained untreated 
for the duration of the recording or were treated with 100nM PMA (as indicated by purple shading). All 
responses were normalised to the peak current of the first EC20 GABA-activated response, recorded 2 
min after achieving the whole-cell recording configuration, designated as t = 0. Example whole-cell 
currents show the potentiation elicited by 50nM THDOC (grey bar) before and after PMA treatment 
(purple bar). Current traces are representative of recordings at the time points indicated. Bar chart 
shows the potentiation of EC20 GABA-activated currents by 50nM THDOC in untreated cells (grey bars, 
measured at 6 min and 42 min, respectively; n = 4) or in treated cells before (black bar) and after (purple 
bar) 100nM PMA treatment (n = 6). (B) Bar chart showing the change in peak receptor response elicited 
by EC20 GABA in untreated cells (UT, black bar) or cells treated with 100nM PMA (purple bar). Change 
was measured between 2 min (before treatment) and 48 min (after treatment or at corresponding time 
points in untreated cells). Responses were normalised to the peak current recorded at 2 min. All data 
points represent mean ± s.e.m. Significant results are indicated by * (P < 0.05, paired t-test). 
 
 
As PMA treatment resulted in a reduction of responses induced by EC20 GABA (Fig. 3.6B), it was 
possible that PMA caused a shift in the GABA dose-response relationship, which could explain 
the change in THDOC-mediated potentiation seen after PMA application. To test this, GABA 
dose-response curves were constructed before and after PMA treatment (Fig. 3.7). The EC50 
values did not differ significantly before and after PMA treatment (3.22 ± 0.71µM and 3.80 ± 
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0.58µM, respectively; P > 0.05; n = 4), indicating that the enhancement of THDOC-mediated 
potentiation seen after PMA treatment was not due to a shift in the GABA concentration-
response relationship.  
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Figure 3.7 Effect of PMA on the GABA dose-response relationship at α1β3γ2L GABAA 
receptors.  
GABA dose-response curves were established in HEK293 cells expressing α1β3γ2L GABAA receptors 
before (black) and after (purple) PMA treatment (n = 5). Each cell was exposed to brief applications of 
GABA, at varying concentrations (0.01-1000µM), before being treated with 100nM PMA for 30 min. 
After the treatment period the responses to the same concentrations of GABA, in each cell, were re-
measured. All data points represent mean ± s.e.m.  
 
 
The concentration of neurosteroids present in vivo is not static but instead undergoes dynamic 
changes in response to various physiological and pathophysiological conditions including 
stress, pregnancy, ovarian cycle and ageing (Purdy et al., 1991; Paul and Purdy, 1992; 
Bäckström et al., 2003; Schumacher et al., 2003; Maguire and Mody, 2009; Sanna et al., 2009), 
as well as in response to administration of some psychoactive drugs such as ethanol, γ-
hydroxybutyrate (GHB) and anti-depressants such as fluoxetine (Uzunov et al., 1996; Sanna et 
al., 2004). The experiments thus far have been carried out using a single concentration of 
neurosteroid, 50nM, which although falls within the concentration range likely to be 
experienced in vivo, does not fully reflect the endogenous environment, as steroid levels will 
fluctuate both above and below this concentration. To investigate this further, similar 
experiments were performed using varying concentrations of THDOC (0.1-100nM) in order to 
elucidate whether PKC can modulate the actions of neurosteroids across a range of 
concentrations. Consistent with previous data, THDOC concentrations of 10nM and above 
were able to significantly potentiate GABAA receptor function (% potentiation = 12.0 ± 3.5 
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(10nM), 66.2 ± 10.0 (50nM), 111.5 ± 17.2 (100nM); P < 0.05, paired t-test; n = 5-11). No 
potentiation was observed in cells exposed to 1nM THDOC (5.3 ± 4.3%, P > 0.05; n = 8) and, as 
expected, 0.1nM THDOC was also unable to potentiate α1β3γ2L GABAA receptor responses. 
After treatment with 100nM PMA for 30 min, potentiation by 1, 10, 50 and 100nM THDOC was 
significantly enhanced by 102.3 ± 43.2%, 152.7 ± 65.4%, 50.8 ± 14.2% and 34.8 ± 14.2%, 
respectively (P < 0.05, paired t-test; n = 5-11; Fig. 3.8). This indicates that PKC can modulate 
THDOC-mediated potentiation across the entire range of neurosteroid concentrations likely to 
be experienced in vivo. Interestingly, treatment with PMA revealed that potentiation can be 
elicited by just 1nM THDOC under conditions of increased PKC activity. 
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Figure 3.8 Effect of PMA on the potentiation of α1β3γ2L GABAA receptor currents by varying 
concentrations of THDOC  
Bar chart showing the mean potentiation of EC20 GABA-activated responses elicited by various 
concentrations of THDOC (0.1nM to 100nM) before (black bars) and after (purple bars) 100nM PMA 
treatment (n = 5-11). All data points represent mean ± s.e.m. Significant results are indicated by * (P < 
0.05, paired t-test). 
 
 
Although the results from the protein kinase inhibition experiments indicated that PKA was 
unlikely to be involved in modulating neurosteroid activity at α1β3γ2L GABAA receptors, other 
studies have implicated PKA in this modulation (Harney et al., 2003). Therefore, to examine 
the role of PKA more fully, the effects of activating PKA were also investigated.  
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3.2.5 Activation of PKA does not alter THDOC-mediated potentiation 
PKA is activated by cyclic adenosine monophosphate (cAMP), which is produced endogenously 
from adenosine triphosphate (ATP) by the enzyme, adenyl cyclase. Therefore, PKA activity was 
enhanced by intracellularly applying exogenous cAMP via the patch electrode. Previous studies 
investigating β3 subunit-containing GABAA receptors have shown that phosphorylation by PKA 
causes enhancement of GABA-activated responses by approximately 30% (McDonald et al., 
1998). Consistent with this, intracellular perfusion of the cells with 300µM cAMP caused a 
significant increase in EC20 GABA-activated responses by 35.7 ± 11.8% (P < 0.05, paired t-test; n 
= 4; Fig. 3.9B). The presence of this enhancement was a good indicator that PKA was being 
activated during the course of the experiment, however there was no concurrent change in 
the THDOC-mediated potentiation. Treatment of cells with 300µM cAMP appeared to cause a 
small decrease in the potentiation elicited by 50nM THDOC, but this was not significant. (9.0 ± 
4.4%, P > 0.05; n = 4; Fig. 3.9A), indicating that activation of PKA does not alter the 
potentiation by neurosteroids at GABAA receptors. 
 
Taken together, the results show that specific activation of PKC, but not PKA, results in an 
enhancement of neurosteroid-mediated potentiation at α1β3γ2L GABAA receptors. This 
supports the results from the protein kinase inhibition experiments, indicating that the activity 
of PKC is important for regulating the magnitude of neurosteroid potentiation at α1β3γ2L 
GABAA receptors.  
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Figure 3.9 Activation of PKA does not affect THDOC-mediated potentiation of α1β3γ2L 
GABAA receptor currents 
(A) Mean peak currents recorded from HEK293 cells expressing α1β3γ2L GABAA receptors in response to 
EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells either remained untreated 
for the duration of the recording or were treated with 300µM cAMP (as indicated by blue shading). All 
responses were normalised to the peak current of the first EC20 GABA-activated response, recorded 2 
min after achieving the whole-cell recording configuration, designated as t = 0. Example whole-cell 
currents show the potentiation elicited by 50nM THDOC (grey bar) before and after cAMP treatment 
(blue bar). Current traces are representative of recordings at the time points indicated. Bar chart shows 
the potentiation of EC20 GABA-activated currents by 50nM THDOC in untreated cells (grey bars, 
measured at 6 min and 26 min, respectively; n = 6) or in treated cells before (black bar) and after (blue 
bar) 300µM cAMP treatment (n = 4). (B) Bar chart showing the change in peak receptor response elicited 
by EC20 GABA in untreated cells (UT, black bar) or cells treated with 300µM cAMP (blue bar). Change was 
measured between 2 min (before treatment) and 32 min (after treatment or at corresponding time 
points in untreated cells). Responses were normalised to the peak current recorded at 2 min. All data 
points represent mean ± s.e.m. Significant results are indicated by * (P < 0.05, paired t-test). 
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3.3 Discussion 
 
3.3.1 Protein kinases positively modulate neurosteroid potentiation at GABAA 
receptors 
An increasing number of studies have indicated that the activity of protein kinases can alter 
the modulatory effects of neurosteroids at GABAA receptors (see Table 3.1). This is supported 
by the results from the present study, which showed that modulation of protein kinase activity 
altered the actions of neurosteroids at α1β3γ2L GABAA receptors expressed in HEK293 cells. 
Inhibition of a broad-spectrum of protein kinases by staurosporine treatment resulted in a 
significant reduction in the potentiation elicited by 50nM THDOC (see Fig. 3.1). This decrease 
was not caused by a staurosporine-mediated shift in the GABA EC50 (see Fig. 3.2), indicating 
that the magnitude of neurosteroid potentiation, at this receptor subtype, is positively 
modulated by the activity of protein kinases. This supports observations from previous studies 
which showed that both recombinant GABAA receptors expressed in Xenopus oocytes 
(Leidenheimer and Chapell, 1997) and native GABAA receptors of the hippocampus (Harney et 
al., 2003) and hypothalamus (Fáncsik et al., 2000), exhibit a positive correlation between 
protein kinase activity and the magnitude of neurosteroid-mediated potentiation. 
Furthermore, a recent behavioural investigation has also demonstrated a similar relationship, 
with results showing that enhancement of lordosis behaviour by neurosteroids in female rats, 
can be reversed by inhibition of PKC (Frye and Walf, 2008). This behaviour is, at least in part, 
thought to be mediated by GABAA receptors (Frye and Vongher, 1999), once again suggesting 
that protein kinase activity has a positive modulatory effect on the action of neurosteroids at 
these receptors. However, other investigations have obtained results which are inconsistent 
with this notion; studies of both the lamina II neurons of the spinal cord (Vergnano et al., 
2007) and the hypothalamic neurons of pregnant rats (Koksma et al., 2003) showed that 
enhancement of protein kinase activity resulted in a significant decrease in the sensitivity of 
GABAA receptors to applied neurosteroid. This indicates that an inverse relationship exists 
between the activity of protein kinases and the actions of neurosteroids in these neuronal 
populations. 
 
The reason for this difference is unclear, but one factor which may affect the modulation of 
neurosteroid activity by protein kinases is the subunit combination of the receptor. It is widely 
accepted that the majority of synaptic GABAA receptors are composed of α, β and γ subunits 
(MacDonald and Olsen, 1994; Rabow et al., 1995). There are multiple isoforms of each of these 
subunits (α1-α6, β1-β3, γ1-γ3; Sieghart et al., 1999) and, although it is thought that nearly all 
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synaptic receptors contain a γ2 subunit, this still leaves the potential for a large number of 
different receptor subtypes to be expressed in vivo. It is therefore likely that the different 
neuronal populations utilised in the various studies to date express different complements of 
GABAA receptor subunits (Laurie et al., 1992a; Wisden et al., 1992; Pirker et al., 2000; Olsen 
and Sieghart, 2009). However, both the α1β3γ2L subunit-containing receptor studied in these 
experiments and the α1β2γ2L receptor investigated previously (Leidenheimer and Chapell, 
1997) have shown a similar relationship between neurosteroids and phosphorylation, with 
neurosteroid-mediated potentiation being positively modulated by the activity of protein 
kinases. The α1, β2/3 and γ2 subunits are thought to be amongst the most highly expressed in 
the CNS (McKernan and Whiting, 1996; Olsen and Sieghart, 2009), but additional receptor 
subtypes, including those containing the α2/3 and/or β1 subunits, are also present, and 
therefore, it is possible that neurosteroid actions at these receptor subtypes may be inversely 
regulated by protein kinases, which may provide an explanation for the conflicting results seen 
in some studies, but this remains to be investigated. 
 
Secondly, there is a small possibility that the changes in neurosteroid potentiation seen after 
the modulation of endogenous protein kinase activity are not due to direct changes in receptor 
phosphorylation, but may be the result of altering the levels of phosphorylation upon an 
accessory protein(s), which could then interact with the GABAA receptor to modulate 
neurosteroid potentiation. The actions of accessory proteins cannot be ruled out for any of the 
previous studies to date as none have demonstrated that the changes in neurosteroid activity 
observed were due to a direct change in the levels of phosphorylation present at the GABAA 
receptor. Therefore, it is possible that the results reported from experiments in some neuronal 
populations may be confounded by the actions of such proteins. However, the present 
investigation goes on to show a direct link between the levels of phosphorylation at the 
receptor and the magnitude of neurosteroid potentiation observed (see Chapter 4), suggesting 
that accessory proteins are unlikely to play a major role in altering neurosteroid potentiation 
at α1β3γ2L GABAA receptors expressed in HEK293 cells. It may be interesting to determine 
whether accessory proteins are having any effect at other GABAA receptor subtypes, as the 
presence or absence of these proteins in vivo may provide an explanation for the conflicting 
results from studies to date concerning the nature of the relationship between neurosteroids 
and protein kinases at GABAA receptors in different neuronal populations. 
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3.3.2 Neurosteroid activity at α1β3γ2L GABAA receptors is modulated by PKC, but not 
PKA 
Contradictory results have also been reported regarding the involvement of specific protein 
kinases in modulating the actions of neurosteroids (see Table 3.1). For example, studies in CA1 
pyramidal neurons of the hippocampus showed that inhibition of PKC or PKA resulted in a 
concurrent decrease in neurosteroid sensitivity (Harney et al., 2003). However, Fáncsik et al. 
(2000) showed that, in hypothalamic neurons, the activity of neurosteroids can be modulated 
by PKC, but inhibiting PKA had no effect. The results from the present investigation 
demonstrated that the magnitude of potentiation elicited by neurosteroids at α1β3γ2L GABAA 
receptors is regulated by PKC, but not PKA or PKG. The results showed that inhibition or 
activation of PKC caused a significant reduction or enhancement of THDOC-mediated 
potentiation, respectively (see Fig. 3.3 and 3.6). In contrast, inhibition or activation of PKA or 
inhibition of PKG had no effect (see Fig. 3.4, 3.5 and 3.9). This mimics very closely the results 
obtained by Fáncsik et al. (2000), as they showed that the activities of both PKA and PKG did 
not affect the actions of neurosteroids. To the contrary, Harney et al. (2003) reported that the 
activity of PKA was also important and that, although inhibition of PKC caused a reduction in 
neurosteroid sensitivity at GABAA receptors, activation of PKC had no effect. 
 
The latter discrepancy may be explained by considering that there may be differences in the 
levels of endogenous protein kinase activity in the CA1 pyramidal neurons of the hippocampus 
and the HEK293 cells used in this investigation. It is possible that, if the level of PKC in the 
pyramidal neurons is high, near saturating, any further activation of PKC will have no effect. 
This would explain why inhibiting PKC is still effective in modulating the activity of 
neurosteroids in these neurons, even though they appear to be insensitive to PKC activation. In 
support of this idea, a previous study examining the effects of PKC-mediated phosphorylation 
on GABAA receptor function in hippocampal CA1 pyramidal neurons showed that activation of 
PKC had no effect on receptor function, whereas activation of PKA caused a significant 
reduction in the amplitudes of mIPSCs recorded from these neurons (Poisbeau et al., 1999). 
However, this is not the case for all neuronal populations as results from another investigation 
showed that activation of PKC caused a significant reduction of GABAA receptor function in 
cortical neurons (Brandon et al., 2000). This suggests that PKC activity may be higher in the 
CA1 pyramidal neurons compared to neurons from other regions of the brain, resulting in 
activation of PKC being ineffective in modulating the GABAA receptor both directly, by 
phosphorylation and indirectly, by regulating the activity of neurosteroids. It may be 
interesting to determine, under conditions whereby these neurons have been pre-incubated 
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with a PKC inhibitor to reduce levels of active PKC, whether activation of PKC would 
subsequently become effective in modulating the actions of neurosteroids at the GABAA 
receptors, mimicking the results seen in this investigation. 
 
The inconsistencies in the results concerning the role played by PKA in the regulation of 
neurosteroid activity at GABAA receptors are, perhaps, more difficult to explain. A factor which 
may affect the ability of PKA to modulate the activity of neurosteroids is, once again, the 
subunit combination of the receptor. Studies have revealed that neurosteroids do not appear 
to exhibit any specific subunit selectivity at GABAA receptors containing α, β and γ subunits 
(Belelli et al., 2002; Herd et al., 2007), however, protein kinases have been shown to 
differentially modulate GABAA receptor function, depending on the subunit-combination of the 
receptor (Moss and Smart, 1996). A well-documented example of this is the disparity between 
the effects of phosphorylation, by PKA, upon β1, β2 and β3 subunit-containing GABAA 
receptors; PKA-mediated phosphorylation at receptors containing the β1 subunit results in a 
reduction in GABAA receptor function, whereas at β3 subunit-containing receptors, 
phosphorylation by PKA causes enhancement of GABA-activated responses. Interestingly, at 
GABAA receptors containing the β2 subunit, PKA phosphorylation has no effect (McDonald et 
al., 1998). Therefore, when considering the actions of protein kinases in conjunction with the 
activity of neurosteroids, it could be hypothesized that different protein kinases may also 
modulate the actions of neurosteroids differently, depending on the subunit-combination of 
the receptor. Many of the studies carried out to date have utilised neurons from distinct 
regions of the brain, which, as discussed earlier, are likely to express different combinations of 
GABAA receptor subunits. Therefore, if subunit combination does indeed play a role in 
determining the co-regulatory relationship between neurosteroids and protein kinases at the 
GABAA receptor, this may explain the variation in the results seen. The results from this 
investigation failed to show any role for PKA in the regulation of neurosteroid-mediated 
potentiation at α1β3γ2L subunit-containing GABAA receptors, which, as discussed earlier, is in 
contrast to a study in hippocampal CA1 pyramidal neurons which showed that PKA positively 
modulates the activity of neurosteroids at the GABAA receptors in these neurons (Harney et 
al., 2003). This suggests that the modulatory effects of PKA seen in these neurons are unlikely 
to be mediated by receptors containing the β3 subunit, which is supported by 
immunocytochemical studies showing β3 subunit expression to be relatively low in 
hippocampal CA1 pyramidal neurons (Pirker et al., 2000). Leidenheimer and Chapell (1997) 
examined the co-regulation of α1β2γ2L subunit-containing GABAA receptors by protein kinases 
and neurosteroids and showed that PKC could regulate the magnitude of neurosteroid-
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mediated potentiation at these receptors however, this study did not examine the effects of 
PKA and therefore it cannot be ruled out that the effects of PKA seen in the hippocampal 
neurons are mediated by α1β2γ2L GABAA receptors, which are known to be highly expressed 
in these neurons (Wisden et al., 1992; Pirker et al., 2000). In addition, it is possible that 
receptors containing other subunits, such as α2/3 and β1, which have not been investigated 
here, may also mediate the modulatory effects of PKA seen in some neurons. Therefore, in 
order to create a clearer picture of how different neuronal populations can be differentially 
regulated by specific protein kinases, further study, similar to that carried out here, is required 
to examine the co-modulation, by neurosteroids and protein kinases, of the multiple GABAA 
receptor subtypes which are likely to be expressed in vivo. 
 
Another factor which may affect the ability of specific protein kinases to modulate 
neurosteroid potentiation at GABAA receptors in some neuronal populations and/or cell lines is 
the relative availability of anchoring proteins for these specific protein kinases. Scaffold 
proteins such as the A-kinase anchoring proteins (AKAPs) or the receptors for activated C-
kinase (RACKs) are required to mediate proximity of the protein kinase with its substrate, as 
well as ensuring specificity of action through compartmentalization of specific protein kinases 
with the receptor complex at the cell surface. (Pawson and Scott, 1997; Colledge and Scott, 
1999). In the case of PKA, the presence of AKAP79 or its murine ortholog AKAP150 has been 
shown to be important for mediating phosphorylation of the GABAA receptor. Studies have 
shown that AKAP79/150 can directly interact with both β1 and β3 receptor subunits, 
facilitating phosphorylation of these two subunits by PKA. Furthermore, in the case of the β3 
subunit, it was reported that this interaction is crucially required for phosphorylation by PKA to 
occur (Brandon et al., 2003). Therefore, the levels of endogenous AKAPs may be of importance 
when considering whether PKA will affect GABAA receptor currents within different neuronal 
populations and ultimately whether PKA will play a role in modulating the actions of 
neurosteroids at the GABAA receptors within these neurons. Interestingly, it has been shown 
that AKAP70/150 is differentially expressed throughout the brain; relatively high levels have 
been detected in the hippocampus and cerebral cortex, whereas neurons of the thalamus and 
hypothalamus exhibited much lower immunoreactivities (Glantz et al., 1992). Therefore, this 
may offer a potential explanation for the discrepancies in results concerning the role played by 
PKA in modulating neurosteroid-mediated potentiation at GABAA receptors in hippocampal 
versus hypothalamic neurons. Given that the levels of AKAP79/150 have been shown to be 
much lower in hypothalamic neurons, the inability to detect a modulatory role for PKA may be 
due to its inability to interact with the receptors in these neurons, resulting in no PKA-
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mediated modulation of neurosteroid activity at hypothalamic GABAA receptors. Ectopic 
expression of AKAP79/150 in hypothalamic neurons could help to solve this controversy. Also, 
it cannot be ruled out that another member of the AKAP family may mediate the actions of 
PKA in these neurons.  
 
In the present study, the results showed that PKA did not play a role in modulating 
neurosteroid-mediated potentiation at α1β3γ2L subunit-containing GABAA receptors. 
However, modulation of the receptor currents by PKA-mediated phosphorylation was evident 
(see Fig. 3.4 and 3.9), indicating that PKA is able to phosphorylate the GABAA receptors 
expressed in these cells. This suggests that appropriate scaffold protein(s) are present within 
HEK293 cells allowing this phosphorylation process to occur successfully and thus, it seems 
extremely unlikely that PKA plays a role in modulating neurosteroid potentiation at α1β3γ2L 
GABAA receptors. Therefore, it is highly likely that the modulatory effects of PKA seen in 
hippocampal neurons are mediated by a different GABAA receptor subtype. As discussed 
earlier, the β2 subunit is highly expressed in the neurons of the hippocampus (Wisden et al., 
1992; Pirker et al., 2000) but, as this subunit has been shown to be unaffected by PKA in vivo 
(McDonald et al., 1998), it is difficult to envisage that the effects of PKA are mediated via 
receptors containing this subunit. However, this cannot be completely ruled out as it is 
possible, as mentioned previously, that PKA may act indirectly by phosphorylating an accessory 
protein which could then modulate neurosteroid potentiation at β2 subunit-containing GABAA 
receptors.  
 
3.3.3 The roles of specific PKC isoforms 
This investigation did not specifically address the potential for differential involvement of 
specific PKC isoforms in the modulation of neurosteroid activity. A previous study examining 
the effects of neurosteroids in PKCε knock-out mice showed that the GABAA receptors in these 
mice exhibit enhanced neurosteroid sensitivity, resulting in a reduction of anxiety-like 
behaviour (Hodge et al., 2002). At the concentrations used in this experiment, the PKC 
inhibitor bisindolylmaleimide I (500nM), and activator PMA (100nM), are likely to show only 
limited isoform specificity. In vitro assays have shown that the IC50 of bisindolylmaleimide I is 
10-20 nM for inhibiting PKCα/βI/βII/γ and 100-200 nM for PKCδ/ε isoforms (Martiny-Baron et 
al., 1993). Therefore, it would be expected that all of these isoforms would be inhibited in the 
present study. PMA is also likely to activate all PKC isoforms, with the exception of the DAG-
independent atypical class (Dimitrijevid et al., 1995). Therefore, this investigation cannot 
distinguish between the effects of the different PKC isoforms; in order to examine this, each 
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isoform must be assessed in isolation, which may prove difficult with the limited complement 
of isoform specific PKC inhibitors and activators that are currently available. 
 
3.3.4 Neurosteroid-mediated potentiation does not require protein kinases. 
An important conclusion that can be drawn from the results is that neurosteroid-mediated 
potentiation is modulated by, but does not require protein kinase activity. Cells exposed to 
staurosporine or bisindolylmaleimide I exhibited significant decreases in the potentiation 
elicited by 50nM THDOC, but potentiation was still evident after both of these treatments (see 
Fig. 3.1 and 3.3). It is possible that this may be because the staurosporine or 
bisindolylmaleimide I treatments were not successful in completely abolishing the activity of 
their target protein kinases. However, the concentrations used (5-20 times the IC50’s) and 
durations of treatments were in excess of those reported to cause inhibition of the target 
protein kinases and therefore it is unlikely that this result is due to incomplete kinase 
inhibition. In addition, later experiments in this study, utilising mutant GABAA receptor 
constructs, have shown that abolition of all candidate phosphorylation sites from the receptor 
complex does not eradicate potentiation by THDOC (see Chapter 4). This strongly suggests that 
the actions of protein kinases are not required for neurosteroid-mediated potentiation at 
α1β3γ2L subunit-containing GABAA receptors, but instead act to modulate the magnitude of 
potentiation that is elicited. 
 
3.3.5 The physiological significance of receptor co-modulation 
Neurosteroids can be synthesised de novo in the CNS with a number of neuronal populations 
known to possess the necessary synthetic enzymes. Studies have shown that neurons of the 
cerebellum, hippocampus, cortex, olfactory bulb and thalamus are immunoreactive for 5α-
reductase (type 1) and 3α-hydroxysteroid dehydrogenase, the enzymes required for the 
synthesis of allopregnanolone and THDOC (Agís-Balboa et al., 2006; Tsutsui, 2006). In addition, 
P450scc, another key steroidogenic enzyme responsible for converting cholesterol into 
pregnenolone, has been detected in neurons of both sensory and pain pathways, including 
dorsal root ganglia, spinal cord dorsal horn and somatosensory cortex (Patte-Mensah et al., 
2003).  GABAA receptor expression is relatively ubiquitous throughout the CNS and, with 
neurosteroids exhibiting no clear receptor isoform specificity, it might be expected that the 
actions of neurosteroids would be globally experienced, causing a generalised potentiation, 
rather than achieving a more localized ‘fine-tuning’ of inhibitory neurotransmission. Such a 
non-specific action would be incompatible with neurosteroids having a physiological role, 
however, a number of studies have shown that neurosteroid action is both brain region and 
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neuron specific.  It has been hypothesized that the differing activities of protein kinases within 
these different brain areas and/or neuronal populations may contribute to the differential 
sensitivity to neurosteroids. Indeed, results from a previous study indicated that the neurons 
of the dentate gyrus are relatively insensitive to physiological concentrations of neurosteroids 
under basal conditions, but when PKC activity is increased these neurons become much more 
sensitive to the effects of applied neurosteroids. In contrast, the same study showed that 
neurons of the CA1 area of the hippocampus were sensitive to neurosteroids under basal 
conditions with activation of PKC having no effect (Harney et al., 2003). This may indicate that 
PKC activity is lower in neurons of the dentate gyrus compared to those in the hippocampal 
CA1 area, which could result in their differing sensitivity to neurosteroids under basal 
conditions. This may offer a potential mechanism by which different populations of neurons 
can be differentially sensitive to the actions of neurosteroids. Interestingly, a similar result was 
obtained from the present investigation with results showing that under basal cell conditions, 
the α1β3γ2L GABAA receptor was insensitive to concentrations of THDOC below 10nM. 
However, after PKC activation, 1nM THDOC was able to induce a modest, although significant, 
potentiation at the GABAA receptor (see Fig. 3.8). This highlights a situation whereby 
enhancing protein kinase activity can cause GABAA receptors to become sensitive to previously 
sub-threshold concentrations of neurosteroid, which would be expected to have a significant 
impact on inhibitory neurotransmission in vivo.  
 
As discussed earlier, the actions of protein kinases are reliant upon the availability of 
appropriate scaffold proteins, such as AKAPs and RACKs, which enable the protein kinase to be 
anchored close to its substrate, within a defined compartment, allowing rapid and successful 
transfer of the phosphate moiety to the target protein. Therefore, the relative expression 
levels of these scaffold proteins across different brain regions as well as their distribution 
within the neurons themselves will act to determine the location(s) that will be subjected to 
the modulatory effects of protein kinases, thus limiting the brain regions and/or neuronal 
populations in which neurosteroid activity will be regulated by protein kinases. This offers an 
additional mechanism by which neurosteroid actions can become both brain region and 
neuron specific, despite showing no clear GABAA receptor isoform specificity.    
 
The ability of protein kinases to positively modulate the actions of neurosteroids at GABAA 
receptors will have important implications under conditions in which activity of protein kinases 
is reduced or elevated. For example, decreased PKC levels have been observed in the brains of 
patients with a number of neurodegenerative diseases, including Alzheimer’s disease (Masliah 
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et al., 1990), Parkinson’s disease (Nishino et al., 1989) and Huntingdon’s disease (Hashimoto et 
al., 1992) as well as in some forms of epilepsy (Terunuma  et al., 2008) and enhanced PKC 
activity has been seen after administration of some psychoactive drugs such as ethanol (Stubbs 
and Slater, 1999) and cocaine (Steketee, 1996; Steketee et al., 1998). Therefore, in situations 
where protein kinase activity is perturbed, particularly PKC, effects will be seen both directly, 
in the alteration of GABAA receptor phosphorylation and indirectly, by modulating the activity 
of neurosteroids at these receptors. 
 
3.3.6 Effects of phosphorylation on GABAA receptor function 
It is well documented that phosphorylation alone can affect the function of GABAA receptors. 
The receptor has been shown to be phosphorylated by a number of protein kinases including 
serine-threonine kinases: PKA, PKC, PKG and CaMKII as well as tyrosine kinases SRC and PYK 
(Moss and Smart, 1996; Brandon et al., 2002a; Houston et al., 2009). Studies have shown that 
phosphorylation of the GABAA receptor can result in both enhancement and reduction of 
GABA-activated currents, depending on the protein kinase present and the subunit 
combination of the receptor (Moss and Smart, 1996). However, in this investigation, inhibition 
of protein kinase activity by staurosporine did not result in an alteration of EC20 GABA-
activated responses (see Fig. 3.1). This may be explained by evidence from previous studies 
which have shown that PKA and PKC have opposing effects at β3 subunit-containing GABAA 
receptors; phosphorylation by PKA has been shown to enhance GABA-activated currents 
(McDonald et al., 1998) whereas phosphorylation by PKC results in a reduction of GABAA 
receptor function (Brandon et al., 2000). Staurosporine would be expected to inhibit both of 
these protein kinases simultaneously and therefore, this may mask the effects of each 
individual protein kinase, resulting in no overall effect on the EC20 GABA-activated response. 
However, treatment of cells with the specific PKC inhibitor, bisindolylmaleimide I, also did not 
result in a significant change in receptor function (see Fig. 3.3), whereas, in contrast, cells 
treated with the PKA peptide inhibitor (14-22 amide) exhibited a significant reduction in EC20 
GABA-activated currents (see Fig. 3.4). This may indicate that PKA, but not PKC-mediated 
phosphorylation exists at the α1β3γ2L GABAA receptor under basal conditions. However, this is 
not consistent with the reduction in THDOC-mediated potentiation observed after 
bisindolylmaleimide I treatment, which suggests that the receptor is basally phosphorylated by 
PKC. Offering support to this notion, Western blot analysis examining the levels of 
phosphorylated β3 in HEK293 cells expressing α1β3γ2L GABAA receptors showed that the 
levels of phosphorylation could be reduced by exposing cells to bisindolylmaleimide I (see 
Chapter 4), suggesting that the β3 subunit is indeed phosphorylated by PKC under basal 
[106] 
 
conditions in the HEK293 cell. Examining the results from the electrophysiology, it is 
interesting to note that during the initial period of bisindolylmaleimide I treatment, a modest 
increase in EC20 GABA-activated current was observed (see Fig. 3.3), however this 
enhancement was not persistent, with the magnitude of the response reverting back to 
baseline levels after 58 min. This suggests that PKC-mediated basal phosphorylation may have 
been present, but that later in the recording some further changes to signalling pathways may 
have occurred, for example, up-regulation of other protein kinases to compensate for the 
depleted activity of PKC, which may have caused the response to EC20 GABA to return to 
baseline levels, however this remains to be investigated. 
 
3.4 Conclusions 
 
 Protein kinase activity positively modulates the actions of neurosteroids at α1β3γ2L 
subunit-containing GABAA receptors. 
 
 The magnitude of neurosteroid-mediated potentiation is modulated by the activity of 
PKC, but not by PKA or PKG. 
 
 Potentiation of α1β3γ2L GABAA receptor currents by neurosteroids does not require 
protein kinase activity per se. 
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Chapter 4 
 
Modulation of neurosteroid activity by PKC: a role for direct receptor 
phosphorylation 
 
4.1 Introduction 
An increasing number of studies have reported that the activity of PKC can alter the 
modulatory effects of neurosteroids at GABAA receptors (Leidenheimer and Chapell, 1997; 
Fáncsik et al., 2000; Harney et al., 2003; Frye and Walf, 2008). This was supported by the 
results from the previous chapter, which showed that, at α1β3γ2L subunit-containing 
receptors, the magnitude of potentiation elicited by the naturally-occurring neurosteroid, 
THDOC, is positively modulated by the activity of PKC. However, it remains to be determined 
whether PKC mediates these effects by directly phosphorylating the GABAA receptor or 
whether it acts indirectly, though the phosphorylation of receptor-associated accessory 
proteins or via the modulation of other downstream signalling pathways. Therefore, the aim of 
experiments in this chapter was to investigate the mechanism by which PKC modulates the 
actions of neurosteroids at α1β3γ2L GABAA receptors, with the objective of establishing 
whether direct receptor phosphorylation is required.  
 
The intracellular domains of GABAA receptor β1-3 and γ2 subunits are known to contain a 
number of consensus phosphorylation sites, which can be targeted by numerous Ser/Thr and 
Tyr protein kinases (Moss et al., 1992a, 1995; McDonald and Moss, 1994, 1997). At the 
α1β3γ2L GABAA receptor, previous studies report that PKC is able to phosphorylate consensus 
sites on both the β3 and γ2L subunits. Studies utilising GST fusion proteins produced from the 
TM3-4 intracellular loops of these receptor subunits showed that PKC can phosphorylate the 
β3 subunit at serines 408 and 409 (McDonald and Moss, 1997) and the γ2L subunit at serines 
327 and 343 (Moss et al., 1992a). Therefore, this indicates that, at the α1β3γ2L GABAA 
receptor, there are four potential sites through which PKC could act to modulate neurosteroid 
activity.  
 
To assess whether phosphorylation at one or more of these residues is required for PKC to 
modulate the actions of neurosteroids, a series of experiments was carried out using mutant 
β3 and γ2L cDNA constructs in which candidate phosphorylation sites had been mutated to 
neutral alanine residues, a mutation that has been shown to be effective in preventing 
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phosphorylation and its functional effects (Moss et al., 1992a; McDonald and Moss, 1997). 
Therefore, these constructs are a reliable method for eliminating phosphorylation at specific 
loci in order to determine whether phosphorylation at a specific receptor site(s) is responsible 
for modulating the actions of neurosteroids at α1β3γ2L GABAA receptors. It was hypothesised 
that, if PKC-mediated phosphorylation at a particular site(s) is important for neurosteroid-
mediated potentiation, under conditions where this site was no longer phosphorylated (i.e. 
when the phosphorylation site had been mutated), any subsequent enhancement or reduction 
in PKC activity would no longer affect the magnitude of the potentiation.  
 
4.2 Results 
In order to explore the mechanism by which PKC acts to modulate the actions of neurosteroids 
at GABAA receptors and, in particular, to examine the involvement of direct receptor 
phosphorylation in this process, HEK293 cells were transfected to express α1β3γ2L GABAA 
receptors containing single or multiple point mutations of consensus phosphorylation sites 
known to be targeted by PKC. As before, cells were co-transfected with eGFP to enable the 
identification of transfected cells. Experiments were carried out using the protocol described 
in the previous chapter, enabling a direct comparison between the results obtained from wild-
type receptors (see Chapter 3) and the mutant receptors used in these experiments. Briefly, 
whole-cell patch clamp electrophysiology was used to assess the magnitude of potentiation 
elicited by 50nM THDOC, before and after cell treatment with compounds to inhibit or activate 
protein kinase activity. For each cell, baseline responses to EC20 GABA and potentiated 
responses after co-applications of EC20 GABA and 50nM THDOC were established under basal 
cell conditions and after the treatment period. To allow a direct comparison of the 
potentiation elicited before and after treatment, each potentiated response was normalised to 
the cell’s preceding response to EC20 GABA alone (see Methods and Materials). In order to 
ensure that the results from wild-type receptors presented in the previous chapter were valid 
as controls for the mutant receptor experiments in this chapter, each set of experiments (wild-
type and mutant receptors) for a given protein kinase inhibitor or activator were carried out in 
parallel, with wild-type control data being collected throughout the experimental period. 
These results were then collated to form the ‘wild-type’ experimental group which is 
presented in this and the previous chapter.     
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4.2.1 Phosphorylation at the β3 subunit is important for modulating THDOC-
mediated potentiation 
The effects of phosphorylation at the β3 subunit are well documented, with a number of 
studies reporting that phosphorylation can result in both enhancement and reduction of the 
GABA-activated current, depending on the protein kinase present (Moss and Smart, 1996). For 
example, PKC-mediated phosphorylation at β3 subunit-containing GABAA receptors has been 
shown to induce a reduction in receptor function (Brandon et al., 2000), whereas 
phosphorylation by PKA results in an enhancement of GABA-activated responses (McDonald et 
al., 1998). Therefore, it was hypothesised that phosphorylation at the β3 subunit may also act 
to modulate the potentiation of GABAA receptor function by neurosteroids. To investigate this, 
cells were transfected to express GABAA receptors containing either β3
S408A, β3S409A or 
β3S408A,S409A in combination with wild-type α1 and γ2L subunits. After establishing the baseline 
and potentiated responses to GABA under basal cell conditions, cells were treated with the 
broad-spectrum protein kinase inhibitor, staurosporine (200nM; Fig. 4.1). As in the previous 
experiments, during the treatment period, the cell’s response to EC20 GABA was monitored 
every 2 min in order to examine the effects of staurosporine on the receptor’s response to 
agonist alone. In cells expressing α1β3S408Aγ2L, α1β3S409Aγ2L or α1β3S408A,S409Aγ2L GABAA 
receptors, treatment with 200nM staurosporine for 20 min caused no significant change in the 
magnitude of the response elicited by EC20 GABA (percentage change measured between 2 
and 32 min = 6.1 ± 7.3%, 2.9 ± 8.4% and 9.4 ± 7.2%, respectively for each receptor isoform, 
mean ± s.e.m., P > 0.05; n = 4-5; Fig. 4.4C).  
 
After treatment with staurosporine, the baseline and potentiated responses were re-measured 
and the potentiation elicited by 50nM THDOC, before and after protein kinase inhibition, was 
compared. Similar to the results obtained for wild-type receptors, THDOC-mediated 
potentiation at both α1β3S408Aγ2L and α1β3S409Aγ2L GABAA receptors was significantly reduced 
after treatment with 200nM staurosporine for 14 min (decrease in potentiation = 36 ± 7.5% 
and 54 ± 6.9%, respectively, P < 0.05, paired t-test; n = 5; Fig. 4.1A,B,C). In contrast, cells 
expressing α1β3S408A,S409Aγ2L GABAA receptors showed no change in the magnitude of 
potentiation elicited (change = 1.74 ± 8.7%, P > 0.05; n = 5; Fig. 4.1A,B,C). This indicated that 
phosphorylation at the β3 subunit is important for the PKC-mediated modulation of 
neurosteroid potentiation at α1β3γ2L GABAA receptors. Furthermore, the requirement for 
both S408 and S409 to be mutated in order to abolish the staurosporine-induced decrease in 
THDOC-mediated potentiation, suggests that phosphorylation at either β3 S408 or S409 is 
sufficient to modulate the actions of neurosteroids at these receptors (Fig. 4.1C).  
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Interestingly, the decrease in potentiation observed with staurosporine at α1β3S408Aγ2L 
receptors was less than that seen at both wild-type and α1β3S409Aγ2L GABAA receptors. This 
suggests that phosphorylation at β3 S408 is more effective at modulating THDOC-mediated 
potentiation. Another notable observation from this experiment was that, under basal cell 
conditions (i.e. before staurosporine treatment), the magnitude of potentiation elicited by 
50nM THDOC at α1β3S408A,S409Aγ2L GABAA receptors was significantly reduced compared to that 
induced at wild-type receptors (48.6 ± 10.8% versus 99.1 ± 13.8%, P < 0.05, ANOVA with 
Tukey’s post hoc test; n = 5-6; Fig. 4.1C, see also Fig. 4.5). This decrease may be due to the β3 
subunit being phosphorylated under basal cell conditions, a post-translational modification 
which cannot occur at the mutated subunit. Therefore, as the magnitude of potentiation was 
reduced under conditions where this subunit cannot be phosphorylated, this supports the 
notion that phosphorylation at the β3 subunit is important for regulating neurosteroid activity 
at α1β3γ2L GABAA receptors.  
 
The use of staurosporine in this experiment was a rapid way of determining that 
phosphorylation of the β3 subunit is important for modulating the actions of neurosteroids at 
GABAA receptors. However, the results from the previous chapter demonstrated that THDOC-
mediated potentiation at α1β3γ2L GABAA receptors was specifically modulated by PKC 
(see Chapter 3) and therefore, in order to investigate the actions of PKC alone, this experiment 
was repeated using compounds that specifically activate or inhibit PKC.   
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Figure 4.1 Staurosporine decreases THDOC-mediated potentiation at α1β3S408Aγ2L and 
α1β3S409Aγ2L, but not at α1β3S408A,S409Aγ2L GABAA receptors  
(A,B) Mean peak GABA currents recorded from HEK293 cells expressing α1β3
S408A
γ2L (upper panel; n = 
5), α1β3
S409A
γ2L (middle panel; n = 5) or α1β3
S408A,S409A
γ2L (lower panel; n = 5) GABAA receptors in 
response to EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells were treated 
with 200nM staurosporine (light blue shading). All responses were normalised to the peak current of the 
first EC20 GABA-activated response, recorded 2 min after achieving whole-cell recording configuration, 
designated as t = 0 (= 100%). Example whole-cell currents (panel A) show the potentiation elicited by 
50nM THDOC (grey bars) before and after staurosporine treatment (light blue bar). Current traces are 
representative of recordings at the time points indicated in B. (C) Bar chart showing the potentiation of 
EC20 GABA-activated currents by 50nM THDOC before (black bars) and after (light blue bars) 
staurosporine treatment in cells expressing α1β3γ2L (n = 6) α1β3
S408A
γ2L (n = 5), α1β3
S409A
γ2L (n = 5) or 
α1β3
S408A,S409A
γ2L (n = 5) GABAA receptors. Data displayed for α1β3γ2L receptors is as shown previously 
in Fig. 3.1. All data points represent mean ± s.e.m. Significant results are indicated by * (P < 0.05, paired 
t-test). 
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4.2.2 Phosphorylation by PKC at β3 S408 or S408 is sufficient to modulate 
neurosteroid activity 
To confirm whether PKC does indeed modulate the actions of neurosteroids through direct 
phosphorylation of the β3 subunit, cells were treated with either 100nM PMA or 500nM 
bisindolylmaleimide I (Bis I), in order to specifically activate or inhibit PKC, respectively. After 
treatment with 100nM PMA, cells expressing α1β3S408Aγ2L or α1β3S409Aγ2L subunit-containing 
GABAA receptors exhibited significant enhancements in THDOC-mediated potentiation of 54.6 
± 13.8% and 61.1 ± 37%, respectively (P < 0.05, paired t-test; n = 4; Fig. 4.2A,B), which were 
similar in magnitude to the increase observed at wild-type receptors (see Fig. 3.6). In contrast, 
potentiation at α1β3S408A,S409Aγ2L receptors was unaffected by treatment with either PMA or 
Bis I (change = 7.3 ± 9.0% and 1.6 ± 8.3%, respectively, P > 0.05; n = 4-5; Fig. 4.2A,B and Fig. 
4.3A,B), indicating that these residues are important for the modulatory effects of PKC 
observed previously. These results support those obtained from the staurosporine experiment, 
demonstrating that PKC-mediated phosphorylation at β3 S408 or S409 is sufficient to 
modulate the magnitude of potentiation elicited by 50nM THDOC at α1β3γ2L GABAA 
receptors. 
 
The results from the PKC inhibition experiment showed once again that, under basal cell 
conditions, the magnitude of THDOC-mediated potentiation induced at α1β3S408A,S409Aγ2L 
GABAA receptors was significantly reduced compared to that observed at wild-type receptors 
(140.6 ± 19.2% versus 45.7 ± 12.9%, P < 0.05, paired t-test; n = 4-5; Fig. 4.3A,B). This supports 
the idea that basal phosphorylation at the wild-type receptor, which is eliminated from the 
mutant receptor, may result in an apparent enhancement in the level of potentiation elicited 
by 50nM THDOC. Curiously, in the PKC activation experiment, no significant difference was 
observed between the potentiation elicited at wild-type and α1β3S408A,S409Aγ2L GABAA 
receptors. However, the results do reveal a trend towards a decrease in the magnitude of 
potentiation elicited at α1β3S408A,S409Aγ2L GABAA receptors, with 50nM THDOC inducing only a 
48.8 ± 6.5% enhancement of the EC20 GABA-activated current at α1β3
S408A,S409Aγ2L GABAA 
receptors compared to the 70.2 ± 17.3% potentiation elicited at wild-type receptors (Fig. 4.2B).  
 
Previous studies have reported that PKC-mediated phosphorylation of β3 subunit-containing 
GABAA receptors causes a decrease in receptor function (Brandon et al., 2000). This was 
supported by results from the present study which showed that, at α1β3γ2L GABAA receptors, 
activation of PKC induces a significant reduction in the EC20 GABA-activated current (see Fig. 
3.6). Similar results were obtained for α1β3S408Aγ2L and α1β3S409Aγ2L GABAA receptors, with 
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both exhibiting significant decreases in the receptor’s response to EC20 GABA after treatment 
with 100nM PMA for 36 min (decrease = 22.6 ± 4.5% and 26.5 ± 7.6%, respectively, P < 0.05, 
paired t-test; n = 4; Fig. 4.2C). Interestingly, the reductions in function observed at these 
receptors were slightly diminished compared to that seen at wild-type receptors (35 ± 8%; Fig. 
4.3C, see also Fig. 3.6), which may reflect the reduction in potential phosphorylation sites from 
four to three, reducing the receptor’s capacity for modulation by PKC. In contrast, at 
α1β3S408A,S409Aγ2L subunit-containing GABAA receptors, the change in EC20 GABA-activated 
current was not statistically significant, indicating that phosphorylation at the β3 subunit plays 
an important role in modulating the receptor’s response to agonist. However, a closer look at 
the results reveals that, although not significant, a trend towards a decrease in the responses 
elicited by EC20 GABA was evident at α1β3
S408A,S409Aγ2L receptors after treatment with 100nM 
PMA (decrease = 25.3 ± 11.6%, P > 0.05; n = 5; Fig. 4.2C). This indicates that, at receptors 
containing the mutated β3S408A,S409A subunit, some reduction in receptor function can still be 
induced after activation of PKC, implying that phosphorylation at sites independent of those 
contained on the β3 subunit may also contribute to this effect. In addition to β3 serines 408 
and 409, PKC can also phosphorylate two residues on the γ2L subunit; serines 327 and 343. 
Therefore, phosphorylation at these sites may also be important for regulating the function of 
α1β3γ2L GABAA receptors and thus, could also play a role in modulating the actions of 
neurosteroids at these receptors.  
 
Curiously, the results from the present study showed that, at both wild-type and 
α1β3S408A,S409Aγ2L GABAA receptors, inhibition of PKC caused no significant alteration of EC20 
GABA-activated responses (Fig. 4.4C). Therefore, it was important to confirm whether Bis I was 
really inhibiting PKC in these experiments. To investigate this, Western blot analysis was used 
to examine the levels of phosphorylated β3 before and after treatment with 500nM Bis I for 40 
min. Lysates were prepared from HEK293 cells expressing α1β3γ2L GABAA receptors and were 
probed in duplicate with β3 and phospho-β3 anti-sera (see Methods and Materials). To enable 
a direct comparison to be made between the untreated and treated cell populations the level 
of phosphorylated β3 was normalized to the corresponding amount of total β3 present. As 
expected, exposure of cells to Bis I resulted in a clear reduction in the extent of β3 subunit 
phosphorylation (Fig. 4.4D), indicating that this compound is indeed effective at inhibiting PKC.  
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Figure 4.2 PMA enhances THDOC-mediated potentiation at α1β3S408Aγ2L and α1β3S409Aγ2L, 
but not at α1β3S408A,S409Aγ2L GABAA receptors 
(A) Mean peak GABA currents recorded from HEK293 cells expressing α1β3S408Aγ2L (upper panel; n = 4), 
α1β3
S409A
γ2L (middle panel; n = 4) or α1β3
S408A,S409A
γ2L (lower panel; n = 5) GABAA receptors in response 
to EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells were treated with 
100nM PMA (purple shading). All responses were normalised to the peak current of the first EC20 GABA-
activated response, recorded 2 min after achieving whole-cell recording configuration, designated as t = 
0. Example whole-cell currents show the potentiation elicited by 50nM THDOC (grey bars) before and 
after PMA treatment (purple bar). Current traces are representative of recordings at the time points 
indicated. (B) Bar chart showing the potentiation of EC20 GABA-activated currents by 50nM THDOC 
before (black bars) and after (purple bars) PMA treatment in cells expressing α1β3γ2L (n = 6), 
α1β3
S408A
γ2L (n = 4), α1β3
S409A
γ2L (n = 4) or α1β3
S408A,S409A
γ2L (n = 5) GABAA receptors. Data displayed for 
α1β3γ2L receptors is as shown previously in Fig. 3.6. (C) Bar chart showing the change in peak receptor 
response elicited by EC20 GABA before (open bar) or after treatment with 100nM PMA (purple bars) in 
cells expressing α1β3γ2L (n = 6), α1β3
S408A
γ2L (n = 4), α1β3
S409A
γ2L (n = 4) or α1β3
S408A,S409A
γ2L (n = 5) 
GABAA receptors. Change was measured between 2 min (before treatment) and 48 min (after 
treatment). Responses were normalised to the peak current recorded at 2 min. Data displayed for 
α1β3γ2L receptors is as shown previously in Fig. 3.6. All data points represent mean ± s.e.m. Significant 
results are indicated by * (P < 0.05, paired t-test). 
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Figure 4.3 Bisindolylmaleimide I does not decrease THDOC-mediated potentiation at 
α1β3S408A,S409Aγ2L GABAA receptors 
(A) Mean peak GABA currents recorded from HEK293 cells expressing α1β3
S408A,S409A
γ2L (n = 4) GABAA 
receptors in response to EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells 
were treated with 500nM Bisindolylmaleimide I (Bis I; green shading). All responses were normalised to 
the peak current of the first EC20 GABA-activated response, recorded 2 min after achieving whole-cell 
recording configuration, designated as t = 0. Example whole-cell currents show the potentiation elicited 
by 50nM THDOC (grey bars) before and after Bis I treatment (green bar). Current traces are 
representative of recordings at the time points indicated. (B) Bar chart showing the potentiation of EC20 
GABA-activated currents by 50nM THDOC before (black bars) and after (green bars) Bis I treatment in 
cells expressing α1β3γ2L (n = 5) or α1β3
S408A,S409A
γ2L (n = 4) GABAA receptors. Data displayed for 
α1β3γ2L receptors is as shown previously in Fig. 3.3. (C) Bar chart showing the change in peak receptor 
response elicited by EC20 GABA before (open bar) or after treatment with 500nM Bis I (green bars) in 
cells expressing α1β3γ2L (n = 5) or α1β3
S408A,S409A
γ2L (n = 4) GABAA receptors. Change was measured 
between 2 min (before treatment) and 58 min (after treatment). Responses were normalised to the 
peak current recorded at 2 min. Data displayed for α1β3γ2L receptors is as shown previously in Fig. 3.3. 
All data points represent mean ± s.e.m. Significant results are indicated by * (P < 0.05, paired t-test). (D) 
Western blot showing the level of GABAA receptor phosphorylation before and after treatment with Bis 
I. HEK293 cells expressing α1β3γ2L GABAA receptors were treated for 40 min with 500nM Bis I and 
probed with β3 and phospho-β3 anti-sera (see Methods and Materials). Untransfected (UT) cells were 
used as a negative control.  
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4.2.3 Phosphorylation at the γ2L subunit does not modulate THDOC-mediated 
potentiation 
In addition to β3 serines 408 and 409, PKC has also been shown to phosphorylate two residues 
on the γ2L subunit. Therefore, further experiments were carried out to investigate whether 
phosphorylation at the γ2L subunit contributes towards the modulatory actions of 
neurosteroids at α1β3γ2L GABAA receptors. Accordingly, HEK293 cells were transfected to 
express GABAA receptors containing γ2L
S327A,S343A subunits in combination with wild-type α1 
and β3, in order to specifically determine whether phosphorylation of γ2L is important for the 
regulation of neurosteroid activity by protein kinases. After treatment with 200nM 
staurosporine for 20 min, cells expressing α1β3γ2LS327A,S343A GABAA receptors exhibited no 
significant change in the current response elicited by EC20 GABA (3.7 ± 9.1%, P > 0.05; n = 4; 
Fig. 4.4C). In contrast, THDOC-mediated potentiation was significantly reduced by 50.3 ± 7.5% 
after staurosporine treatment (P < 0.05, paired t-test; n = 4; Fig. 4.4A,B), a decrease very 
similar to that observed for wild-type receptors (Fig 4.4. A,B see also Fig. 3.1). This suggests 
that phosphorylation at γ2L S327 and/or S343 does not play a significant role in the 
modulation of neurosteroid activity at α1β3γ2L GABAA receptors.  
 
Taken together, the results indicate that, at α1β3γ2L GABAA receptors, PKC acts to modulate 
THDOC-mediated potentiation through direct phosphorylation at the β3, but not the γ2L 
subunit. Furthermore, it appears that PKC-mediated phosphorylation at either S408 or S409 is 
sufficient for this modulation to occur.  
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Figure 4.4 Staurosporine decreases THDOC-mediated potentiation at α1β3γ2LS327A,S343A  
GABAA receptors 
(A) Mean peak currents recorded from HEK293 cells expressing α1β3γ2L
S327A,S343A
 (n = 4) GABAA 
receptors in response to EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells 
were treated with 200nM staurosporine (light blue shading). All responses were normalised to the peak 
current of the first EC20 GABA-activated response, recorded 2 min after achieving whole-cell recording 
configuration, designated as t = 0. Example whole-cell currents show the potentiation elicited by 50nM 
THDOC (grey bars) before and after staurosporine treatment (light blue bar). Current traces are 
representative of recordings at the time points indicated. (B) Bar chart showing the potentiation of EC20 
GABA-activated currents by 50nM THDOC before (black bars) and after (light blue bars) staurosporine 
treatment in cells expressing α1β3γ2L (n = 6) or α1β3γ2L
S327A,S343A
 (n = 4) GABAA receptors. Data 
displayed for α1β3γ2L GABAA receptors is as shown previously in Fig. 3.1 (C) Bar chart showing the 
change in peak receptor response elicited by EC20 GABA before (open bar) or after treatment with 
200nM staurosporine (light blue bars) in cells expressing α1β3γ2L (n = 6), α1β3
S408A
γ2L (n = 5), 
α1β3
S409A
γ2L (n = 5), α1β3
S408A,S409A
γ2L (n = 5) or α1β3γ2L
S327A,S343A
 GABAA receptors. Change was 
measured between 2 min (before treatment) and 32 min (after treatment). Responses were normalised 
to the peak current recorded at 2 min. Data displayed for α1β3γ2L receptors is as shown previously in 
Fig. 3.1. All data points represent mean ± s.e.m. Significant results are indicated by * (P < 0.05, paired t-
test).  
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4.2.4 Phosphorylation is not required for THDOC-mediated potentiation 
An interesting conclusion from the previous chapter was that neurosteroid-mediated 
potentiation is modulated by, but does not absolutely require protein kinase activity. This was 
demonstrated by the fact that potentiation was still evident after cells had been exposed to 
protein kinase inhibitors (see Fig. 3.1 and 3.3). However, it remains possible that this may be 
because the staurosporine or bisindolylmaleimide I treatments did not completely abolish the 
activity of their target protein kinases, resulting in potentiation being induced due to residual 
protein kinase activity. Therefore, in order to investigate this further, the magnitude of 
potentiation elicited by 50nM THDOC was assessed in cells expressing 
α1β3S408A,S409Aγ2LS327A,S343A GABAA receptors, effectively eliminating PKC-induced 
phosphorylation at all known sites within the receptor. Consistent with the results presented 
in the previous chapter, potentiation was still observed at these receptors (potentiation 
induced by 50nM THDOC = 45.7 ± 7.1%; Fig. 4.5), once again indicating that phosphorylation, 
by protein kinases, is not required for the potentiation of GABAA receptor function by 
neurosteroids.  
 
The magnitude of the neurosteroid potentiation induced at α1β3S408A,S409Aγ2LS327A,S343A GABAA 
receptors was significantly reduced compared to that observed at wild-type receptors (45.7 ± 
7.1% versus 99.1 ± 13.8%, P < 0.05, ANOVA with Tukey’s post hoc test; n = 4-5; Fig. 4.5, see 
also Fig. 4.1). This is, perhaps, unsurprising given that the results from the present study have 
indicated that the level of basal phosphorylation of the receptor may be an important 
determinant of the extent of potentiation. However, it is interesting to note that the level of 
potentiation elicited at these receptors is very similar to that seen at α1β3S408A,S409Aγ2L 
receptors (45.7 ± 7.1% versus 48.6 ± 10.8%, P > 0.05; Fig. 4.5, see also Fig. 4.1), indicating that 
additional mutation of γ2L serines 327 and 343 does not reduce the magnitude of potentiation 
beyond that previously observed for α1β3S408A,S409Aγ2L receptors. This supports the results 
obtained in earlier experiments, suggesting that phosphorylation at the β3, but not the γ2L 
subunit, is important for regulating neurosteroid potentiation at α1β3γ2L GABAA receptors.  
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Figure 4.5 THDOC-mediated potentiation is still evident at α1β3S408A,S409Aγ2LS327A,S343A GABAA 
receptors 
Mean peak currents recorded from HEK293 cells expressing α1β3
S408A,S409A
γ2L
S327A,S343A
 (n = 4) GABAA 
receptors in response to EC20 GABA or EC20 GABA + 50nM THDOC (as indicated). Bar chart shows the 
potentiation of EC20 GABA-activated currents by 50nM THDOC in cells expressing α1β3γ2L (n = 6), 
α1β3
S408A,S409A
γ2L (n = 5) or α1β3
S408A,S409A
γ2L
S327A,S343A
 (n = 4) GABAA receptors. Data displayed for 
α1β3γ2L and α1β3
S408A,S409A
γ2L GABAA receptors is as shown previously in Fig. 3.1 and 4.1, respectively. 
All data points represent mean ± s.e.m. Significant results are indicated by * (P < 0.05, ANOVA with 
Tukey’s post hoc test). 
 
 
4.2.5 THDOC enhances β3 subunit phosphorylation via an interaction with the GABAA 
receptor 
The experiments conducted throughout this study have focused on the ability of 
phosphorylation, by protein kinases, to modulate the actions of neurosteroids at GABAA 
receptors. However, this reflects just one aspect of the co-regulatory relationship and does not 
address the potential for this modulation to be bi-directional. Therefore, in order to investigate 
whether, in the reverse situation, neurosteroids can act to modulate the activities of protein 
kinases, Western blot analysis was used to assess the extent of β3 subunit phosphorylation in 
HEK293 cells expressing α1β3γ2L GABAA receptors, before and after exposure to a 
neurosteroid. Cells either remained untreated or were exposed to 50nM THDOC for 5, 10 or 20 
min. To enable direct comparisons to be made between the separate cell populations 
undergoing different treatment protocols, lysates were probed in duplicate with both β3 and 
phospho-β3 anti-sera and for each treatment group, the level of phosphorylated β3 was 
normalized to the corresponding amount of total β3 present.  
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To verify the specificity of the antibodies, control experiments were carried out in HEK293 cells 
expressing either α1β3S408A,S409Aγ2L or α1 and γ2L subunits in the absence of β3. As expected, 
no phosphorylated β3 was detected in cells expressing α1β3S408A,S409Aγ2L (Fig. 4.6A lane 1) and 
signals for both β3 and phosphorylated β3 were absent in cells expressing just α1 and γ2L 
subunits (Fig. 4.6A lane 2), confirming that the antibodies are indeed specific for their 
respective targets.  
 
Experiments carried out in untreated cells confirmed that there is some basal phosphorylation 
of the β3 subunit when it is co-expressed with α1 and γ2L in HEK293 cells (Fig. 4.6A lane 3). 
After treatment of cells with 50nM THDOC for 5 min, there was little change in the level of β3 
subunit phosphorylation (10.7 ± 11.6% increase, P > 0.05; n = 3; Fig. 4.6A lane 4, Fig. 4.6C). A 
tendency towards increased phosphorylation was detected in cells treated with THDOC for 10 
min (increase = 78.7 ± 34.9%, P > 0.05; n = 3; Fig. 4.6A lane 5, Fig. 4.6C), and cells exposed to 
THDOC for 20 min exhibited a significant enhancement in the extent of β3 subunit 
phosphorylation of 96.3 ± 27.9% (P < 0.05, ANOVA with Dunnett’s post hoc test; n = 3; Fig. 4.6A 
lane 6, Fig. 4.6C). This indicates that THDOC can enhance β3 subunit phosphorylation, implying 
the presence of a ‘reverse’ transduction pathway in which neurosteroids can modulate the 
phosphorylation of the α1β3γ2L GABAA receptor.  
 
To gauge the extent to which THDOC can increase β3 subunit phosphorylation, the effects of 
the neurosteroid were compared to those of PMA, a potent activator of PKC. Cells treated with 
100nM PMA for 30 min exhibited a 193.3 ± 34.9% increase in the level of phosphorylated β3 
(Fig. 4.6A lane 7), an enhancement twice as large as that observed for THDOC, indicating that 
neurosteroids are less effective at enhancing β3 subunit phosphorylation when compared to 
compounds which can directly activate PKC. 
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Figure 4.6 THDOC enhances phosphorylation of β3 S408/S409 by binding to the GABAA 
receptor. 
(A,B) Western blots showing the level of β3 subunit phosphorylation in HEK293 cells expressing (A) 
α1β3γ2L or (B) α1
Q241W
β3γ2L GABAA receptors. Cells either remained untreated (UT) or were exposed to 
50nM THDOC for 5, 10 or 20 min or 100nM PMA for 30 min (as indicated) and probed with β3 or 
phospho-β3 anti-sera. Cells transfected with α1β3
S408A,S409A
γ2L or α1γ2L GABAA receptor subunits were 
used as negative controls. (C) Bar chart shows the levels of phosphorylated β3 subunits present in cells 
expressing α1β3γ2L (black/grey bars; n = 3) or α1
Q241W
β3γ2L (red bars; n = 3), in untreated cells (UT) or 
cells treated with 50nM THDOC for 5, 10 or 20 min or 100nM PMA for 30 min. All data points represent 
mean ± s.e.m. Significant results are indicated by * (P < 0.05, ANOVA with Dunnett’s post hoc test). 
 
 
Although this experiment demonstrated that THDOC is able to modulate the levels of 
phosphorylation at the GABAA receptor, it remained unclear whether neurosteroids are 
mediating this effect through a direct interaction with the GABAA receptor. Neurosteroids are 
thought to potentiate GABAA receptor function by binding at a discrete site located within the 
transmembrane region of the α subunit (Hosie et al., 2006; Hosie et al., 2008). Three key 
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residues have been identified to date, Q241, N407 and Y410, which when replaced with 
hydrophobic residues, resulted in the attenuation, or in the case of Q241 mutants, the 
complete ablation of potentiation by neurosteroids (Hosie et al., 2006). Therefore, in order to 
examine whether THDOC acts to enhance receptor phosphorylation through an interaction 
with the GABAA receptor, the previous experiment was repeated in cells expressing 
α1Q241Wβ3γ2L GABAA receptors. In untreated cells, basal phosphorylation was still evident at 
the β3 subunit (Fig. 4.6B lane 3), indicating that these receptors can be phosphorylated as 
normal, however, after treatment of cells with 50nM THDOC for 5, 10 or 20 min, no significant 
alteration in β3 subunit phosphorylation was observed (Changes = -2.7 ± 18.4%, 25.0 ± 22.7% 
and 9.3 ± 27.4%, respectively, P > 0.05; n = 3; Fig. 4.6B lanes 4-6). This suggests that THDOC 
acts to modulate GABAA receptor phosphorylation through a direct interaction with the 
receptor complex. Furthermore, as the mutation of Q241 is sufficient to eliminate any 
enhancement in receptor phosphorylation, this indicates that occupancy of the neurosteroid 
binding site is likely to be facilitating this modulation.  
 
Taken together, the results show that a complex, bi-directional relationship exists between 
neurosteroids and protein kinases at the α1β3γ2L GABAA receptor, with phosphorylation at the 
receptor acting to modulate the actions of neurosteroids and, in the reverse situation, 
exposure to neurosteroids causing an alteration in the extent of receptor phosphorylation.   
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4.3 Discussion 
 
4.3.1 PKC-mediated phosphorylation at the β3 subunit regulates neurosteroid 
potentiation at α1β3γ2L GABAA receptors 
Using recombinant GABAA receptors containing mutations designed to prevent 
phosphorylation at one or more candidate sites on the receptor, it has been possible to 
identify the residues at which PKC acts to modulate the potentiating actions of neurosteroids. 
The results from this study showed that, at GABAA receptors incorporating mutant β3
S408A,S409A 
subunits, the magnitude of potentiation elicited by 50nM THDOC was significantly reduced 
compared to that observed at wild-type receptors. Furthermore, the potentiation induced at 
α1β3S408A,S409Aγ2L GABAA receptors was unaffected by treatment with either staurosporine, 
bisindolylmaleimide I or PMA (see Fig. 4.1, 4.2, 4.3 and 4.5). This indicates that 
phosphorylation at the β3 subunit is important for regulating the potentiation of GABAA 
receptor function by neurosteroids. In addition, the apparent decrease in the magnitude of 
potentiation induced at α1β3S408A,S409Aγ2L versus wild-type GABAA receptors suggests that, in 
HEK293 cells, the β3 subunit is likely to be phosphorylated under basal cell conditions, which, 
when eliminated from the mutant receptor, results in the reduced level of neurosteroid-
mediated potentiation observed in these experiments. This was confirmed by Western blot 
analysis which demonstrated that the β3 subunit is indeed phosphorylated under basal cell 
conditions (see Fig. 4.4 and 4.6) and, moreover, that this phosphorylation is mediated, at least 
in part, by PKC (see Fig. 4.4), which is consistent with the previous results demonstrating that 
the actions of neurosteroids at α1β3γ2L GABAA receptors are modulated exclusively by PKC 
(see Chapter 3).  
 
Basal phosphorylation at the GABAA receptor β3 subunit has also been detected in a number of 
neuronal populations, including those from the cortex, hippocampus and striatum (Brandon et 
al., 2000; Brandon et al., 2003; Terunuma et al., 2008). Therefore, the results from the present 
study provide a good indication that, in these neurons, the actions of neurosteroids could be 
both enhanced and reduced, depending on the activity of PKC, which may provide an ideal 
mechanism for the rapid fine-tuning of GABAA receptor function in vivo, particularly at 
inhibitory synapses.  
 
Curiously, the results from the PMA experiment differed slightly from those obtained from 
cells treated with either staurosporine or bisindolylmaleimide I in that, although there was a 
trend towards a decrease in the magnitude of potentiation elicited at α1β3S408A,S409Aγ2L versus 
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wild-type GABAA receptors, this did not reach statistical significance (see Fig. 4.2). The reason 
for this is unclear but one potential explanation is that, in the PMA experiment, the results 
obtained from the cells expressing wild-type receptors (see Fig. 3.6) may have been 
unintentionally skewed. A number of studies have shown that the activation of PKC results in a 
reduction in GABAA receptor function (Krishek et al., 1994; Brandon et al., 2000). Therefore, in 
order to ensure that PKC was definitely being activated in this experiment, those cells which 
exhibited no clear decrease in EC20 GABA-activated current after treatment with PMA were 
excluded from analysis. It can be hypothesized that the cells in which PMA appeared to have 
no effect on GABAA receptor function are likely to be those which contained the highest levels 
of basal receptor phosphorylation, meaning that further increases in PKC activity would have 
no further effect on GABA-activated responses. Therefore, considering the results from the 
present study, these cells are also likely to be those which display the highest levels of 
neurosteroid potentiation, thus eliminating these cells from analysis could have resulted in a 
slight decrease in the mean potentiation calculated for the wild-type cell group, hence the 
magnitude of neurosteroid-mediated potentiation induced in these cells does not differ 
significantly from that observed at α1β3S408A,S409Aγ2L GABAA receptors.  
 
4.3.2 Phosphorylation at β3 S408 or S409 is sufficient to modulate neurosteroid 
activity 
A notable observation from the present study was that, in contrast to α1β3S408A,S409Aγ2L GABAA 
receptors, cells expressing either α1β3S408Aγ2L or α1β3S409Aγ2L receptors exhibited similar 
changes in neurosteroid-mediated potentiation, after treatment with either staurosporine or 
PMA, to those observed at wild-type receptors (see Fig. 4.1 and 4.2). This indicates that PKC-
mediated phosphorylation at either S408 or S409 is sufficient to modulate the actions of 
neurosteroids at α1β3γ2L GABAA receptors. Interestingly, after treatment with staurosporine, 
the decrease in potentiation observed at α1β3S408Aγ2L GABAA receptors appeared to be less 
than that seen at α1β3S409Aγ2L receptors (see Fig. 4.1). This may suggest that phosphorylation 
at S408 is slightly more effective at modulating the actions of neurosteroids. Alternatively, this 
discrepancy may be due to the presence of higher levels of basal phosphorylation at S408 
which could result in this site having a greater potential for modulation by protein kinases. 
 
Although the β3 subunit contains two potential phosphorylation sites, the results from the 
present study showed that phosphorylation at either site was sufficient to modulate 
neurosteroid-mediated potentiation (see Fig. 4.1 and 4.2). This suggests that the mechanism 
by which phosphorylation acts to alter the actions of neurosteroids at α1β3γ2L GABAA 
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receptors most likely requires the addition of just a single phosphate moiety at the β3 subunit.  
Therefore, it may be interesting to explore whether GABAA receptors containing β1 or β2 
subunits are modulated to a similar extent as β3 subunit-containing receptors, as previous 
studies have shown that, although all members of the β subunit family contain a conserved 
phosphorylation site at S409 (S410 in the β2 subunit; Moss et al., 1992a; McDonald and Moss, 
1997), the β3 subunit also contains a unique site at S408, which is not present in either β1 or 
β2 (see Fig. 4.7; McDonald and Moss, 1997; McDonald et al., 1998). Given that the extent of 
receptor phosphorylation appears to be important for regulating the actions of neurosteroids 
at GABAA receptors, this may indicate that, at β3 subunit-containing GABAA receptors, the 
actions of protein kinases may act to modulate neurosteroid-mediated potentiation to a 
greater extent than at receptors containing either β1 or β2. However, if phosphorylation at a 
single site is sufficient to induce an alteration of neurosteroid activity, then phosphorylation of 
β1 or β2 may induce similar levels of modulation to that seen at β3 subunit-containing GABAA 
receptors.  
β2 406RRRASQLK413
TM1 TM2 TM3 TM4N C
β1 405RRRASQLK412
β3 405RRRSSQLK412
N C
 
Figure 4.7 Conserved phosphorylation sites on the GABAA receptor β subunit family  
Schematic diagram showing the proposed topology of the major transmembrane domains of the GABAA 
receptor β subunit along with the locations of the phosphorylation sites identified to date. Highlighted 
are the conserved phosphorylation site, at S409/S410 (red) and the additional phosphorylation site, at 
S408, found only on the β3 subunit (yellow).  
 
 
In support of this notion, preliminary results from HEK293 cells expressing α1β2γ2L GABAA 
receptors showed that, after treatment with staurosporine, the magnitude of potentiation 
elicited by 50nM THDOC was reduced by 65.6 ± 4.6% (P < 0.05, paired t-test; n = 4; Fig. 4.8), a 
decrease very similar to that observed at α1β3γ2L receptors (see Fig. 4.8). This indicates that, 
at β2 subunit-containing GABAA receptors, the activity of protein kinases can modulate the 
actions of neurosteroids to a similar extent to that seen at receptors incorporating the β3 
[127] 
 
subunit. Furthermore, as the β2 subunit contains just one phosphorylation site (S410), this 
suggests that phosphorylation at a single site may be sufficient to induce this modulation.  
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Figure 4.8 Staurosporine decreases THDOC-mediated potentiation at α1β2γ2L and α1β3γ2L 
subunit-containing GABAA receptors to a similar extent  
Bar chart showing the potentiation of 3µM GABA-activated currents by 50nM THDOC before (black bars) 
and after (light blue bars) staurosporine treatment in cells expressing α1β3γ2L (n = 5) or α1β2γ2L (n = 4) 
GABAA receptors. Cells were treated with 200nM staurosporine for 14 min and the potentiation elicited 
by 50nM THDOC is expressed as a percentage of the cell’s preceding response to 3µM GABA alone 
(=100%). All data points represent mean ± s.e.m. Significant results are indicated by * (P < 0.05, paired t-
test). 
 
 
4.3.3 Phosphorylation at the γ2L subunit is not important for the modulation of 
neurosteroid-mediated potentiation 
In addition to investigating the involvement of β subunit phosphorylation in the regulation of 
neurosteroid activity at GABAA receptors, it was also important to examine whether the 
magnitude of potentiation elicited by neurosteroids could be altered by phosphorylation of 
other subunits within the receptor complex. Studies utilising purified fusion proteins have 
demonstrated that the intracellular domains of both the γ2 short (γ2S) and γ2 long (γ2L) 
subunits are phosphorylated by PKC at serine 327 (Moss et al., 1992a). In addition, the γ2L 
subunit, which differs from the γ2S by the presence of an 8 amino acid insertion within the 
major TM3-4 intracellular domain (Whiting et al., 1990; Kofuji et al., 1991), contains an 
additional consensus site for PKC, at serine 343 (Moss et al., 1992a; Machu et al., 1993). 
Further studies exploring the functional effects of phosphorylation at the γ2 subunit have 
shown that phosphorylation at S327 and/or S343 causes a reduction in GABAA receptor 
function (Kellenberger et al., 1992; Krishek et al., 1994). Furthermore, the results have also 
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indicated that phosphorylation at S343 appears to produce the largest modulatory effect 
(Krishek et al., 1994). However, an additional study reported that, to the contrary, PKC-
mediated phosphorylation at the γ2L subunit results in an enhancement of GABA-activated 
responses (Lin et al., 1996). The reason for this discrepancy is unknown but it has been 
suggested that it may be due to disparities in experimental conditions, with different 
heterologous expression systems and experimental protocols being employed (Moss and 
Smart, 1996). Although these studies yielded different results, taken together, they indicate 
that PKC-mediated phosphorylation at the γ2L subunit plays a role in the functional 
modulation of GABAA receptors.  
 
Further to its effects on GABA-activated currents, phosphorylation at the γ2 subunit has also 
been shown to alter the actions of some GABAA receptor modulators, including ethanol and 
benzodiazepines (Wafford and Whiting, 1992; Qi et al., 2007). However, the results from the 
present study demonstrated that phosphorylation at the γ2L subunit is not required for the 
modulation of neurosteroid-mediated potentiation by protein kinases. At α1β3γ2LS327A,S343A 
receptors, exposure to staurosporine resulted in a significant reduction in the magnitude of 
potentiation elicited by 50nM THDOC. Thus, in contrast to α1β3S408A,S409Aγ2L GABAA receptors, 
the elimination of phosphorylation at the γ2L subunit does not affect neurosteroid-mediated 
potentiation, suggesting that phosphorylation at this subunit is not important for the 
modulation of neurosteroid activity at α1β3γ2L GABAA receptors. This is supported by further 
results which showed that, although the magnitude of potentiation elicited by neurosteroids at 
α1β3S408A,S409Aγ2LS327A,S343A GABAA receptors was significantly reduced compared to that 
observed at wild-type receptors, it was no different to that seen at α1β3S408A,S409Aγ2L subunit-
containing receptors, indicating that additional mutation of γ2L serines 327 and 343 does not 
further modulate the actions of neurosteroids at these receptors.  
 
4.3.4 Phosphorylation is not required for the induction of potentiation by 
neurosteroids 
The results from the previous chapter indicated that neurosteroid-mediated potentiation at 
GABAA receptors is modulated by, but does not require, protein kinase activity. This was 
demonstrated by the fact that potentiation was still evident after cells were treated with 
either staurosporine or bisindolylmaleimide I. Furthermore, neurosteroid-mediated 
potentiation was still apparent at receptors containing mutations at all known phosphorylation 
sites (α1β3S408A,S409Aγ2LS327A,S343A), indicating that phosphorylation is not required for the 
potentiation of GABAA receptor function by neurosteroids. However, there is a slight possibility 
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that phosphorylation of, as yet, unidentified sites may be contributing to the induction of 
neurosteroid-mediated potentiation, causing the residual level of potentiation observed at 
α1β3S408A,S409Aγ2LS327A,S343A GABAA receptors in the present study. It has been suggested that 
additional phosphorylation sites may exist at the GABAA receptor although their location is yet 
to be determined. A study by McDonald and Moss (1997) reported that a further site for PKC 
may exist on the β3 subunit and, although the levels of phosphorylation present at this site 
were thought to be minimal, it is still possible that phosphorylation at this or another 
unidentified site may be affecting the actions of neurosteroids at α1β3γ2L GABAA receptors. 
Identifying these novel phosphorylation sites may prove difficult if, as suggested by McDonald 
and Moss (1997), these sites are only subject to low levels of phosphorylation. A more 
effective method may be to examine the actions of neurosteroids at receptors containing 
truncated subunits which lack the large TM3-4 intracellular domain, which is thought to be the 
major target for protein kinase activity. Such subunits have been successfully constructed for 
GABAA ρ1 receptors, with Jansen et al (2008) demonstrating that replacement of the large 
intracellular loop of the ρ1 subunit with the comparatively short loop present in the 
prokaryotic homolog from Gloeobacter violaceus (Glvi) yielded functional receptors with 
similar pharmacological profiles to their wild-type counterparts. Therefore, it is conceivable 
that similar constructs could be created for the β3 and γ2L subunits, which could then be used 
to investigate whether neurosteroid-mediated potentiation can be induced at GABAA 
receptors when phosphorylation is completely and undisputedly eliminated. 
 
4.3.5 Modulation of GABAA receptors by neurosteroids and protein kinases is bi-
directional  
The results from the present investigation, together with those obtained from a number of 
previous studies, have demonstrated that levels of receptor phosphorylation can alter the 
modulatory effects of neurosteroids at GABAA receptors. Interestingly, the results from this 
study also showed that neurosteroids can modulate the phosphorylation of the receptor. 
Western blot analysis showed that, after treatment with neurosteroid for 20 min, cells 
expressing α1β3γ2L GABAA receptors exhibited a significant increase in the levels of β3 subunit 
phosphorylation, suggesting the presence of a ‘reverse’ signalling pathway in which 
neurosteroids can alter the extent of GABAA receptor phosphorylation. This effect was 
mediated via a direct interaction with the neurosteroid-binding site, since cells expressing 
mutant α1Q241W subunit-containing receptors exhibited no change in the level of β3 subunit 
phosphorylation after treatment with neurosteroid. Glutamine 241 is the most important of 
three key residues identified to date which are thought to form part of a neurosteroid binding 
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site at the GABAA receptor. Replacement of the polar glutamine residue with a hydrophobic 
tryptophan (Q241W) was sufficient to eliminate neurosteroid-mediated potentiation at GABAA 
receptors, suggesting that this residue is a crucial determinant for the neurosteroid-receptor 
interaction (Hosie et al., 2006). As mutation of α1 Q241 was sufficient to prevent the 
neurosteroid-mediated enhancement of receptor phosphorylation, this indicates that a direct 
interaction between the neurosteroid and GABAA receptor complex was necessary and 
sufficient for its effect. However, the signalling pathway downstream of this interaction, which 
results in the enhancement of β3 subunit phosphorylation, is yet to be determined (see 
General Discussion).  
 
4.3.6 Neurosteroids enhance GABAA receptor phosphorylation to a lesser extent than 
direct activation of PKC 
The extent to which neurosteroids could enhance β3 subunit phosphorylation was less than 
that induced by PMA, indicating that neurosteroids are less effective at promoting GABAA 
receptor phosphorylation than via the direct activation of PKC. This may suggest that 
neurosteroids are unlikely to be increasing receptor phosphorylation by directly activating PKC.  
This is, perhaps, unsurprising as this mechanism would be difficult to reconcile with the results 
from the mutant α1Q241Wβ3γ2L GABAA receptors. The difference in the effects of neurosteroids 
versus PMA may also be explained by the fact that cells were exposed to PMA for 30 min 
whereas the duration of neurosteroid treatment was shorter, at just 20 min, which may have 
resulted in the larger increase in receptor phosphorylation observed. Furthermore, it is unclear 
whether the neurosteroid-receptor interaction acts to directly activate protein kinases or 
whether it simply recruits active protein kinase molecules to the receptor microdomain or 
makes the kinase binding site on the receptor more accessible, thus facilitating 
phosphorylation. It may, therefore, be interesting to determine whether neurosteroids can 
enhance β3 subunit phosphorylation under conditions where the activation of protein kinases 
is perturbed, for example, by inhibiting the activities of phospholipase C or diacylglycerol. The 
experiments conducted in the present study have focused on the ability of neurosteroids to 
modulate phosphorylation at the β3 subunit. Therefore, it would also be of interest to discover 
whether this effect is specific to β3 or if neurosteroids can also enhance phosphorylation at 
the γ2L subunit. This may also provide further insight into whether the co-modulatory 
relationship between neurosteroids and protein kinases at GABAA receptors is mediated via 
interplay between neurosteroid-binding and the extent of phosphorylation at the β3 subunit, 
or whether the γ2L subunit may also play a role. In addition, as the results from the present 
study indicated that neurosteroid activity at α1β3γ2L GABAA receptors is modulated by the 
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activity of PKC alone, it is also important to determine whether the enhancement in receptor 
phosphorylation observed here is also mediated by PKC or whether the activities of other 
protein kinases can also be similarly modulated. 
 
4.3.7 Physiological significance of bi-directional modulation 
Perhaps the most intriguing question concerns the physiological significance of this modulation 
and the possible implications for GABAA receptors in vivo. A number of studies have indicated 
that, in addition to modulating receptor function, the activity of protein kinases, particularly 
PKC, may also be involved in the regulation of GABAA receptor trafficking. Activation of PKC 
promotes receptor internalization, causing a reduction in the number of receptors expressed 
at the cell surface (Chapell et al., 1998; Connolly et al., 1999; Filippova et al., 2000; Kittler et 
al., 2000). Although it is thought that this PKC-mediated endocytosis is independent of 
receptor phosphorylation (Chapell et al., 1998; Connolly et al., 1999), it may still be interesting 
to determine whether the enhancement of receptor phosphorylation by neurosteroids may be 
acting to modulate receptor trafficking. To investigate this, the levels of β3 subunit 
phosphorylation, before and after neurosteroid treatment, must be probed in the membrane 
and cytosolic cell fractions independently. A discrepancy in the extent of phosphorylation 
present at cell surface versus intracellular receptors may suggest that the neurosteroid-
mediated enhancement of receptor phosphorylation could be acting to modulate the 
trafficking of α1β3γ2L GABAA receptors, which will have important consequences for synaptic 
inhibition.   
 
In support of this idea, preliminary experiments examining the effects of neurosteroids on the 
trafficking of GABAA receptors showed that, in hippocampal neurons, treatment with 10μM 
allopregnanolone for 1hr significantly reduced the number of GABAA receptor α1 subunits 
expressed on the cell surface (decrease = 30.6 ± 2.6%, P < 0.05, ANOVA with Tukey’s post hoc 
test; n = 16; Fig. 4.9). This indicates that, in these neurons, exposure to neurosteroids can 
modulate the trafficking of GABAA receptors. This decrease was comparable to that induced by 
exposure to 100nM diazepam (decrease = 32.3 ± 1.3%, P < 0.05; n = 15; Fig. 4.9), which is 
consistent with results from a number of previous studies which have reported that exposure 
to benzodiazepines can induce a down-regulation of GABAA receptors from the cell surface 
(Miller et al., 1988; Brown and Bristow, 1996). This benzodiazepine-induced trafficking of 
receptors has been proposed to be mediated by protein kinases, with results showing that the 
decrease in cell surface expression of GABAA receptors can be abolished by treating cells with 
the protein kinase inhibitor, staurosporine (Brown and Bristow, 1996). Therefore, this, taken 
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together with the fact that neurosteroids have been shown to promote phosphorylation at the 
GABAA receptor (see Fig. 4.6), may suggest the neurosteroid-induced enhancement of 
phosphorylation may indeed act to modulate the trafficking of GABAA receptors. However, in 
order to confirm this, further study is required to investigate whether the effects of 
neurosteroids observed in hippocampal neurons can be abolished when cells are treated with 
protein kinase inhibitors. Furthermore, in these preliminary experiments, 10μM neurosteroid 
was used, a much higher concentration than that experienced in vivo. Therefore, it is also 
important to repeat these experiments with a lower, more physiological concentration of 
neurosteroid to determine whether at lower concentrations, neurosteroids can still induce a 
reduction in cell surface expression of GABAA receptor α1 subunits.  
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Figure 4.9 Neurosteroids reduce cell surface expression of α1 GABAA receptor subunits in 
cultured hippocampal neurons 
Immunofluorescence labeling for the GABAA receptor α1 subunit in cultured hippocampal neurons (7-
11DIV). Cells either remained untreated (left panel) or were exposed to either 10μM allopregnanolone 
(centre panel) or 100nM diazepam (right panel) for 1hr at 37°C. After treatment cells were fixed with 
paraformaldehyde (PFA) and labelled using an α1 antibody specific for the extracellular N-terminus of 
the protein (Alomone). Images in the bottom row are enlargements of the areas indicated. Scale bars = 
15μm (upper) and 3μm (lower). Bar chart shows the number of fluorescent, α1-positive puncta present 
per μm of dendrite in hippocampal neurons which were either untreated (white bar; n = 30) or exposed 
to 10μM allopregnanolone (allopreg; black bar; n = 16) or 100nM diazepam (grey bar; n = 15). Data is 
expressed as a % of the puncta present in untreated cells (=100%). All data points represent mean ± 
s.e.m. Significant results are indicated by * (P < 0.05, ANOVA with Tukey’s post hoc test).  
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4.3.8 Neurosteroid-induced enhancement of receptor phosphorylation may act as a 
positive feedback mechanism 
Given that previous results have indicated that the magnitude of neurosteroid-mediated 
potentiation can be enhanced by phosphorylation at the β3 subunit, neurosteroids increasing 
receptor phosphorylation may act as a kind of ‘positive feedback’ mechanism, promoting an 
enhancement in the magnitude of the potentiation induced. Indeed, a form of positive 
feedback, termed ‘auto-modulation’ has been reported in a study by Wegner et al (2007), 
showing that, at a number of GABAA receptor subtypes (including α1β3γ2L), repetitive co-
applications of GABA and neurosteroid, resulted in a ‘run-up’ of neurosteroid-mediated 
potentiation. This progressive enhancement in potentiation could be prevented by treatment 
of cells with Protein Kinase Inhibitor (PKI), indicating that this increase is likely to be mediated 
by PKA. Although this study did not examine whether direct receptor phosphorylation was 
required for this ‘auto-modulation’ to occur, the results from the present study suggest that 
this could be a feasible explanation. However, the study by Wegner et al also showed that this 
‘auto-modulation’ was only observed when GABA was co-applied with neurosteroid 
concentrations of 300nM and above and therefore, this is inconsistent with the results from 
the present study, where 50nM THDOC was able to induce a significant enhancement of 
receptor phosphorylation. This discrepancy may be explained by considering the time-course 
of the effects observed in this and the previous study. The ‘auto-modulatory’ effects described 
by Wegner et al were induced by repeated co-applications of GABA and neurosteroid, lasting 
around 2-5s, whereas, cells exposed to 50nM THDOC did not exhibit a significant enhancement 
of β3 subunit phosphorylation until cells had been exposed to the neurosteroid for 20 min. 
Therefore, it could be hypothesized that, if the ‘run-up’ of potentiation is indeed mediated by 
direct receptor phosphorylation, then two or three applications of 30nM alphaxalone, lasting a 
maximum of around 10-15s, is unlikely to be sufficient to cause receptor phosphorylation, 
which could explain the lack of ‘auto-modulation’ seen in cells exposed to this concentration of 
neurosteroid. 
 
4.3.9 Effects of phosphorylation on GABAA receptor function 
Phosphorylation has been shown to play an important role in the regulation of GABAA receptor 
function, with numerous studies demonstrating that this modulation can result in both 
enhancement and reduction of GABA-activated responses, depending on the protein kinase 
present and the subunit combination of the receptor (Moss and Smart, 1996). However, the 
results from the previous chapter showed that inhibition of protein kinase activity by 
staurosporine did not alter the magnitude of the EC20 GABA-activated currents recorded from 
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cells expressing α1β3γ2L GABAA receptors (see Chapter 3). It is, therefore, unsurprising that, in 
the present study, GABAA receptors containing mutations to prevent phosphorylation at one or 
more candidate sites also did not exhibit significant changes in the receptor’s response to EC20 
GABA after treatment with staurosporine. As discussed previously, this may be due to the 
disparate functional effects of PKC and PKA at β3 subunit-containing GABAA receptors, which, 
as staurosporine would be expected to inhibit both of these protein kinases, may result in a 
masking of the effects mediated by each individual protein kinase.  
 
However, this does not explain the results obtained at α1β3S408A,S409Aγ2L GABAA receptors, as, 
although the sites which remain intact on the γ2L subunit are only subject to phosphorylation 
by PKC (Moss et al., 1992a), there is still no obvious modulation of the EC20 GABA-activated 
currents after staurosporine treatment. A potential explanation for this is that there may be no 
basal phosphorylation present at the γ2L subunit, thus, any subsequent inhibition of protein 
kinases will have no functional effect. Another reason for this anomaly could be that the γ2L 
subunit may be targeted for phosphorylation by other protein kinases which may act to mask 
the modulatory effects mediated by PKC. In order to identify the protein kinases which are 
able to phosphorylate the γ2L subunit, many of the experiments carried out to date have 
utilised purified fusion proteins (Moss et al., 1992a), which, although offering a good indication 
of the protein kinases acting at this subunit, may not fully reflect the complex environment 
present within a native neuronal system. Therefore, this method may have failed to detect the 
effects of other protein kinases, however this remains to be determined.  
 
In contrast to the results from the staurosporine experiments, specific activation of PKC 
induced a significant reduction of EC20 GABA-activated currents recorded from cells expressing 
both wild-type and mutant GABAA receptors. Previous studies have demonstrated that 
phosphorylation at β3 subunit-containing GABAA receptors by PKC results in a decrease of 
receptor function (Brandon et al., 2000). Interestingly, at α1β3S408A,S409Aγ2L GABAA receptors, 
the PMA-induced reduction of GABA-activated current was not statistically significant, most 
likely reflecting the reduction in potential phosphorylation sites from four to two, resulting in a 
reduced capacity for modulation by PKC. This is supported by observations from both 
α1β3S408Aγ2L and α1β3S409Aγ2L GABAA receptors, which also exhibited slight reductions in the 
functional effects of PKC.  
 
Curiously, treatment of cells with the specific PKC inhibitor, bisindolylmaleimide I, caused no 
significant alteration of EC20 GABA-activated responses recorded from cells expressing either 
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wild-type or mutant GABAA receptors. This is inconsistent with the results from Western blot 
analysis which showed that the level of basal phosphorylation present at the β3 subunit could 
be reduced by treating cells with bisindolylmaleimide I, indicating that PKC-mediated 
phosphorylation is present at the GABAA receptor under basal cell conditions and that 
bisindolylmaleimide I is effective at ablating this phosphorylation within the duration of the 
experiment. Therefore, this suggests that there may be additional modifications occurring 
which could compensate for the effects of the PKC inhibitor. For example, it is possible that 
there may be an up-regulation of phosphorylation at other sites, such as those on the γ2L 
subunit, which may act to oppose the changes in GABAA receptor function caused by the 
decrease in β3 subunit phosphorylation.  
 
4.3.10 Are all GABAA receptor subtypes modulated similarly? 
The experiments carried out in this study so far have focussed on the co-modulatory 
relationship between neurosteroids and protein kinases at typical ‘synaptic-type’ GABAA 
receptors. However, other receptor subtypes have been shown to exist outside of inhibitory 
synapses (Somogyi et al., 1989; Nusser et al., 1998; Wei et al., 2003; Jia et al., 2005). These 
‘extrasynaptic’ receptors mediate a slow ‘tonic’ form of neuronal inhibition thought to play an 
important role in the regulation of CNS excitability (Semyanov et al., 2004; Farrant and Nusser, 
2005; Belelli et al., 2009). Therefore, it was of interest to determine whether the actions of 
neurosteroids at typical ‘extrasynaptic-type’ GABAA receptors could also be modulated by 
protein kinase activity.   
 
4.4 Conclusions 
 
 PKC acts to modulate the actions of neurosteroids at α1β3γ2L subunit-containing 
GABAA receptors via direct phosphorylation of the β3 subunit.  
 
 Phosphorylation at β3 S408 or S409, but not γ2L S327 or S343 modulates neurosteroid 
potentiating activity. 
 
 Induction of neurosteroid-mediated potentiation does not require direct receptor 
phosphorylation. 
 
 THDOC enhances phosphorylation at the β3 subunit via a direct interaction with the 
GABAA receptor. 
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Chapter 5 
 
Neurosteroid modulation of extrasynaptic-type GABAA receptors: 
regulation by protein kinases via direct receptor phosphorylation 
 
5.1 Introduction 
Activation of GABAA receptors has been shown to generate two distinct forms of inhibition. 
Synaptic or ‘phasic’ inhibition is mediated by the rapid, transient release of GABA from pre-
synaptic terminals which diffuses rapidly across the synaptic cleft to activate receptors 
clustered at the postsynaptic site. In contrast, GABAA receptors located extrasynaptically to 
inhibitory synapses are responsible for mediating a slower ‘tonic’ form of inhibition in 
response to their persistent activation by low, ambient concentrations of GABA (Farrant and 
Nusser, 2005). The differing spatial and temporal characteristics of these two modes of 
inhibition results in them having profoundly different effects on neuronal network activity. 
Synaptic inhibition mediates its effects in a precise, neuron-specific manner, whereas, 
prolonged activation of spatially diverse extrasynaptic receptors generates a more widespread 
inhibitory effect (Semyanov et al., 2004; Farrant and Nusser, 2005).  
 
The presence of tonic inhibition was initially discovered in cerebellar granule cells, with studies 
showing that the application of GABAA receptor antagonists resulted in a decrease in the 
‘holding current’ recorded from these neurons, implying the presence of a ‘background’ 
conductance which is mediated by the persistent activation of GABAA receptors (Kaneda  et al., 
1995; Brickley et al., 1996). Subsequent studies have indicated that tonic inhibition is also 
present in a number of other neuronal populations including: thalamic relay neurons (Porcello 
et al., 2003; Cope et al., 2005; Jia et al., 2005), dentate gyrus granule cells (Nusser and Mody, 
2002) and neurons from the CA1 region of the hippocampus (Bai et al., 2001; Semyanov et al., 
2003). Moreover, the tonic inhibition present in these neurons has been shown to be 
mediated by GABAA receptors located outside of synapses, with studies from knock-out mice 
showing that deletion of the extrasynaptically located δ subunit (Nusser et al., 1998; Wei et al., 
2003; Jia et al., 2005), significantly reduces the tonic conductance recorded from cerebellar 
granule cells (Brickley et al., 2001; Stell et al., 2003), dentate gyrus granule cells (Stell et al., 
2003) and thalamic relay neurons (Porcello et al., 2003). In accordance with this, extrasynaptic 
receptors have been shown to contain specific subsets of receptor subunits which convey 
biophysical properties consistent with their involvement in tonic inhibition. In contrast to 
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synaptic receptors, which are thought to consist of γ2 subunits, in combination with α1, α2 or 
α3, it has been suggested that the majority of extrasynaptic receptors contain the δ subunit in 
association with α4 or α6, possibly supplemented with α5βγ and also αβ receptors (Farrant 
and Nusser, 2005; Mortensen and Smart, 2006; Glykys et al., 2008; Olsen and Sieghart, 2008). 
The inclusion of these subunits within extrasynaptic receptors results in their enhanced 
sensitivity to agonist as well as a reduction in the speed and extent to which they undergo 
desensitisation (Saxena and Macdonald, 1994; Fisher and Macdonald, 1997; Haas and 
Macdonald, 1999; Brown et al., 2002) making them ideally specialised for prolonged exposure 
to low concentrations of GABA which receptors positioned outside of the synapse are likely to 
encounter. However, recently, αβδ receptors have been shown to desensitise to a far greater 
extent than originally envisaged (Mortensen et al., 2010).  
 
Although the effects mediated by tonic inhibition are thought to be more widespread, it is still 
considered to be an important mechanism for the regulation of neuronal excitability in vivo. In 
fact, the dysfunction of tonic inhibition has been shown to be a common feature of a number 
of neurological disorders including epilepsy (Dibbens et al., 2004; Maguire et al., 2005; Naylor 
et al., 2005; Scimemi et al., 2005; Feng et al., 2006; Zhang et al., 2007; Cope et al., 2009), stress 
(Maguire and Mody, 2007), Fragile X syndrome (Curia et al., 2009) and mood disorders 
associated with the ovarian cycle (Maguire et al., 2005; Shen et al., 2007) and pregnancy 
(Maguire and Mody, 2008; Maguire et al., 2009). Therefore, it is important to understand the 
mechanisms by which extrasynaptic receptors are modulated in vivo as this may provide 
further insight into the pathogenesis of these conditions as well as identifying potential 
therapeutic targets.  
 
Studies of recombinant GABAA receptors have shown that neurosteroids can potentiate GABA-
activated currents at typical ‘extrasynaptic-type’ receptors, although early studies indicated 
that inclusion of the exclusively extrasynaptic δ subunit significantly reduced the magnitude of 
potentiation induced (Zhu et al., 1996). However, more recent studies showed that, to the 
contrary, receptors incorporating the δ subunit exhibited enhanced neurosteroid potentiation 
compared to those containing γ2 (Belelli et al., 2002; Brown et al., 2002; Wohlfarth et al., 
2002). Moreover, studies of native GABAA receptors have shown that neurosteroids can 
potentiate GABA-mediated tonic currents in a number of neuronal populations including 
cerebellar granule cells (Hamann et al., 2002; Stell et al., 2003) and dentate gyrus granule cells 
(Stell et al., 2003), suggesting that neurosteroids may play an important role in the regulation 
of tonic inhibition. In fact, in both of these sets of neurons, physiological concentrations of 
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neurosteroid (10nM) have been shown to selectively enhance tonic currents, with little or no 
effect observed at synaptic GABAA receptors (Stell et al., 2002; Harney et al., 2003). 
Furthermore, the enhancement of tonic currents by neurosteroids was abolished in δ knock-
out mice (Stell et al., 2002). Collectively, these results suggest that the actions of neurosteroids 
at extrasynaptic GABAA receptors may play a significant role in the regulation of tonic 
inhibition and therefore, it is important to understand how the presence of other endogenous 
modulators, such as protein kinases, may affect this regulatory relationship in vivo. 
 
5.2 Results 
In order to investigate whether the activity of protein kinases is important for regulating the 
magnitude of neurosteroid potentiation at ‘extrasynaptic-type’ receptors, HEK293 cells were 
transfected to express α4β3δ subunit-containing GABAA receptors. Cells were transfected with 
cDNAs encoding each receptor subunit in a 1:1:1 ratio and, as in previous experiments, were 
co-transfected with eGFP to enable the identification of expressing cells. The δ subunit has 
proved difficult to express in recombinant cell systems, however, a number of previous studies 
have shown that co-expression of δ, in combination with α4 and β3 subunits, produces 
functional receptors at the cell surface that exhibit pharmacological profiles consistent with 
the incorporation of the δ subunit (Brown et al., 2002; Stórustovu and Ebert, 2006; Hosie et al., 
2008; Meera et al., 2009). To ensure that the receptors expressed in the present study did 
indeed contain the δ subunit, sensitivity to the hypnotic drug, 4,5,6,7-tetrahydroisothiazolo-
[5,4-c]pyridine-3-ol (THIP) was examined. THIP has been shown to exhibit ‘super-agonist’ 
activity at δ subunit-containing receptors compared to its partial agonism at αβγ receptors 
(Brown et al., 2002; Stórustovu and Ebert, 2006; Mortensen et al., 2010). Therefore, this drug 
can be used as a reliable indicator of the presence of δ subunits within the receptor complex. 
To investigate the agonist activity of THIP, peak currents were recorded in response to brief 
(usually 3s) applications of either, near saturating 100μM GABA or 100μM THIP (Fig. 5.1A). The 
results showed that 100μM THIP induced currents that were significantly larger than those 
elicited by 100μM GABA (increase = 35.6 ± 4.1%, mean ± s.e.m., P < 0.05, paired t-test; n = 15; 
Fig. 5.1B), with the magnitude of the THIP responses being indicative of receptors 
incorporating α4β3δ, rather than α4β3 subunits. Therefore, this indicates that the receptors 
expressed here contain the δ subunit. This process was completed in all cells prior to the 
experimental period to ensure that each cell expressed functional α4β3δ subunit-containing 
GABAA receptors at the cell surface. After THIP sensitivity was assessed, cells were exposed to 
brief applications of EC20 GABA at 2 min intervals until a stable current response was achieved. 
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After this period, further experiments investigating the effects of phosphorylation, by protein 
kinases, on the potentiation of GABAA receptor function by neurosteroids were carried out.  
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Figure 5.1 HEK293 cells expressing α4β3δ GABAA receptors exhibit THIP ‘super-agonist’ 
activity  
(A) Peak currents recorded from HEK293 cells expressing α4β3δ subunit-containing GABAA receptors in 
response to either 100μM GABA (grey bar) or 100μM THIP (black bar). (B) Bar chart showing the mean 
agonist-activated currents recorded (n = 15). Each response elicited by 100μM THIP was normalised to 
the peak current induced by 100μM GABA in the same cell (= 100%). All data points represent mean ± 
s.e.m. Significant results are indicated by * (P < 0.05, paired t-test). 
 
 
Experiments were conducted as in the previous two chapters, with whole-cell patch clamp 
electrophysiology being used to assess the magnitude of potentiation elicited by 50nM THDOC, 
before and after cell treatment with compounds to inhibit protein kinase activity. For each cell, 
baseline responses to EC20 GABA and potentiated responses after co-applications of EC20 GABA 
and 50nM THDOC were established under basal cell conditions and after the treatment period. 
Each potentiated response was normalised to the cell’s preceding response to EC20 GABA alone 
in order to allow direct comparisons to be made between the potentiation elicited before and 
after the treatment period.  
 
5.2.1 THDOC-mediated potentiation at α4β3δ GABAA receptors is decreased after 
protein kinase inhibition  
To determine whether the actions of neurosteroids at α4β3δ GABAA receptors could be 
modulated by the activity of protein kinases, cells were treated with the broad-spectrum 
protein kinase inhibitor, staurosporine. After establishing the baseline and potentiated 
responses elicited by GABA under basal cell conditions, cells were treated with 200nM 
staurosporine, applied extracellularly via the bath perfusion. During the treatment period the 
cell’s response to EC20 GABA was monitored every 2 min in order to examine the effects of 
staurosporine on the receptor’s response to agonist alone. In cells expressing α4β3δ GABAA 
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receptors, inhibition of protein kinase activity by staurosporine did not significantly alter the 
EC20 GABA-activated response, with a negligible change of only 10.2 ± 6.8% being observed, 
which did not differ significantly from that seen in untreated cells (3.4 ± 9.2%, mean ± s.e.m., P 
> 0.05; n = 5-9; Fig. 5.2B). 
 
After staurosporine treatment, the baseline and potentiated responses were re-measured and 
the potentiation elicited by 50nM THDOC before and after protein kinase inhibition was 
compared.  Control experiments carried out in cells which remained untreated for the duration 
of the experiment showed no change in THDOC-mediated potentiation (change = 4.7 ± 7.9%, P 
> 0.05; n = 5; Fig. 5.2A). By contrast, cells treated with 200nM staurosporine for 14 min 
exhibited a significant reduction in the magnitude of potentiation induced by 50nM THDOC 
(decrease = 38.1 ± 5.8%, P < 0.05, paired t-test; n = 9; Fig. 5.2B). This indicates that the actions 
of neurosteroids at α4β3δ GABAA receptors can be modulated by the activity of protein 
kinases. Furthermore, the results showed that the protein kinases are not required for the 
induction of THDOC-mediated potentiation at these receptors, with 50nM THDOC still 
enhancing the EC20 GABA-activated current by 83.7 ± 18.5% after staurosporine treatment (Fig. 
5.2B).  
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Figure 5.2 Staurosporine decreases THDOC-mediated potentiation at α4β3δ GABAA receptors  
(A) Mean peak currents recorded from HEK293 cells expressing α4β3δ GABAA receptors in response to 
EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells either remained untreated 
for the duration of the recording (upper panel) or were treated with 200nM staurosporine (lower panel; 
light blue shading). All responses were normalised to the peak current of the first EC20 GABA-activated 
response, recorded 2 min after achieving the whole-cell recording configuration, designated as t = 0 (= 
100%). Example whole-cell currents show the potentiation elicited by 50nM THDOC (grey bar) before 
and after staurosporine treatment (light blue bar). Current traces are representative of recordings at the 
time points indicated. Bar chart shows the potentiation of EC20 GABA-activated currents by 50nM 
THDOC in untreated cells (grey bars, measured at 6 min and 26 min, respectively; n = 5) or in treated 
cells before (black bar) and after (light blue bar) 200nM staurosporine treatment (n = 9). (B) Bar chart 
showing the change in peak receptor response elicited by EC20 GABA in untreated cells (UT, black bar; n 
= 5) or cells treated with 200nM staurosporine (light blue bar; n = 9). Change was measured between 2 
min (before treatment) and 32 min (after treatment or at corresponding time points in untreated cells). 
Responses were normalised to the peak current recorded at 2 min. All data points represent mean ± 
s.e.m. Significant results are indicated by * (P < 0.05, paired t-test). 
 
 
Interestingly, staurosporine induces a smaller decrease in THDOC potentiation at α4β3δ GABAA 
receptors compared to that observed at α1β3γ2L receptors (38.1 ± 5.8% versus 54.8 ± 9.1% 
reduction, respectively; Fig. 5.3). This indicates that, although the activity of protein kinases 
acts to modulate neurosteroid potentiation at extrasynaptic GABAA receptors, this occurs to a 
lesser extent than at synaptic-type receptors. Another potential explanation for this 
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discrepancy is that there may be a reduced level of basal phosphorylation present at α4β3δ 
receptors, reducing its capacity for modulation by staurosporine.   
 
A number of studies have reported that GABAA receptors incorporating the δ subunit are more 
sensitive to the potentiating actions of neurosteroids (Belelli et al., 2002; Brown et al., 2002; 
Wohlfarth et al., 2002). However, in the present study, the magnitude of potentiation elicited 
by 50nM THDOC at α4β3δ GABAA receptors did not differ significantly from that observed 
previously at α1β3γ2L receptors (potentiation = 128 ± 23.6% and 99.1 ± 13.8%, respectively, P 
> 0.05; n = 5-9; Fig. 5.3).    
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Figure 5.3 Comparison between the effects of staurosporine at α4β3δ versus α1β3γ2L GABAA 
receptors  
Bar chart showing the potentiation of EC20 GABA-activated currents by 50nM THDOC in HEK293 cells 
expressing either α1β3γ2L or α4β3δ GABAA receptors, before and after treatment with 200nM 
staurosporine for 14 min. Responses were normalised to the peak response elicited by EC20 GABA alone 
(= 100%). All data points represent mean ± s.e.m. Significant results are indicated by * (P < 0.05, paired 
t-test) and ns = not statistically significant.    
 
 
Although the results from this experiment indicated that the actions of neurosteroids at 
extrasynaptic-type GABAA receptors are positively modulated by the activity of protein kinases, 
it remained to be determined whether, similar to synaptic-type receptors, this effect was 
mediated by direct phosphorylation of the receptor complex. Therefore, mutant receptors 
were examined to explore whether phosphorylation at a specific site(s) was important for the 
regulation of neurosteroid potentiation at α4β3δ GABAA receptors. 
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5.2.2 Phosphorylation of β3 subunits is insufficient to account for protein kinase 
modulation of THDOC potentiation at α4β3δ GABAA receptors 
The results presented in the previous chapter showed that, at α1β3γ2L GABAA receptors, the 
extent of β3 subunit phosphorylation regulates the magnitude of neurosteroid potentiation. 
Therefore, it was hypothesized that phosphorylation at the β3 subunit may also be important 
for the modulation of neurosteroid activity at α4β3δ receptors. To investigate this, cells were 
transfected to express GABAA receptors containing mutant β3
S408A,S409A subunits, in 
combination with wild-type α4 and δ. As discussed previously, serine to alanine amino acid 
substitutions have been shown to be effective at preventing phosphorylation at the target site 
(Moss et al., 1992; McDonald and Moss, 1997). After staurosporine treatment, cells expressing 
α4β3S408A,S409Aδ GABAA receptors exhibited no significant change in EC20 GABA-activated 
currents (percentage change measured between 2 and 32 min = 6.5 ± 4.7%; n = 10; Fig. 5.6C). 
By contrast, THDOC-mediated potentiation was significantly reduced after staurosporine 
treatment (decrease = 27.2 ± 4.6%, P < 0.05, paired t-test; n = 9; Fig. 5.4), implying that 
phosphorylation at the β3 subunit is not required for the modulation of neurosteroid 
potentiation by protein kinases. However, staurosporine was notably less effective at 
α4β3S408A,S409Aδ GABAA receptors, with a smaller decrease in potentiation being observed at 
these compared to wild-type receptors (27.2 ± 4.6% versus 38.1 ± 5.8%; Fig. 5.4). This suggests 
that phosphorylation at the β3 subunit may play a role in the modulation of neurosteroid 
activity at α4β3δ receptors, but that phosphorylation at this subunit is not sufficient to 
completely account for the modulatory effects of protein kinases observed at wild-type 
receptors. Therefore, this indicates that phosphorylation at other residues and/or subunits 
may also be important for the regulation of neurosteroid potentiation at this receptor subtype.  
 
Interestingly, there was a modest decrease in the potentiation elicited by 50nM THDOC at 
α4β3S408A,S409Aδ versus wild-type GABAA receptors under basal cell conditions (potentiation = 
107 ± 30.3% and 128 ± 23.6%, respectively, P > 0.05; n = 9-10; Fig. 5.4), which, once again, 
implies that phosphorylation at the β3 subunit may be involved in the regulation of 
neurosteroid potentiation at α4β3δ GABAA receptors. However, as this decrease was much less 
than that observed at wild-type receptors after protein kinase inhibition, this indicates that 
phosphorylation at other residues and/or subunits must also contribute to this effect.  
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Figure 5.4 Staurosporine decreases THDOC-mediated potentiation at α4β3S408A,S409Aδ GABAA 
receptors  
Mean peak currents recorded from HEK293 cells expressing α4β3
S408A,S409A
δ GABAA receptors in response 
to EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open squares). Cells were treated with 
200nM staurosporine (as indicated by light blue shading). All responses were normalised to the peak 
current of the first EC20 GABA-activated response, recorded 2 min after achieving whole-cell recording 
configuration, designated as t = 0. Example whole-cell currents show the potentiation elicited by 50nM 
THDOC (grey bar) before and after staurosporine treatment (light blue bar). Current traces are 
representative of recordings at the time points indicated. Bar chart shows the potentiation of EC20 
GABA-activated currents by 50nM THDOC before (black bars) and after (light blue bars) staurosporine 
treatment in cells expressing α4β3δ (n = 9) or α4β3
S408A,S409A
δ (n = 7) GABAA receptors. Data displayed 
for α4β3δ receptors is as shown previously in Fig. 5.2. All data points represent mean ± s.e.m. Significant 
results are indicated by * (P < 0.05, paired t-test). 
 
 
5.2.3 Presence of a novel phosphorylation site on the GABAA receptor α4 subunit 
As discussed previously, the GABAA receptor has been shown to possess a number of 
consensus phosphorylation sites which can be targeted by numerous Ser/Thr and Tyr protein 
kinases (Moss et al., 1992a, 1995; McDonald and Moss, 1994, 1997). To date, sites have been 
identified on the β and γ2 subunit families, indicating that, at α4β3δ GABAA receptors, there 
are only two potential phosphorylation sites (β3 serines 408 and 409) through which protein 
kinases could act to modulate the actions of neurosteroids. However, this is inconsistent with 
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the results from the present study which showed that abolition of phosphorylation at the β3 
subunit was not sufficient to prevent the staurosporine-induced decrease in neurosteroid 
potentiation at this receptor subtype. Interestingly, however, recent experiments have 
identified a novel PKC phosphorylation site on the α4 subunit, at serine 443 (Abramian and 
Moss, unpublished; Fig. 5.5), which is not thought to be present on other members of the α 
subunit family (Moss et al., 1992a; Moss and Smart, 1996). Therefore, further experiments 
were carried out in order to examine the role of phosphorylation at α4 S443 in the regulation 
of neurosteroid activity at α4β3δ GABAA receptors.  
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Figure 5.5 Existence of a novel PKC phosphorylation site, at S443 on the GABAA receptor α4 
subunit 
(A) COS7 cells expressing either α4β3 (top panel) or α4
S443A
β3 (bottom panel) GABAA receptors were pre-
labelled with 0.5 mCi/ml [
32
P]-orthophosphoric acid for 4 hours. After the labeling period, cells were 
incubated with 500nM PDBu (or DMSO for control cells) for 10 min. Cells were then lysed and subject to 
immunoprecipitation using α4 anti-sera. Bead samples were separated using SDS-PAGE followed by 
autoradiography to assess 
32
P incorporation. (B) Bar chart showing the amount of 
32
P incorporated in 
COS7 cells expressing either α4β3 or α4
S443A
β3 in response to treatment with 500nM PDBu for 10 min. 
The levels of phosphorylation were normalised to the amount detected in the corresponding DMSO 
treated control cell group (= 100%). All data points represent mean ± s.e.m. Significant results are 
indicated by * (P < 0.05, paired t-test). Data presented in this figure was obtained from experiments 
carried out by Matthew Abramian in the laboratory of Professor Stephen J Moss at Tufts University 
School of Medicine, Boston, USA.  
 
 
5.2.4 Phosphorylation of both the α4 and β3 subunits regulates neurosteroid activity 
at α4β3δ GABAA receptors 
To explore the involvement of α4 subunit phosphorylation in the modulation of neurosteroid 
potentiation, site-directed mutagenesis was used to substitute serine 443 with a neutral 
alanine residue in order to prevent phosphorylation at this site (see Materials and Methods). 
The resulting α4S443A cDNA construct was expressed in HEK293 cells in combination with either 
wild-type β3 and δ or with mutant β3S408A,S409A and wild-type δ subunits. The magnitude of 
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potentiation elicited by 50nM THDOC was then assessed before and after staurosporine 
treatment. Similar to the results obtained for α4β3S408A,S409Aδ GABAA receptors, cells expressing 
α4S443Aβ3δ receptors exhibited a significant decrease in THDOC-mediated potentiation after 
treatment with 200nM staurosporine for 14 min (decrease = 24.5 ± 4.3%, P < 0.05, paired t-
test; n = 7; Fig. 5.6A,B). The effects of staurosporine were notably less effective at receptors 
containing α4S443A subunits compared to wild-type receptors (decrease = 24.5 ± 4.3% versus 
38.1 ± 5.8%, respectively; Fig. 5.6A,B). This suggests that phosphorylation at α4 S443 is likely to 
be involved in regulating neurosteroid activity at α4β3δ GABAA receptors, although, again, it is 
not sufficient to induce the full modulation observed at wild-type receptors. By contrast, in 
cells expressing α4S443Aβ3S408A,S409Aδ receptors the magnitude of potentiation elicited by 50nM 
THDOC was unaffected by staurosporine treatment (change = 0.9 ± 6.5%, P > 0.05; n = 7; Fig. 
5.6A,B), thus, phosphorylation at both the α4 and β3 subunits must be abolished in order to 
fully prevent the staurosporine-induced decrease in THDOC potentiation. This indicates that 
phosphorylation at both α4 and β3 is important for regulating neurosteroid activity at α4β3δ 
GABAA receptors. However, the fact that a reduced, but significant reduction of THDOC-
mediated potentiation can be induced by the inhibition of protein kinase activity at α4S443Aβ3δ 
and α4β3S408A,S409Aδ GABAA receptors, suggests that phosphorylation at either α4 S443 or β3 
S408/S409 is able to modulate the actions of neurosteroids to some extent, although it 
appears that phosphorylation at both subunits is required to induce the full modulatory effect.  
 
Interestingly, the decrease in potentiation observed at α4S443Aβ3δ and α4β3S408A,S409Aδ GABAA 
receptors was not additive compared to that induced at wild-type receptors, with results 
showing that, at α4S443Aβ3δ and α4β3S408A,S409Aδ receptors, respectively, staurosporine 
treatment induced a decrease in neurosteroid potentiation that was 64.3% and 71.4% of that 
observed at α4β3δ receptors (Fig. 5.4 and 5.6B). This indicates that phosphorylation at each 
subunit can induce approximately two thirds of the total modulation observed at wild-type 
receptors and that additional phosphorylation at the second subunit acts to enhance this 
effect by around 50% of its own modulatory capacity. Curiously, it appears that 
phosphorylation at either subunit is capable of inducing the initial two thirds of this 
modulation, with the actions of protein kinases at one subunit not appearing to be more 
effective at regulating the activity of neurosteroids than the other. 
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Figure 5.6 Staurosporine decreases THDOC-mediated potentiation at α4S443Aβ3δ, but not at 
α4S443Aβ3S408A,S409Aδ GABAA receptors  
(A) Mean peak currents recorded from HEK293 cells expressing α4
S443A
β3δ (n = 7) or α4
S443A
β3
S408A,S409A
δ 
(n = 7) GABAA receptors in response to EC20 GABA (filled squares) or EC20 GABA + 50nM THDOC (open 
squares). Cells were treated with 200nM staurosporine (light blue shading). All responses were 
normalised to the peak current of the first EC20 GABA-activated response, recorded 2 min after achieving 
whole-cell recording configuration, designated as t = 0. Example whole-cell currents show the 
potentiation elicited by 50nM THDOC (grey bar) before and after staurosporine treatment (light blue 
bar). Current traces are representative of recordings at the time points indicated. (B) Bar chart showing 
the mean potentiation of EC20 GABA-activated currents by 50nM THDOC before (black bars) and after 
(light blue bars) staurosporine treatment in cells expressing α4β3δ (n = 9), α4
S443A
β3δ (n = 7) or 
α4
S443A
β3
S408A,S409A
δ (n = 7) GABAA receptors. Data displayed for α4β3δ receptors here, and in (C), is as 
shown previously in Fig. 5.2. (C) Bar chart showing the change in peak receptor response elicited by EC20 
GABA before (open bar) or after treatment with 200nM staurosporine (light blue bars) in cells 
expressing α4β3δ, α4
S443A
β3δ or α4
S443A
β3
S408A,S409A
δ  GABAA receptors. Change was measured between 2 
min (before treatment) and 32 min (after treatment). All data points represent mean ± s.e.m. Significant 
results are indicated by * (P < 0.05, paired t-test).  
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Another notable observation from this experiment was that, similar to α4β3S408A,S409Aδ GABAA 
receptors, the magnitude of potentiation elicited at α4S443Aβ3δ receptors, under basal cell 
conditions, did not differ significantly from that observed at wild-type receptors, implying, 
once again, that phosphorylation at either subunit can sustain the majority of the THDOC 
potentiation at α4β3δ GABAA receptors. Intriguingly, although the results showed a trend 
towards a decrease in the magnitude of basal THDOC potentiation induced at 
α4S443Aβ3S408A,S409Aδ versus wild-type receptors, this was not statistically significant 
(potentiation = 89.7 ± 15.3% at α4S443Aβ3S408A,S409Aδ compared to 128 ± 23.6% at α4β3δ 
receptors; Fig. 5.2A and 5.6A,B). However, this modest decrease of approximately 30% is 
consistent with the relatively low levels of staurosporine-induced modulation observed at 
α4β3δ receptors (38.1 ± 5.8%; Fig. 5.2). Therefore, this may suggest that the level of basal 
phosphorylation at this receptor subtype is low compared to that present at α1β3γ2L 
receptors, resulting in a reduced potential for modulation after either protein kinase inhibition 
or the abolition of phosphorylation through the mutation of consensus sites.  
 
Interestingly, the results from the mutant receptor experiments showed that neurosteroid 
potentiation is still evident at α4S443Aβ3S408A,S409Aδ GABAA receptors, with 50nM THDOC still 
inducing a 89.7 ± 15.3% enhancement of the EC20 GABA-activated current (Fig. 5.6C). This 
supports the results from the protein kinase inhibition experiment and demonstrates that 
phosphorylation, by protein kinases is not required to induce THDOC-mediated potentiation at 
α4β3δ GABAA receptors.  
 
As in previous experiments, the EC20 GABA-activated current was monitored throughout the 
staurosporine treatment period in order to assess the effects of protein kinase inhibition on 
the receptor’s response to agonist alone. Similar to the results obtained for wild-type 
receptors, cells expressing α4S443Aβ3δ or α4S443Aβ3S408A,S409Aδ GABAA receptors exhibited no 
change in the magnitude of responses elicited by EC20 GABA after treatment with 200nM 
staurosporine for 20 min (change = 7.7 ± 15.6% for α4S443Aβ3δ and 5.5 ± 5.5% for 
α4S443Aβ3S408A,S409Aδ receptors, P > 0.05; n = 7; Fig. 5.6C).  
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5.3 Discussion 
 
5.3.1 Protein kinases positively modulate the actions of neurosteroids at 
‘extrasynaptic-type’ GABAA receptors 
GABAA receptors containing the δ subunit are located extrasynaptically to inhibitory synapses 
and are responsible for mediating a widespread ‘tonic’ inhibition in response to low, ambient 
concentrations of GABA. Modulation of tonic inhibition has been shown to alter the overall 
excitability of neurons (Semyanov et al., 2004; Farrant and Nusser, 2005) and therefore, 
endogenous agents that modulate extrasynaptic receptors will have important consequences 
for neural network activity. To date, studies investigating the relationship between 
neurosteroids and phosphorylation have predominantly focussed on their effects at typical 
‘synaptic’ GABAA receptors, however, studies have shown that receptors located 
extrasynaptically are also subject to modulation by both neurosteroids and protein kinases 
(Herd et al., 2007; Smith et al., 2007; Bright and Smart, unpublished). Therefore, it was 
hypothesised that, a similar co-modulatory relationship may exist between neurosteroids and 
protein kinases at extrasynaptic GABAA receptors. This was confirmed by results from the 
present study which showed that, at α4β3δ receptors, inhibition of protein kinase activity 
caused a significant decrease in the magnitude of potentiation elicited by 50nM THDOC. (see 
Fig. 5.2). GABAA receptors incorporating α4 and δ subunits have been shown to be located 
outside of inhibitory synapses in a number of brain regions including the dentate gyrus and 
thalamus (Sperk et al., 1997; Sur et al., 1999; Pirker et al., 2000; Peng et al., 2004; Jia et al., 
2005) and therefore, these results indicate that the actions of neurosteroids at extrasynaptic 
receptors are positively modulated by the activity of protein kinases. 
 
5.3.2 Protein kinases are less effective at modulating neurosteroid activity at 
extrasynaptic- compared to synaptic-type GABAA receptors  
An interesting observation from the present study was that, although staurosporine treatment 
induced a significant decrease in neurosteroid potentiation at α4β3δ GABAA receptors, this 
decrease was less than that seen at α1β3γ2L subunit-containing receptors (see Chapter 3), 
indicating that the modulatory effects mediated by protein kinases at synaptic and 
extrasynaptic GABAA receptors may not be equivalent. This may have important implications 
for the regulation of phasic and tonic inhibition in vivo, suggesting that the phasic inhibition 
mediated by synaptically located GABAA receptors has a greater potential to undergo ‘fine-
tuning’ through the co-operative actions of neurosteroids and protein kinases. However, 
another reason for this discrepancy is that α4β3δ GABAA receptors may be subject to reduced 
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levels of basal phosphorylation, resulting in a reduced potential for modulation by protein 
kinase inhibitors such as staurosporine. The actions of protein kinases are reliant upon the 
availability of appropriate accessory proteins, such as RACK-1 and AKAP79/150, which enable 
the protein kinase to be anchored to the receptor, within a defined compartment, facilitating 
the phosphorylation process (Pawson and Scott, 1997; Colledge and Scott, 1999). Therefore, 
one factor which will determine whether GABAA receptors are phosphorylated under basal cell 
conditions is the presence of these proteins and their ability to bind to the receptor, which 
could differ between the synaptic and extrasynaptic receptor populations. It is possible that, 
given the mobility of extrasynaptic receptors in the membrane (Thomas et al., 2005), as well 
as, for the majority of extrasynaptic receptors, the inability to detect interactions with any 
defined scaffolding proteins, they may be less amenable to rigid interactions with protein 
kinases and their associated proteins, resulting in them being phosphorylated to a lesser 
extent.  
 
5.3.3 THDOC potentiates α4β3δ and α1β3γ2L subunit-containing GABAA receptors to 
a similar extent 
A number of studies have reported that GABAA receptors incorporating the δ subunit exhibit 
enhanced sensitivity to neurosteroids (Belelli et al., 2002; Brown et al., 2002; Wohlfarth et al., 
2002). However, the results from the present study showed that the magnitude of 
potentiation elicited by 50nM THDOC at α4β3δ GABAA receptors was not significantly different 
from that induced at receptors containing α1β3γ2L subunits (see Fig. 5.3). The δ subunit is 
considered difficult to express in recombinant cell systems and therefore it is possible that this 
lack of difference between the potentiation observed at δ versus γ2L subunit-containing 
receptors may be due to the receptors not incorporating the δ subunit. However, the results 
from the present study showed that co-expression of δ, in combination with α4 and β3 
subunits, produced functional receptors which incorporated the δ subunit. This was 
determined by the magnitude of THIP ‘super-agonist’ activity, which was indicative of 
receptors incorporating α4β3δ, rather than α4β3 subunits (Stórustovu and Ebert, 2006; 
Krogsgaard-Larsen et al., 2002). This is consistent with a number of previous studies which 
have also shown that expression of α4, β3 and δ subunits produces functional receptors at the 
cell surface which exhibit pharmacological profiles indicative of them incorporating the δ 
subunit (Belelli et al., 2002; Brown et al., 2002; Stórustovu and Ebert, 2006; Hosie et al., 2008; 
Meera et al., 2009; see Fig. 5.1). Therefore, in the present study, the absence of enhanced 
neurosteroid sensitivity at α4β3δ GABAA receptors is not likely to be due to the receptors 
failing to incorporate the δ subunit.  
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Another factor which may affect the relative sensitivities of α1β3γ2L and α4β3δ GABAA 
receptors to neurosteroids is the presence of different α subunit isoforms. It is possible that, 
any enhancement in neurosteroid sensitivity conveyed by the presence of the δ subunit may 
be masked by opposing effects mediated by the incorporation of the α4 subunit. Consistent 
with this notion, some studies have reported that the extent of neurosteroid potentiation 
induced at GABAA receptors can be modestly altered depending on the α subunit isoform 
present (Belelli et al., 2002). However, this effect was not evident at concentrations of 
neurosteroid between 30 and 100nM, with no significant difference between the magnitudes 
of potentiation induced at receptors containing α1-α6 being observed (Belelli et al., 2002). 
Furthermore, Hosie et al. (2009) demonstrated that the binding site which is responsible for 
the potentiating effects of neurosteroids at GABAA receptors is conserved across all α subunits. 
Therefore, in the present study, it is unlikely that the expression of different α subunits acts to 
modulate the extent of neurosteroid potentiation.  
 
It is interesting to note that, although a number of studies have reported that neurosteroids 
display enhanced sensitivity at receptors containing the δ subunit, a closer look at the results 
reveals that the overall efficacy of the neurosteroid was increased, but the EC50 for 
potentiation remained unchanged (Belelli et al., 2002; Brown et al., 2002; Wohlfarth et al., 
2002). In addition, for THDOC, a significant enhancement in potentiation at δ versus γ2 
containing receptors was only observed at concentrations of 100nM and above, indicating 
that, at low, physiological concentrations, the difference between the sensitivities of δ and γ2 
subunit-containing receptors is unlikely to be significant. This is consistent with studies of 
dentate gyrus granule cells, which have shown that, during development, THDOC sensitivity is 
reduced in these neurons (Cooper et al., 1999), despite the concurrent increase in δ subunit 
expression (Laurie et al., 1992b). Therefore, this reinforces the conclusion that, under 
physiological conditions, δ subunit-containing receptors may not exhibit enhanced sensitivity 
to neurosteroids, thus, indicating that it is unlikely that this effect will be observed at the 
concentration of neurosteroid used in the present study.  
 
However, experiments carried out using knock-out mice have shown that deletion of the δ 
subunit results in diminished behavioural responses to alphaxalone, ganaxolone and 
pregnenolone (Mihalek et al., 1999), suggesting that, in these mice, the δ subunit-containing 
receptors convey much of the animal’s sensitivity to neuroactive steroids. However, this study 
focused on the effects of therapeutic doses of steroids, which are likely to be much higher than 
those present under physiological conditions, in fact, this study reports no difference in the 
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basal levels of anxiety between δ-/- and wild-type mice, indicating that the actions of the 
endogenous neurosteroids in the knock-out mice may be normal. It might be expected that if 
neurosteroid sensitivity was blunted, these mice would exhibit behaviours consistent with 
enhanced anxiety, although it cannot be discounted that compensatory mechanisms 
attempting to counteract the loss of δ subunits may be masking this effect.  
 
Therefore, taken together, these results suggest that, under physiological conditions, when 
low concentrations of neurosteroid are likely to be present, there may be no significant 
difference between neurosteroid sensitivities at δ versus γ2 subunit-containing GABAA 
receptors, however, when concentrations of neurosteroids rise, for example during the late 
stages of pregnancy (Paul and Purdy, 1992), δ subunit-containing receptors may become more 
sensitive to neurosteroids than those containing γ2 subunits, which will have important 
implications for the regulation of tonic inhibition in vivo.  
 
5.3.4 Phosphorylation of β3 subunits is not sufficient to induce complete modulation 
of neurosteroid potentiation 
The results from the previous chapter indicated that phosphorylation at the β3 subunit is 
important for regulating neurosteroid activity at α1β3γ2L GABAA receptors, with results 
showing that the effects of inhibiting protein kinase activity were absent in cells expressing 
α1β3S408A,S409Aγ2L GABAA receptors (see Chapter 4). By contrast, a significant decrease in 
neurosteroid potentiation was still observed after staurosporine treatment in cells expressing 
α4β3S408A,S409Aδ receptors (see Fig. 5.4), implying that phosphorylation at the β3 subunit is not 
absolutely required for the modulation of neurosteroid activity at α4β3δ GABAA receptors. 
However, staurosporine was notably less effective at α4β3S408A,S409Aδ receptors, which suggests 
that phosphorylation at the β3 subunit may be involved in regulating neurosteroid 
potentiation at α4β3δ receptors, although it is not sufficient to induce the full modulatory 
effect observed. This was supported by further observations which showed that there was only 
a modest decrease in the magnitude of neurosteroid potentiation induced under basal cell 
conditions at α4β3S408A,S409Aδ compared to wild-type GABAA receptors. Therefore, under 
conditions where the β3 subunit cannot be phosphorylated, the magnitude of potentiation 
elicited by 50nM THDOC is only moderately affected. This suggested that, in addition to 
phosphorylation at the β3 subunit, phosphorylation at other residues/subunits must also 
contribute to neurosteroid potentiation.  
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To date, consensus sites for phosphorylation have been identified on the GABAA receptor β 
and γ2 subunit families (Moss et al., 1992, 1995; McDonald and Moss, 1994, 1997), which 
suggests that, at α4β3δ receptors, phosphorylation can only occur at the β3 subunit. This 
indicates that there are just two potential sites (serines 408 and 409) through which protein 
kinases could act to modulate neurosteroid potentiation. This is inconsistent with the results 
from the present study which showed that phosphorylation at the β3 subunit was not 
sufficient to induce the full modulation of neurosteroid potentiation that was observed at 
wild-type receptors. However, a recent study has identified a novel phosphorylation site, at 
serine 443 on the α4 subunit, which can be phosphorylated by PKC (Abramian and Moss, 
unpublished; see Fig. 5.5). This site is not thought to be present on the other members of the α 
subunit family (Moss et al., 1992; Moss and Smart, 1996; see Fig. 5.7), which is, perhaps, 
unsurprising given that, not only are the large TM3-4 intracellular domains of the GABAA 
receptor the least conserved portion of the protein, but the α4 subunit has also been shown to 
contain an exceptionally long intracellular loop when compared to the other α subunits (Ymer 
et al., 1989). In fact, the novel phosphorylation site appears to be located within a seemingly 
expanded region of the TM3-4 loop that is almost completely absent from the other members 
of the α subunit family (see Fig. 5.7). The presence of an additional phosphorylation site on the 
α4 subunit has important implications for the functional regulation of GABAA receptors 
incorporating this subunit, suggesting that they may have an enhanced potential for 
modulation by protein kinases. As the α4 subunit is thought to preferentially co-assemble with 
β and δ subunits at extrasynaptic sites (Sur et al., 1999; Peng et al., 2002), this enhanced 
modulation by protein kinases provides a promising mechanism for additional ‘fine-tuning’ of 
tonic inhibition in vivo. Furthermore, phosphorylation at the α4 subunit may also act to 
modulate the actions of neurosteroids at α4β3δ GABAA receptors.  
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α1 YFTKRGYAWDGK-SVVPEKPKKVKDPLIK--KNNTY------------APTATSY
α2 YFTKRGWAWDGK-SVVNDK-KKEKGSVMI--QNNAY------------AVAVANY
α3 YFTKRSWAWEGK-KVPEALEMKKKTPAAPTKKNTTF------------NIVGTTY
α4 YFTNIQMQKAKK-KISKPPPEVPAAPVLKEKHTETSLQNTHANLNMRKRTNALVH
α5 YFTKRGWAWDGKKALEAAKIKKKERELILNKSTNAF------------TTGKLTH
α6 YFTNLQSQKAER-QAQT----AATPPVAKSKASES------------LEAEIVVH
***:       :                    . :                   :
α1 TPNLARGDPGLATIAKSATIEPKEVKPE---------------------------
α2 APNLSK-DPVLSTISKSATTPEPNKKPE---------------------------
α3 PINLAK-DTEFSTISKSAAAPSASSTPTAI-------------------------
α4 SESDVKSRTEVGNHSSKTSAVQESSEATPKAHLASSPNPFSRANAAETMSAAARG
α5 PPNIPKEQPPAGTANAPTVS---IKASE---------------------------
α6 SDSKYHLKKRIS---SLTLPIVPSSEAS-------------------------KA
. .  :           :        .
α1 --------------------------------------------------TKPPE
α2 --------------------------------------------------NKPAE
α3 ------------------------------------------ASPKATYVQDSPA
α4 LSSAASPSPHGTLRPASLGSASTRPAFGSRLGRIKTTVNTTGAAGNVSATPPPPA
α5 --------------------------------------------------EKTAE
α6 LS-----------RTPILKS---------------------------TPVSPPLL
.
α1 PKKTFNSVSKIDR
α2 AKKTFNSVSKIDR
α3 ETKTYNSVSKVDK
α4 PPPSGSGTSKIDK
α5 SKKTYNSISKIDK
α6 LPATG-GTSKIDQ
:  . **:*:
TM1 TM2 TM3 TM4N C
N C
 
 
Figure 5.7 The major TM3-4 intracellular domains of the GABAA receptor α subunit family are 
poorly conserved 
Sequence alignment of the TM3-4 intracellular domain of murine GABAA receptor α1-6. Fully conserved 
residues are indicated by *, with : and . symbols depicting strongly and weakly conserved residues, 
respectively.  Highlighted in red is the novel phosphorylation site present on the α4 subunit (serine 443), 
which is present in the expanded region of the α4 intracellular domain, a region that appears to be 
mostly absent from the other members of the α subunit family. Yellow box highlights arginine 353, the 
residue crucial for the inhibitory effects of allopregnanolone at α4βδ GABAA receptors (Shen et al., 
2007). Sequence alignment performed using clustalw.  
 
 
5.3.5 Phosphorylation at β3 S408/S409 and novel α4 site, S443 is important for 
regulating neurosteroid activity at α4β3δ GABAA receptors  
In order to determine whether phosphorylation at the α4 subunit was important for regulating 
neurosteroid potentiation at α4β3δ GABAA receptors, S443 was mutated to a neutral alanine 
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residue to prevent phosphorylation at this site. Interestingly, the results obtained from 
α4S443Aβ3δ GABAA receptors were very similar to those observed at α4β3
S408A,S409Aδ receptors, 
with staurosporine still inducing a significant decrease in neurosteroid potentiation, although 
to a notably lesser extent than observed at wild-type receptors (See Fig. 5.6). This implies that 
phosphorylation at α4 S443 may play a role in regulating the actions of neurosteroids at α4β3δ 
GABAA receptors, but once again, it is not sufficient to induce the complete modulatory effect. 
By contrast, at α4S443Aβ3S408A,S409Aδ GABAA receptors, the staurosporine-induced reduction in 
neurosteroid potentiation was completely abolished (see Fig. 5.6), indicating that 
phosphorylation at both the α4 and β3 subunits is important for regulating neurosteroid 
activity at ‘extrasynaptic-type’ α4β3δ GABAA receptors.  
 
Intriguingly, these results suggest that phosphorylation at at least two sites is required to 
achieve a complete modulation of neurosteroid potentiation at α4β3δ receptors, which is in 
contrast to α1β3γ2L subunit-containing receptors, where phosphorylation at just one residue 
was sufficient (see Chapter 4). This is a curious result which implies that, when the GABAA 
receptor contains α1, phosphorylation at the β3 subunit is able to initiate a modulatory 
mechanism, probably via either a conformational change or through the alteration of other 
signalling pathways to alter the potentiating actions of neurosteroids. However, when the α1 
subunit is replaced with the α4, this mechanism is re-routed, with phosphorylation at the β3 
subunit no longer sufficient to induce a complete modulation of neurosteroid potentiation, but 
instead, phosphorylation at the α4 subunit is also required. The reason for this is unclear but, 
as discussed previously, it is known that the α4 subunit has an exceptionally long TM3-4 
intracellular domain (Ymer et al., 1989; see also Fig. 5.8) and therefore, it is plausible that it 
may hold a rather different conformation compared to the shorter loop present in the α1 
subunit. Therefore, if phosphorylation at the β3 subunit acts to alter the actions of 
neurosteroids via a conformational change, this additional structure present in the α4 subunit 
might act to perturb this alteration, resulting in an incomplete modulation of neurosteroid 
potentiation, as seen for α4β3δ GABAA receptors.  
 
5.3.6 Phosphorylation at either α4 or β3 can modulate neurosteroid activity to some 
extent, although their effects are not additive 
A notable observation from the present study was that, although the effects are reduced, 
phosphorylation at the α4 or β3 subunit alone can significantly alter the actions of 
neurosteroids at α4β3δ GABAA receptors (see Fig. 5.4 and 5.6). Interestingly, the modulation 
induced by phosphorylation at each subunit was not linearly additive, with phosphorylation at 
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either the α4 or β3 subunit resulting in a decrease in neurosteroid potentiation of 
approximately 27% and 25%, respectively, the combined total of which is much greater than 
the 38% reduction observed at wild-type receptors. This suggests that there may be some 
redundancy in the modulatory mechanism, with phosphorylation at a single subunit able to 
compensate to some degree for the lack of phosphorylation at the other. Alternatively, there 
may be a maximum threshold for this modulation which is less than the sum of the individual 
regulatory abilities of each subunit. 
 
The non-additive nature of this modulation is not unusual, for example, Krishek et al. (1994) 
showed that the effects of phosphorylation at the β1 and γ2L subunits individually were not 
linearly additive compared to the modulation of GABA responses seen when both could be 
phosphorylated by PKC at wild-type α1β1γ2L GABAA receptors. Similarly, the results presented 
in the previous chapter showed that the sum of the decreases in GABA-activated current 
induced by PMA at α1β3S408Aγ2L and α1β3S409Aγ2L receptors was not equal to the reduction 
observed at wild-type receptors.  
 
5.3.7 Direct receptor phosphorylation is not required for the induction of 
neurosteroid potentiation at α4β3δ GABAA receptors 
The results from the present study have indicated that neurosteroid potentiation at α1β3γ2L 
GABAA receptors is modulated by, but does not require, the activity of protein kinases. This 
was also the case for α4β3δ receptors, with results showing that neurosteroid potentiation 
was still evident after treatment with the broad-spectrum protein kinase inhibitor, 
staurosporine. Furthermore, potentiation could still be elicited at receptors containing 
mutations at all known phosphorylation sites (α4S443Aβ3S408A,S409Aδ). However, as discussed 
previously, there is a small possibility that phosphorylation at, as yet, unidentified sites may 
also contribute to the induction of neurosteroid potentiation, with some previous studies 
reporting that there may be an additional site(s) located on the β3 subunit (McDonald and 
Moss, 1997). Moreover, as initial studies examining the α1 subunit reported that 
phosphorylation was not observed (Moss et al., 1992), it was inferred that other members of 
the α subunit family were also unlikely to be phosphorylated, leading to a lack of studies 
investigating potential phosphorylation sites on the α2-6 subunits. However, the recent 
discovery of a novel phosphorylation site on the α4 subunit suggests that there may be further 
sites present on other α subunit isoforms. In addition, the δ subunit has received relatively 
little attention in studies investigating potential phosphorylation sites and therefore 
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experiments to determine whether this subunit can also be phosphorylated could prove 
interesting.  
 
5.3.8 Roles of specific protein kinases 
This investigation did not specifically address the roles of individual protein kinases in the 
modulation of neurosteroid activity at α4β3δ GABAA receptors. For α1β3γ2L receptors, results 
showed that the actions of neurosteroids are regulated by PKC alone (see Chapter 3), although 
other studies have reported that, in some neuronal populations, other protein kinases may 
also be involved (Harney et al., 2003). At α4β3δ GABAA receptors, it is likely that PKC is 
involved in the modulation of neurosteroid activity as all three phosphorylation sites present 
on these receptors can be phosphorylated by PKC (McDonald and Moss, 1997; Abramian and 
Moss, unpublished). However, as both the α4 and β3 subunits are substrates for 
phosphorylation by other protein kinases (Moss and Smart, 1996; Abramian and Moss, 
unpublished), it is possible that any of these could be involved in the modulation of 
neurosteroid potentiation. Therefore, in order to identify the roles of specific protein kinases 
in the regulation of neurosteroid activity at α4β3δ GABAA receptors, further study is required 
using specific protein kinase inhibitors/activators.  
 
5.3.9 Physiological significance of co-modulation at extrasynaptic GABAA receptors 
The actions of GABA at extrasynaptic receptors have been shown to generate a widespread, 
tonic inhibition, which is an important regulator of neuronal excitability in vivo. Therefore, 
endogenous agents that can modulate the function of extrasynaptic receptors will have 
important consequences for neural network activity. The results from the present investigation 
showed that, at extrasynaptic-type, α4β3δ GABAA receptors, a co-modulatory relationship 
exists between neurosteroids and protein kinases and therefore, this provides important 
insight into how tonic inhibition may be regulated in vivo.  
 
Interestingly, a number of neurological and psychiatric disorders that are associated with the 
dysfunction of neurosteroid activity may be attributable to an alteration in their actions at 
extrasynaptic receptors. For example, it has been shown that, in the dentate gyrus, fluctuating 
levels of neurosteroids during the ovarian cycle (Paul and Purdy, 1992; Bäckström et al., 2003), 
results in cyclic changes in δ subunit expression and a concurrent modulation of tonic 
inhibition (Maguire and Mody, 2007). These changes have been associated with altered seizure 
susceptibility in catamenial epilepsy as well as the appearance of enhanced anxiety during 
certain phases of the menstrual cycle (Maguire et al., 2005). Furthermore, the alterations in δ 
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subunit expression have been shown to be induced rapidly, appearing after exposure to 
neurosteroid for just 30 min. Therefore, these changes may also be initiated by episodes of 
stress, which have been also shown to rapidly enhance levels of the neurosteroid, THDOC 
(Purdy et al., 1991). During pregnancy, levels of neurosteroids are thought to increase to 
around 100nM (Paul and Purdy, 1992) and therefore, a concurrent decrease in δ subunit 
expression is thought to occur as a homeostatic mechanism in order to maintain normal levels 
of neuronal excitability (Maguire and Mody, 2008; Maguire et al., 2009). Interestingly, studies 
of δ-/- mice, which cannot regulate δ subunit expression during pregnancy and the post-partum 
period, showed that these mice exhibit abnormal maternal behaviours, with the appearance of 
a depression-like phenotype (Maguire and Mody, 2008). Therefore, it has been suggested that 
a failure to restore normal δ subunit expression following the rapid decline in neurosteroid 
levels post-partum could lead to hyper-excitability in certain neuronal networks which may 
contribute to the appearance of post-partum depression in humans (Maguire and Mody, 
2008).  
 
Collectively, these studies demonstrate that the actions of neurosteroids at extrasynaptic 
GABAA receptors are crucially important for regulating tonic inhibition in vivo, with 
perturbations in this process contributing to a number of debilitating disorders. Therefore, as 
the results from the present study indicated that the actions of neurosteroids at extrasynaptic 
receptors can be modulated by the extent of receptor phosphorylation, the basal activities of 
protein kinases as well as conditions where these activities are enhanced or reduced may also 
affect the manifestation of these disorders. Furthermore, the existence of a co-regulatory 
relationship between neurosteroids and protein kinases at extrasynaptic receptors provides an 
increased number of potential targets for therapeutic interventions.    
 
Another disorder associated with abnormal neurosteroid modulation at extrasynaptic GABAA 
receptors is the appearance of enhanced anxiety during puberty. Curiously, although 
administration of the neurosteroid, allopregnanolone, produces anxiolytic effects in adult 
mice, paradoxically, it increases anxiety in pubertal female mice (Shen et al., 2007). This effect 
has been attributed to the increased expression of extrasynaptic, α4βδ subunit-containing 
GABAA receptors in the CA1 region of the hippocampus during puberty, which generate 
outward currents and, in stark contrast to the reported potentiating actions of neurosteroids, 
are in fact inhibited by allopregnanolone, resulting in enhanced tonic inhibition and increased 
neuronal excitability in the hippocampus (Shen et al., 2007). This effect is thought to be unique 
to receptors containing the α4 subunit as it has been shown to be dependent upon arginine 
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353, a non-conserved residue located within the large TM3-4 intracellular domain of the α4 
subunit (see Fig. 5.8). Given the position of this residue and its proximity to the recently 
identified consensus phosphorylation site, S443, it may be interesting to investigate whether 
the actions of protein kinases can modulate the generation of anxiety during puberty, as this 
may present additional targets for treatment of mood disorders associated with puberty. 
 
GABAA receptors consisting of α4βδ subunits have a well-defined expression within the CNS, 
with studies showing that they are predominately expressed at extrasynaptic sites in the 
thalamus and dentate gyrus (Sperk et al., 1997; Sur et al., 1999; Pirker et al., 2000; Peng et al., 
2004; Jia et al., 2005). Therefore, the results from the present study provide an insight into the 
regulatory mechanisms controlling tonic inhibition in these regions of the brain. Interestingly, 
previous studies have shown that, in the dentate gyrus, physiological concentrations of 
neurosteroid exclusively modulate the tonic conductance, with no effect at synaptic receptors 
(Harney et al., 2003; Stell et al., 2003). This highlights the importance of understanding the 
regulatory mechanisms controlling the actions of neurosteroids at extrasynaptic receptors in 
these neurons. At α4β3δ GABAA receptors, neurosteroid potentiation can be modulated by the 
activities of protein kinases. This implies that the tonic conductance present in the dentate 
gyrus is also likely to be subject to a similar co-modulation, which could provide an ideal 
mechanism by which the actions of two distinct modulators act in concert to achieve a rapid 
and precise fine-tuning of neuronal excitability. Furthermore, the presence of an additional 
consensus phosphorylation site on the α4 subunit also provides the potential for an added 
level of regulation, which may indicate that extrasynaptic receptors can undergo ‘fine-tuning 
to a greater extent than synaptic receptors, although the relevance of this remains to be 
determined in vivo.   
 
5.4 Conclusions 
 
 Protein kinase activity positively modulates the actions of neurosteroids at 
‘extrasynaptic-type’, α4β3δ GABAA receptors. 
 
 Protein kinases act to modulate the actions of neurosteroids via direct 
phosphorylation of the α4 and β3 subunits.  
 
 Phosphorylation at either α4 or β3 can alter neurosteroid potentiation, but 
phosphorylation at both subunits is required to induce the full modulatory effect. 
[160] 
 
 Induction of neurosteroid potentiation at α4β3δ GABAA receptors does not require 
direct receptor phosphorylation. 
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Chapter 6 
 
General Discussion 
 
GABAA receptors are subject to modulation by a number of endogenous compounds, which, by 
acting to alter receptor function, have a significant impact on neural activity. Neurosteroids 
and protein kinases are among the most potent modulators of the GABAA receptor, which, 
when acting individually, can enhance or depress receptor function depending on the type of 
neurosteroid or kinase present and the subunit combination of the receptor (Belelli and 
Lambert, 2005; Moss and Smart, 1996). However, in vivo, these agents are most likely to act in 
concert to achieve a precise fine-tuning of inhibitory neurotransmission by regulating GABAA 
receptor function. 
 
Studies of both recombinant and native GABAA receptors have indicated that the activity of 
protein kinases can modulate the potentiating actions of neurosteroids (Leidenheimer and 
Chapell, 1997; Harney et al., 2003; Fáncsik et al., 2000). This is supported by the results from 
the present study, which showed that the magnitude of potentiation induced by neurosteroids 
at α1β3γ2L GABAA receptors is positively modulated by the activity of PKC. PKC was shown to 
mediate this effect through direct phosphorylation of the β3 subunit, with phosphorylation at 
either S408 or S409 being sufficient. Furthermore, at α1β3γ2L GABAA receptors, the co-
modulatory relationship between neurosteroids and protein kinases was shown to be bi-
directional, with phosphorylation at the receptor acting to modulate the actions of 
neurosteroids and, in the reverse situation, exposure to neurosteroids causing an increase in 
the extent of receptor phosphorylation. These findings provide an important insight into the 
regulation of GABAA receptors in vivo, and into the mechanisms by which fine-tuning of 
GABAergic inhibitory transmission may be achieved via the actions of two endogenous 
neuromodulators. 
 
Interestingly, results showed that the co-modulatory relationship between neurosteroids and 
protein kinases was not identical for all receptor subtypes, with neurosteroid potentiation at 
extrasynaptic-type α4β3δ GABAA receptors being modulated to a lesser extent than synaptic-
type α1β3γ2L receptors. This may have important implications for the regulation of phasic and 
tonic inhibition in vivo, suggesting that the phasic inhibition mediated by synaptically located 
GABAA receptors has a greater potential to undergo ‘fine-tuning’ through the cooperative 
actions of neurosteroids and protein kinases. Furthermore, at α4β3δ receptors, 
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phosphorylation on both the β3 and α4 subunits was required to achieve a complete 
modulation of neurosteroid potentiation, which is in contrast to α1β3γ2L subunit-containing 
receptors, where phosphorylation at just one residue was sufficient. Therefore, this suggests 
that, although neurosteroid potentiation at α4β3δ receptors may be modulated to a lesser 
extent by protein kinases, the actions of neurosteroids at this receptor may be under greater 
incremental control due to the effect being regulated by phosphorylation at multiple residues, 
as opposed to the ‘all or none’ effect mediated by phosphorylation at a single residue on the 
α1β3γ2L receptor.  
 
6.1 Mechanism of co-modulation 
The mechanism by which phosphorylation influences the interaction between neurosteroids 
and the GABAA receptor is unknown. However, a number of possible mechanisms have been 
proposed. One such theory is that the GABAA receptor is phosphorylated under basal cell 
conditions and this is required for neurosteroid binding and subsequent potentiation (Tasker, 
2000). However, the results from the present study are inconsistent with this notion, showing 
that neurosteroid potentiation is still evident at receptors containing mutations at all known 
phosphorylation sites, indicating that phosphorylation is not absolutely required for the 
potentiation of GABAA receptor function by neurosteroids.   
 
A second potential mechanism is that the binding of the neurosteroid to the receptor causes a 
conformational change which unmasks a PKC consensus site, allowing it to be phosphorylated 
(Tasker, 2000). Although it is accepted that phosphorylation can occur in the absence of 
neurosteroid, this could provide a possible explanation for the enhancement of 
phosphorylation after neurosteroid treatment, perhaps suggesting that the binding of 
neurosteroid causes the sites for phosphorylation to become more accessible. However, 
exposure of receptors to the PKC activator, PMA resulted in a greater enhancement of 
receptor phosphorylation than observed after neurosteroid treatment, perhaps implying that 
the sites for phosphorylation are fully accessible in the absence of neurosteroids. Furthermore, 
as neurosteroids were less effective at promoting GABAA receptor phosphorylation than PMA, 
this suggests that neurosteroids are unlikely to increase receptor phosphorylation by directly 
activating protein kinases. This is supported by the results obtained from α1Q241Wβ3γ2L GABAA 
receptors, which showed that neurosteroids up-regulate phosphorylation through a direct 
interaction with the receptor, indicating that the increase in phosphorylation is more likely to 
be mediated via an alteration of receptor-associated signalling pathways. An alternative 
mechanism by which neurosteroids may facilitate GABAA receptor phosphorylation is by 
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recruiting active protein kinase molecules to the receptor microdomain, however further 
experiments would be required to elucidate this in more detail, perhaps using biochemical 
techniques to investigate the association between protein kinases and the receptor in the 
presence and absence of neurosteroids.  
 
The results from the present investigation showed that, at α1β3γ2L GABAA receptors, 
phosphorylation by PKC at either β3 S408 or S409 was sufficient to modulate neurosteroid 
potentiation, indicating that phosphorylation at just one of these residues is required to 
regulate the actions of neurosteroids at this receptor subtype. Similar results were also 
obtained in preliminary studies of α1β2γ2L subunit-containing receptors, where 
phosphorylation at S410 was sufficient to modulate neurosteroid potentiation to a similar 
extent to that observed at receptors incorporating the β3 subunit. This indicates that only a 
small negative charge is required to enhance neurosteroid activity, which may be in the form 
of a conformational change or modification of the signal transduction mechanism through 
which neurosteroids act to potentiate GABAA receptors. In addition, the fact that, at α1β3γ2L 
receptors, phosphorylation at the second PKC site does not further modulate the magnitude of 
neurosteroid potentiation indicates that the addition of a single phosphate moiety induces the 
full modulatory effect. This has interesting implications for the modulation of GABAA receptors 
in vivo, suggesting that the actions of neurosteroids at receptors containing different β 
subunits are not subject to differential regulation by PKC.  
 
One possible mechanism by which phosphorylation may act to enhance neurosteroid 
potentiation is by inducing a conformational change which increases the accessibility of the 
neurosteroid binding site. Glutamine 241, one of the three key residues identified as being 
important for the interaction between neurosteroid molecules and the GABAA receptor (Hosie 
et al., 2006), is proposed to be located at the base of a water-filled cavity formed between 
TM1 and TM4 of the α subunit (Hosie et al., 2007). Interestingly, studies using substituted 
cysteine accessibility methods have shown that this cavity increases in volume in the presence 
of GABA (Williams and Akabas, 1999), leading to the hypothesis that this GABA-induced 
increase in volume may facilitate entry of the neurosteroid into the cavity, allowing it to bind 
Q241, stabilizing the receptor in its open conformation and resulting in potentiation of the 
GABA current (Hosie et al., 2007). Therefore, it is a possibility that phosphorylation may act to 
increase the volume of this cavity further, promoting even greater access to the neurosteroid 
binding site, which may lead to an increase in neurosteroid binding, resulting in an 
enhancement of its potentiating effects. To investigate this in more detail, further experiments 
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could be conducted using the substituted cysteine accessibility method in order to identify any 
further conformational changes which may occur within this cavity in the presence of 
phosphorylation. Williams and Akabas (1999) reported that, at α1β1γ2 receptors, the presence 
of GABA causes an increase in the depth and volume of this cavity as demonstrated by the 
exposure of four previously inaccessible residues on the TM3 domain, residues which are 
deeper within this cavity. Therefore, in order to determine whether this cavity enlarges further 
in the presence of both GABA and phosphorylation, accessibility of residues not exposed by 
GABA alone could be investigated. It can be hypothesised that, if additional residues present 
on the TM3 domain become accessible in the presence of GABA and phosphorylation, this may 
indicate that further conformational changes are occurring in this cavity which may facilitate 
the interaction between neurosteroids and their binding site. In addition, if the presence of 
phosphorylation does indeed increase the accessibility of the neurosteroid binding site, it 
would be expected that the potency of neurosteroids would be increased. Therefore, this 
could be investigated by constructing neurosteroid dose-response curves in the presence and 
absence of phosphorylation. A curve shift would be indicative of a change in neurosteroid 
potency with a leftward shift reflecting an increase in the neurosteroid interaction.  
 
6.2 Relative contribution of each neurosteroid potentiation site 
Given that phosphorylation on the β3, but not the γ2L subunit is important for regulating 
neurosteroid potentiation at α1β3γ2L GABAA receptors, it may be interesting to consider the 
relative positioning of the neurosteroid binding sites within the receptor complex. 
Neurosteroids are thought to mediate their potentiating actions through a discrete site located 
within the transmembrane region of the α subunit, of which there are two copies within each 
pentameric GABAA receptor assembly. Interestingly, studies investigating the stoichiometry 
and relative positioning of subunits within the GABAA receptor complex have suggested that 
one α subunit is flanked by two β subunits whereas the second is located between a β and a γ 
(Sieghart et al., 1999). Therefore, although the use of concatemeric receptors has suggested 
that these sites are functionally equivalent with respect to their ability to induce neurosteroid 
potentiation (Akk et al., 2009; Bracamontes and Steinback, 2009), it is possible that one site 
may be subject to greater modulation by phosphorylation at its surrounding β subunits. To 
investigate this, experiments similar to those conducted in the present study could be 
conducted using concatemeric receptors which contain mutations within one of the 
neurosteroid binding sites, thus allowing the influence of phosphorylation at each site to be 
determined.  
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6.3 Additional mechanistic complexity for α4β3δ GABAA receptors 
Interestingly, although phosphorylation at the β3 subunit was shown to be sufficient to 
modulate neurosteroid potentiation at α1β3γ2L GABAA receptors, this was not the case for 
α4β3δ receptors, with results showing that phosphorylation at both the α4 and β3 subunits 
was important for regulating neurosteroid potentiation at this receptor subtype. Therefore, 
this suggests that phosphorylation at at least two sites is required to achieve the complete 
modulatory effect at α4β3δ receptors, which is in contrast to α1β3γ2L subunit-containing 
receptors, where phosphorylation at just one residue was sufficient. This indicates that 
phosphorylation sites present on the α subunit also play a role in modulating neurosteroid 
potentiation at GABAA receptors and therefore this introduces the potential for differential 
regulation depending upon the identity of the α subunit. For example, when the receptor 
contains the α1 subunit, which is not thought to possess any consensus sites for PKC (Moss et 
al., 1992), phosphorylation at the β3 subunit is able to initiate the modulatory mechanism 
which results in the enhancement of neurosteroid activity. However, when the α1 subunit is 
replaced with the α4, which contains a phosphorylation site at S443 (Abramian and Moss, 
unpublished), this mechanism is either perturbed or re-routed, with phosphorylation at the β3 
subunit no longer sufficient to induce a complete modulation of neurosteroid potentiation. 
The reason for this is unclear but as the α4 subunit has been shown to possess an 
exceptionally long TM3-4 intracellular domain (Ymer et al., 1989), it is possible that it may hold 
a different conformation compared to the shorter loop present in the α1 subunit, with this 
additional structure acting to perturb the mechanism by which β3 subunit phosphorylation 
alters neurosteroid activity at this receptor. In order to investigate this further, it may be 
interesting to determine how neurosteroid potentiation at receptors containing different α 
subunits is modulated by protein kinases, particularly those which also contain long 
intracellular domains such as α5 and α6. Furthermore, experiments investigating the co-
modulatory relationship between neurosteroids and protein kinases at αβ GABAA receptors 
may help to determine whether the δ or γ subunits are involved in modulating neurosteroid 
potentiation, either through direct phosphorylation or by contributing to or modifying the 
mechanism by which phosphorylation acts to alter neurosteroid potentiation. 
  
6.4 Specificity of co-modulation 
The results from the present study indicate the existence of a co-modulatory relationship 
between neurosteroids and protein kinases at GABAA receptors. However, previous studies 
have shown that the actions of protein kinases can also modify the activities of other GABAA 
receptor modulators including, ethanol (Proctor et al., 2003; Qi et al., 2007; Choi et al., 2008) 
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and benzodiazepines (Leidenheimer et al., 1993; Hodge et al., 1999; Qi et al., 2007). Therefore, 
to extend the present study, it may be interesting to determine whether phosphorylation at 
the β3 and/or α4 subunits specifically acts to modulate the actions of neurosteroids or 
whether the activities of other modulators are also affected. If phosphorylation at these 
subunits also modulates the actions of other compounds at the GABAA receptor, this may 
suggest that phosphorylation at the β3 or α4 subunits acts to modify a common modulatory 
pathway, thus providing a further insight into the mechanism by which phosphorylation acts to 
regulate the actions of neurosteroids at the receptor.  
 
The present study investigated the effects of protein kinases on the actions of THDOC, a 
potentiating neurosteroid which is endogenously produced within the CNS. However, a second 
class of neurosteroid is also synthesised within the mammalian CNS, which have inhibitory 
effects on GABAA receptors, resulting in an increase in neuronal excitability. Therefore, it may 
be interesting to determine whether the actions of these inhibitory neurosteroids are also 
modulated by protein kinases, and if so, whether the same residues which modify the actions 
of potentiating neurosteroids are involved.   
 
6.5 Role of phosphatases 
Phosphorylation of the GABAA receptor is controlled by both protein kinases and 
phosphatases, with the balance of activities between the two determining the overall 
functional effect. This study examined the roles of protein kinases in modulating the activity of 
neurosteroids at GABAA receptors, however, the role of phosphatases was not investigated. 
Some previous studies have suggested that the activity of phosphatases may also be 
important, with blockade of phosphatases 1 and 2A resulting in a decrease in neurosteroid 
sensitivity at GABAA receptors in the hypothalamus (Koksma et al., 2003). It is likely that both 
protein kinases and phosphatases will be present and active in neurons and therefore, it may 
be instructive to extend this study to examine the effects of phosphatase inhibitors on 
neurosteroid-mediated potentiation, enabling a clearer picture of the co-modulatory 
relationship between neurosteroids and protein kinases at GABAA receptors in vivo to be 
determined. 
 
6.6 Involvement of other protein kinases 
In addition to PKC, PKA and PKG, the GABAA receptor can also be phosphorylated by CaMKII 
(Machu et al., 1993; McDonald and Moss, 1994; McDonald and Moss, 1997; Houston et al., 
2008), the effects of which were not investigated in this study. The use of HEK293 cells meant 
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that it was impossible to assess the potential effects of CaMKII on neurosteroid-mediated 
potentiation at GABAA receptors as CaMKII is not thought to be active in this cell line (Houston 
and Smart, 2006). The reason for this is unclear, but it is thought that due to their non-
neuronal lineage, HEK293 cells may lack the necessary trafficking or scaffolding machinery 
required for CaMKII to phosphorylate the receptor. Therefore, any further studies to examine 
the potential role of CaMKII, would need to be conducted using a neuronal cell line, such as 
NG108-15 cells, in which phosphorylation by CaMKII has been shown to mediate functional 
effects at GABAA receptors (Houston and Smart, 2006). 
 
6.7 Physiological importance of co-modulation 
The ability of protein kinases to positively modulate the actions of neurosteroids at GABAA 
receptors has important implications under conditions in which the activity of protein kinases 
is reduced or elevated. For example, decreased PKC levels have been observed in the brains of 
patients with a number of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and 
Huntingdon’s disease (Nishino et al., 1989; Masliah et al., 1990; Hashimoto et al., 1992), as 
well as in some forms of epilepsy (Terunuma et al., 2008). By contrast, enhanced PKC activity 
has been seen after the administration of some psychoactive drugs including ethanol (Stubbs 
and Slater, 1999) and cocaine (Steketee, 1996; Steketee et al., 1998). Therefore, in situations 
where protein kinase activity is perturbed, particularly PKC, effects will be seen both directly, 
in the alteration of GABAA receptor phosphorylation and indirectly, by modulating the activity 
of neurosteroids at these receptors. These changes will inevitably lead to alterations of 
GABAergic inhibition, which may contribute to disease aetiology or exacerbate symptomatic 
profiles.  
 
Interestingly, the results from the present study showed that, at α1β3γ2L GABAA receptors, the 
co-modulatory relationship between neurosteroids and protein kinases is bi-directional with 
phosphorylation at the receptor acting to modulate the actions of neurosteroids and, in the 
reverse situation, exposure to neurosteroids causing an alteration in the extent of receptor 
phosphorylation. Therefore, any variations in neurosteroid concentrations, such as those 
observed during pregnancy, stress or at certain phases of the ovarian cycle will not only 
modulate GABAA receptor function directly, but also indirectly through the alteration of 
receptor phosphorylation. Furthermore, the bi-directional nature of this modulation provides 
an ideal mechanism for the fine-tuning of GABAergic inhibition. The function of this ‘reverse’ 
modulation in which neurosteroids alter the extent of receptor phosphorylation remains to be 
determined, however, there is some evidence to suggest that it may have a role in regulating 
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the trafficking of GABAA receptors or could be involved in the generation of ‘automodulation’, 
a kind of positive feedback whereby repetitive co-applications of GABA and neurosteroid 
causes a ‘run-up’ of neurosteroid potentiation (Wegner et al., 2007; see Chapter 4).  
 
GABAA receptor expression is relatively ubiquitous throughout the CNS and, with 
neurosteroids exhibiting no clear receptor isoform specificity (Hadingham et al., 1993; Belelli 
et al., 1996, 2002), it could be hypothesised that the actions of neurosteroids would be 
globally experienced, causing a generalised potentiation, rather than achieving a more 
localized ‘fine-tuning’ of inhibitory neurotransmission. Such a non-specific action is 
incompatible with neurosteroids having a physiological role, however, studies have shown that 
the actions of neurosteroids are both brain region and neuron specific. For example, low, 
physiological concentrations of neurosteroids have been shown to prolong mIPSCs recorded 
from hippocampal CA1 neurons (Harney et al, 2003), cerebellar granule cells (Cooper et al., 
1999; Hamann et al., 2002; Vicini et al, 2002) and cerebellar Purkinje neurons (Cooper et al., 
1999); whereas concentrations above those seen physiologically are required to produce 
similar effects in hypothalamic neurons (Brussaard et al., 1997; Fancsik et al., 2000; Koksma et 
al., 2003). Further experiments have shown that even neurons within the same brain structure 
can be differentially modulated, for example, in rat hippocampal brain slices approximately 30 
times higher concentrations of allopregnanolone are required to prolong mIPSCs in dentate 
gyrus granule cells than in CA1 pyramidal neurons (Harney et al., 2003). It has been suggested 
that the differing activities of protein kinases within these different brain areas and neuronal 
populations may contribute to their differential sensitivity to neurosteroids. The results from a 
previous study showed that, under basal conditions, dentate gyrus granule cells are relatively 
insensitive to physiological concentrations of neurosteroids. However, when PKC activity is 
increased these neurons become much more sensitive to the effects of applied neurosteroids 
(Harney et al., 2003). A similar result was obtained in the present study, with results showing 
that activation of PKC caused α1β3γ2L GABAA receptors to become sensitive to lower, 
previously ineffective concentrations of THDOC (1nM). Therefore, taken together, these 
results indicate that differing activities of protein kinases offers a plausible mechanism for 
regulating the effects of neurosteroids within different neuronal populations.  
 
6.8 Implications for the treatment of pathological conditions 
Dysfunction of GABAergic neurotransmission has been implicated in a number of neurological 
and psychiatric disorders including epilepsy, anxiety and some neurodegenerative conditions 
such as Huntington’s and Alzheimer’s disease (Armstrong et al., 2003; Fritschy and Brϋnig, 
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2003; Lϋscher and Keller, 2004). Therefore, given their essential role in controlling neuronal 
excitability, it is important to elucidate the cellular mechanisms by which GABAA receptors are 
regulated in vivo. The results from the present study provide an important insight into the 
mechanisms by which GABAergic inhibition may be regulated by the co-operative actions of 
neurosteroids and protein kinases and therefore these results may also help to identify 
potential therapeutic targets for conditions associated with GABAA receptor dysfunction.  
 
Dysfunction of neurosteroid activity is also associated with a number of pathological 
conditions such as catamenial epilepsy, stress, depression, as well as mood disturbances 
associated with the ovarian cycle and pregnancy (Bäckström et al., 2003; Maguire et al., 2005; 
Maguire and Mody, 2007; Maguire et al., 2009). In the majority of these conditions, alterations 
in the concentrations of CNS neurosteroids have been shown to cause a perturbation of 
inhibitory transmission. This can lead to hypo- or hyper-excitability in certain neuronal 
networks, which may contribute to the appearance of these conditions or exacerbate the 
associated symptoms. Therefore, as the results from the present study indicate that the 
actions of neurosteroids at GABAA receptors can be modulated by the extent of receptor 
phosphorylation, this provides an increased number of potential therapeutic targets for the 
treatment and prevention of these debilitating conditions.  
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